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Abstract 
 
Vibrational spectroscopy, including Raman micro-spectroscopy, has attracted 
considerable attention over the last few years, as a powerful, non-invasive tool for clinical 
applications, especially in cancer diagnosis, in vivo and ex vivo. As a molecular 
fingerprinting technique with optical resolution, Raman micro-spectroscopy is able to 
monitor biochemical processes, drug uptake, efficacy and mode of action and 
mechanisms of interaction of chemotherapeutic drugs at a subcellular level. 
In vitro applications may be more strategically achievable, and can help guide drug design 
and discovery, and eventually evaluate signatures of drug resistance, towards potential 
applications in personalised therapy and as a companion diagnostic tool. 
However, to evaluate accurately the potential of Raman micro-spectroscopy for such 
applications, it is essential to optimise measurement and data processing protocols 
associated with subcellular analysis in order to extract all valuable spectroscopic 
information and to demonstrate the ability of this technique to distinguish not only 
between normal and cancer cells but also between cancer cell lines before exploring its 
potential as a chemotherapeutic screening and assessment protocol using commercially 
available chemotherapeutic agents. To be considered as an in vitro companion diagnostics 
technique to screen for personalised therapies, Raman micro-spectroscopy should be able 
to monitor subcellular interaction with chemotherapeutic drugs and to characterise 
cellular resistance. 
To this end, different lung cell lines were used and Raman micro-spectroscopy was 
coupled to valuable other techniques such as Confocal Laser Scanning Fluorescence 
Microscopy, Flow Cytometry and Atomic Force Microscopy, in order to explore its 
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potential to elucidate drug pathways, chemical binding signature, mechanisms of action 
and efficacy and physiological cellular responses to the drug exposure. As 
chemotherapeutic agents, Doxorubicin and Actinomycin D, both anthracyclines widely 
used in clinics especially for lung cancer were employed as pilot molecules. Multivariate 
data analysis, consisting of Principal Component Analysis, Linear discriminant and 
Partial Least Square Regression analysis were employed to deeply investigate the spectral 
features related to drug effects and cellular responses.  
Investigations demonstrate the ability of Raman micro-spectroscopy not only to track the 
subcellular accumulation of the drug as function of time but also to identify its mechanism 
of action, the subsequent cellular response and to differentiate cellular resistance. 
Moreover, despite the fact that different cell lines show different chemotherapeutic 
resistance, the chemical binding signature appears to be identical from anti-cancer drugs 
which belongs to same chemotherapeutic group with implications of different 
mechanisms of action function of time and dose. 
In human lung cancer cell lines which show different cytotoxic sensitivities to the drugs, 
different spectroscoic response profiles to the drugs are observed, which can be 
potentially linked to cellular defence mechanisms, such as the expression of anti-
apoptotic proteins, and DNA repair.  
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Chapter 1: General introduction 
1.1. Raman micro-spectroscopy: 
Traditional diagnostic methods such as clinical assessment, histopathological 
examination performed on biopsies after staining, imaging techniques such as endoscopy, 
ultrasonography, tomography and magnetic resonance imaging and molecular diagnostic 
techniques, principally based on the recently developed polymerase chain reaction (PCR) 
technique, are by and large lengthy, invasive and painful (De Abreu, Wells, and 
Tsongalis, 2013; Ohno et al., 2008; Shahzad et al., 2015; Takahashi, Saikawa, and 
Kitagawa, 2013). Moreover, with the exception of the latter, they are largely based on 
identification of morphological changes in cells or tissues, rather than analysis of the 
underlying biochemistry, and so are subjective and prone to error. Therefore, there is a 
need to develop more effective non-invasive diagnostic and prognostic techniques for a 
single clinical investigation either in real time diagnosis or an in vitro way which could 
be applied to in vivo situations. An increased emphasis on in vitro techniques for 
evaluation of drug mechanisms and efficacies has also emerged from the introduction of 
European and US legislation which restrict the use of animal models in cosmetic and 
pharmaceutical development (EU Directive-2010/63/EU and US Public Law 106-545, 
2010, 16th Congress), adding further to the demand for novel biological screening 
methodologies (Kallaway et al., 2013). 
Raman micro-spectroscopy is a powerful non-invasive analytical method that can 
measure the chemical composition of biological samples, cells, tissues or biofluids at a 
molecular level (Huser and Chan, 2015; Kong et al., 2015). Raman micro-spectroscopy 
is an optical technique based on inelastic scattering of light by vibrating molecules, 
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demonstrated by C.V. Raman in 1928 (Byrne et al., 2014; Gala and Chauhan, 2015; 
Paudel, Raijada, and Rantanen, 2015; Smith et al., 2015). It is based on the interaction of 
photons with the vibrational states of the molecules in the sample, causing them to scatter 
inelastically, giving rise to the “Raman effect”. As the vibrations are molecularly specific, 
the technique can provide chemical fingerprints of complex biological samples (Kong et 
al., 2015). In the process, a laser is used as an excitation source and the incident photons 
can pass through the material without interaction or be absorbed or scattered, giving rise 
to two types of scattering, Rayleigh and Raman scattering (Tu and Chang, 2012). 
As each molecular vibration can give rise to scattering, a molecule or collection of 
molecules generates a Raman spectrum, which is characteristic of the sample. Raman 
spectroscopy can therefore be employed to fingerprint materials, or processes, and has 
found a wide range of applications from basic research to forensics and pharmacology. 
Raman spectroscopy has more recently been expanded to include surface enhanced 
Raman spectroscopy (SERS) (McAughtrie, Faulds, and Graham, 2014) and Coherent 
Anti-Stokes Raman Scattering (CARS) (Yu, Ramachandran, and Wang, 2014) which is 
increasingly employed in medical diagnostic imaging (Kong et al., 2014; Tu and Chang, 
2012). The potential of Raman spectroscopy has been well demonstrated, especially for 
cancer diagnostics, in for example oral (Carvalho et al., 2015; Knipfer et al., 2014), gastric 
(Feng et al., 2011; Yao et al., 2009), breast (Abramczyk et al., 2012; Lee et al., 2014), 
cervical (Ramos, Malkin, and Lyng, 2015; Rashid et al., 2014), skin (Legesse et al., 2015) 
cancer, amongst many other anatomical sites, although translation to the clinical 
environment is still limited (Byrne et al., 2015; Kong et al., 2015).  
However, potential clinical applications of Raman micro-spectroscopy are not limited to 
cancer diagnostics. This project will explore its potential as a pharmacological tool to 
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monitor drug kinetics and cellular interactions due to its subcellular resolution and signal 
reproducibility for applications such as potential personalised therapy and companion 
diagnostic. In fact, according to the US FDA (Food and Drug Administration), a 
companion diagnostic is defined as a device that provides information that is essential for 
the safety and effectiveness of a therapeutic product. Companion diagnostic assays have 
so far been reserved for oncology and mostly for a specific cancer and chemotherapeutic 
drug. For example, the drug vemurafenib and its companion diagnostic, the Cobas 4800 
BRAF V600 mutation test, were approved for use in melanoma, and the drug Crizotinib 
and EML-4 ALK mutation test for the treatment of patients with late stage non-small cell 
lung cancer with an ALK gene rearrangement  (Cheng, Koch, and Wu, 2012; Parkinson, 
Johnson, and Sledge, 2012).  
The study will seek to demonstrate, using established chemotherapeutic agents of known 
mechanisms of action, in human lung cell lines as models, that the spectroscopic 
signatures of the modes of action of the drug are reproducible in different cell lines, and 
for different drugs of similar modes of action, and furthermore that the subsequent 
responses of different cell lines with varying cytotoxic response are characterisable 
according to their spectroscopic signatures. 
1.2. Cancer: 
Cancer is the name given to a collection of related diseases which can start anywhere on 
the human body, but can be different in morphologic, genetic and clinical levels. The 
disease results from an uncontrolled cell development and a disruption of cells apoptosis 
inducing abnormal cells formation (Almeida and Barry, 2011; Hesketh, 2013; Weinberg, 
2013). Among all cancers, lung cancer is the second most common and the leading cause 
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of death around the world. The number of deaths worldwide is continuously increasing, 
with 1.5 million new cases recorded per year. The most important percentage of lung 
cancer is related to non-small cell lung cancer (NSCLC), which represents almost 80 % 
(Cataldo et al., 2011; Reck et al.). For diagnosis and analysis of lung cancer, Raman 
micro-spectroscopy has been employed to distinguish tumour from normal lung cells, to 
predict the prognosis of non-small cell lung cancer patients by analysing surgically 
resected tissue sections and screen the pre-neoplastic lesions increasing the early 
detection of cancer (Huang et al., 2003; Kong et al., 2015; McGregor et al., 2017; Song 
et al., 2016; Zeng et al., 2010). 
1.3. Chemotherapy: 
The treatment of non-small-cell lung cancer is undergoing fundamental changes and 
many new approaches have been developed like adjuvant therapy, growth factors 
inhibitors and combined therapy but chemotherapy remains the major player and the most 
powerful arm for patients with advanced NSCLC (Biswas et al., 2013; Cataldo et al., 
2011; Reck et al.; Schiller et al., 2013). Chemotherapy, involving the use of cytotoxic 
antineoplastic agents, remains an important strategy in the overall management of patients 
with malignant tumours (Riddick et al., 2005). Despite its significant side effects, in 
recent years chemotherapy has become a routine treatment for cancer, alone or in 
combination with radiotherapy, immunotherapy, hormonal therapy and surgery. There 
are many approved chemotherapeutic agents, divided into 5 groups according to their 
mechanism of action: alkylating agents, antimetabolites, anti-tumour antibiotics 
(including anthracyclines), topoisomerase inhibitors, and mitotic inhibitors (Reddy and 
Couvreur, 2010). A well-established anti-cancer drug (since 1960), and one of the 10 
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most frequently used drugs in cancer chemotherapy, especially for the treatment of 
aggressive and metastatic tumours, is Doxorubicin (DOX) (Yokochi and Robertson, 
2004), an anthracycline antibiotic extract from Streptomyces peucetius, consisting of a 
conjugated anthraquinone ring structure bonded to an aminoglycoside (Figure 1.1 A) 
(Farhane et al., 2015; Hurley, 2002). DOX, alone, or in combination with other 
chemotherapeutic or with radiotherapy, is currently in clinical trials for treatment of 
advanced stages of NSCLC. However, treatment with DOX is associated with numerous 
side-effects including severe cardiotoxicity (Biswas et al., 2013).   
Another anthracycline widely used in clinics for treatment of aggressive cancers is 
Actinomycin D (ACT), which was developed in the 1950s and clinically approved 10 
years later (Cibi and Jayakumaran Nair, 2016; Liu et al., 2016). It blocks both DNA and 
RNA expression, and as a consequence protein synthesis, by inhibition of RNA 
polymerase and transcription in nucleoli and therefore induces cellular p53-independant 
apoptosis. It also intercalates into DNA using its phenoxazone ring at binding sites (GpC 
principally and also GpT, GpA, GpG, and CpG) such that the two cyclic pentapeptides of 
the drug are located in the DNA minor groove (Figure 1.1 B) (Cassé et al., 1999; 
Hasanzadeh and Shadjou, 2016; Kleeff et al., 2000; Lo et al., 2013; Nazari et al., 2012; 
Schwartz et al., 1965; Snyder et al., 1989; Yung, Bor, and Chan, 1990). 
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A.                                                      B. 
  
C.     D. 
  
Figure 1.1: Chemical structures of A. DOX, B. ACT, C. Vinc and D. Cisp (Dasari and 
Tchounwou, 2014; Farhane et al., 2015; Lo et al., 2013; Mohammadgholi, Rabbani-
Chadegani, and Fallah, 2013). 
Similar to DOX, the mechanism of action of Vincristine (Vinc), an alkaloid, is not fully 
understood. Its principal mode of action is that of binding to tubulin monomers, which 
leads to a change in the dynamics of the microtubule assembly and prevention of the 
formation of bi-polar spindles, blocking mitosis at the metaphase/anaphase transition, and 
as a consequence inducing cell death. However, recent studies show that it can also act as 
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a DNA intercalator, due to its donor/acceptor O-H and N-H groups in the catherantine 
structure and –CHO group at the indoline ring nitrogen in the vindoline structure, which 
can H-bond (Figure 1.1 C) (Himes et al., 1976; Jordan, 2002; Mohammadgholi, Rabbani-
Chadegani, and Fallah, 2013; Nawaz et al., 2013). 
Cisplatin (Cisp), a platinium compound with a square planar geometry (Figure 1.1 D) and 
another chemotherapeutic drug with considerable side effects, also used for lung cancer 
treatment in combination with other chemotherapeutic drugs, was first synthesized by M. 
Peyrone in 1844. Its chemical structure was first elucidated by Alfred Werner in 1893 and 
its cytotoxic properties were discovered in the 1960s. The cytotoxic mode of action of 
Cisp is mediated by its interaction with DNA to form DNA inter-strand and intra-strand 
adducts, which leads to cell cycle arrest and apoptosis (Dasari and Tchounwou, 2014; 
Nawaz et al., 2011; Siddik, 2003). 
Early diagnostic and therapeutic follow-up protocols are of the utmost importance in lung 
cancer and the detailed mechanism of action of chemotherapeutic drugs and their specific 
effects on cancer cells need to be known in detail for a more targeted therapy, reducing 
the side effects and the drug resistance. However, medical investigations are complex, 
most of them invasive, involve many combined techniques and have certain limitations 
whether in cancer diagnostics or in therapeutic follow up.  
It is not only critical to diagnose cancer but also to assess the medical therapy and the 
interaction between the cells and drugs (Kann et al., 2015), minimising the toxicity 
produced by chemotherapeutic drugs in the surrounding environment, normal cells and 
tissues, (in the absence of targeted therapy) especially when the difference between drug 
sensitivity and resistance of tumours cells is so small. Drug resistance itself is an area of 
emerging concern, despite the progress made in therapeutic protocols (Sun, 2015). 
28 
 
1.4. Objectives and methodology: 
Both in terms of existing chemotherapeutic agents and developing protocols, there is a 
need to develop a sensitive in vitro analytical method not only to screen and track drugs 
inside cells but also to monitor the mechanism of action of and the cellular response to 
chemotherapeutic exposure. Raman micro-spectroscopy satisfies the criteria for 
sensitivity, specificity and non-invasive screening and seems to be a perfect tool for this 
application. 
The objective of this thesis is to explore the potential of Raman micro-spectroscopy for 
screening and assessment of chemotherapeutic drug pathways inside cells in vitro, their 
chemical binding signature, their effects on cancer cells and the physiological cellular 
response to clinical exposure. 
To this end, A549 human lung adenocarcinoma cells and Calu-1 human lung epidermoid 
cells, both non-small lung cells, were used in this study and DOX and ACT were 
employed, as model drugs for the validation of the Raman micro-spectroscopic method, 
as well as to further understand their detailed mechanism of action and their specific 
effects on cancer cells, for a more targeted therapy, reducing the side effects and the drug 
resistance. Raman micro-spectroscopy was coupled with Laser Scanning Confocal 
Microscopy, Atomic Force Microscopy (AFM) and Flow Cytometry and results were 
correlated to cell morphology and cell physiology.   
Chapter 2 describes the material and methods used for the study as well as the 
optimisation process in order to get the most sensitive and specific results. 
Chapter 3 is published in Analyst, 2015, 140, 5908. It describes the use of Raman micro-
spectroscopy to determine the difference between the two cancer cell lines, A549 and 
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Calu-1, compared to a normal lung cell line, BEAS2B. PCA was used to compare the 
spectral profiles between the cell lines and, coupled to LDA, to explore the optimum 
sensitivity and specificity of discrimination. To support the analysis, Raman micro-
spectroscopy was coupled with Flow Cytometry, Confocal Laser Scanning Microscopy 
and Atomic Force Microscopy. Results show that the three subcellular regions, nucleolus, 
nucleus and cytoplasm differentiate normal and cancer lines while, optimum 
discrimination between cancer cell lines is obtained according to the nucleolar region, 
highlighting the importance of this sub-nuclear area in diagnostic applications of Raman 
micro-spectroscopy. 
Chapter 4 is published in Analyst, 2015, 140, 4212, investigates the effects of 
Doxorubicin on the A549 cell line, specifically on the nucleolus compared to the nucleus. 
Raman micro-spectroscopy was coupled with Confocal Laser Scanning Microscopy to 
localise and follow the drug inside cells, showing that Raman micro-spectroscopy is able 
to track Doxorubicin at a subcellular level and to detect biomolecular changes due to drug 
exposure and physiological cellular response.  
Chapter 5 is published in J. Biophotonics 10, No. 1, 151–165 (2017) / DOI 
10.1002/jbio.201600019 and further illustrates the potential of Raman micro-
spectroscopy to elucidate drug mechanisms of action and distinguish the cellular 
resistance of two lung cancer cell lines A549 and Calu-1. Raman investigations show that 
Calu-1 cells exhibit spectroscopic signatures of both direct DNA damage due to 
intercalation of DOX in the nucleus and indirect damage due to oxidative stress in the 
cytoplasm, whereas the A549 cell line only exhibits signatures of the former mechanism 
of action. Biomarkers related to the drug mechanism of action and cellular resistance to 
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apoptosis, namely reactive oxygen species (ROS) and bcl-2 protein expression, 
respectively, were also measured and correlated to Raman spectral profiles. 
In Chapter 6, published in Anal Bioanal Chem (2017) 409:1333-1346/DOI 
10.1007/s00216-016-0065-0, Raman investigations were extended to monitor the time 
evolution of the A549 cellular responses to DOX exposure using Partial Least Squares 
Regression, in order to track the drug mechanism of action and cellular reactions for early 
and late stage exposure at subcellular level and monitor the subsequent cellular responses. 
The study demonstrates the potential of Raman micro-spectroscopy to monitor the drug 
uptake and the cellular responses at a subcellular level, but also elucidate details of the 
pharmacodynamics and drug cellular kinetics of the clinically prescribed drug. 
Chapter 7, published in J. Biophotonics 1–14 (2017) / DOI 10.1002/jbio.201700060, 
further extends the Raman investigations to track cellular uptake, signatures of chemical 
binding and subsequent cellular responses, of DOX in two lung cancer cell lines, A549 
and Calu-1. Multivariate statistical analysis was used to elucidate the spectroscopic 
signatures associated with DOX uptake and subcellular interaction. Biomarkers related to 
DNA damage and repair, and mechanisms leading to apoptosis were also measured and 
correlated to Raman spectral profiles. Results confirm the potential of Raman 
spectroscopic profiling to elucidate both drug kinetics and pharmacodynamics and 
differentiate cellular drug resistance associated with different subcellular accumulation 
rates and subsequent cellular response to DNA damage, pointing towards a better 
understanding of drug resistance for personalised targeted treatment. 
In Chapter 8, published in J. Biophotonics DOI: 10.1002/jbio.201700112, exposure of 
A549 and Calu-1 cells to the analogous anthracycline ACT was similarly monitored using 
Raman micro-spectroscopy. Multivariate data analysis, consisting of PCA and ICA, was 
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used to extract biological information contained in the Raman spectra. Results show that 
the ACT uptake and mechanism of action are similar in the two cell lines, while A549 
cells exhibit spectral signatures of resistance to apoptosis related to its higher 
chemoresistance to the anticancer drug ACT, confirming the potential of Raman micro-
spectroscopy as an in vitro analytical tool for biological analyses and in the prediction of 
drug mechanisms of action and cellular reactions.  
Chapter 9 is an accepted review (J. Biophotonics, DOI: 10.1002/jbio.201700258) which 
summarises the results of the study of the cellular uptake binding and cellular responses 
of the anthracyclic chemotherapeutic agents in the lung cancer cell lines, and also puts 
them in context with similar studies of other anticancer agents, of different mode of 
action. The study confirms the ability of Raman micro-spectroscopy to elucidate 
subcellular transport and accumulation pathways of chemotherapeutic agents, 
characterise and fingerprint their mode of action, and potentially identify cellular 
resistance. Doxorubicin and Actinomycin D, elicit similar spectroscopic signatures of 
subcellular interaction characteristic of the mode of action of intercalation. Although 
Cisplatin and Vincristine show markedly different signatures at low exposure doses, their 
signatures at higher doses show similarities to those elicited by the intercalating 
anthracyclines, confirming that anticancer agents can have different modes of action with 
different spectroscopic signatures, depending on the dose. 
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Chapter 2: Sample preparation, Materials, Methods and 
Protocol optimisation  
The following chapter outlines the materials and methods and the background to the 
experimental techniques used throughout this thesis. All experimental conditions, from 
sample preparation to all spectroscopic and microscopic methods used, were optimised 
in order to get the best data from cellular and drug investigations and to produce accurate, 
reproducible and valid scientific results. Where appropriate, further specific details are 
provided in the relevant chapters. 
2.1. Materials: 
A549 human lung adenocarcinoma cells with the alveolar type II phenotype, and BEAS-
2B normal human bronchial epithelium (ATCC® CRL-9609™), virus transformed, 
infected with a replication-defective SV40/Adenovirus 12 hybrid and cloned, were all 
obtained from ATCC (Manassas, VA, USA). Calu-1 human lung epidermoid cells were 
kindly provided by Dr. Josep Sulé-Suso, Institute for Science & Technology in Medicine, 
Keele University, Guy Hilton Research Centre UK and Cancer Centre, Royal Stoke 
University Hospital, University Hospitals of North Midlands, UK. 
Alamar blue (AB) (10X ready to use solution) and 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl tetrazolium bromide (MTT) were obtained from Sigma Aldrich, Ireland. 
SYTOX® Green Fluorescent Nucleic Acid Stains, a high-affinity nucleic acid stain that 
easily penetrates cells with compromised plasma membranes, Wheat Germ Agglutinin 
conjugates (WGA), a cell membrane glycoconjugates binder, SYTO® 14 green 
fluorescent, nucleic acid stain exhibits bright green fluorescence, Nucred® live 647 ready 
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probe a bright, far-red, cell-permeant nuclear stain and Calcein, a cell-permeant dye 
converted to a green-fluorescent Calcein after acetoxymethyl ester hydrolysis by 
intracellular esterase, were purchased from BioSciences (Ireland, suppliers for Life 
Technologies), were employed to image the nuclear compartment and cytoplasmic 
membrane of cells using Confocal Laser Fluorescence Scanning Microscopy. 
The fixation/permeabilization kit, BD Cytofix/Cytoperm (BD 554714), and FITC Mouse 
Anti-Human bcl-2 set with an IgG1 isotype control (BD 556357) was purchased from 
BioSciences, Ireland. 
γH2AX reagents, Alexa Fluor® 647 anti H2AX phospho (Ser 139) and Alexa Fluor® 647 
mouse IgG1 isotype control (ICFC), Biolegends, were supplied through Medical Supply 
Company Ltd., Ireland. 
Doxorubicin hydrochloride® (DOX) powder (Sigma Life Sciences, Ireland) was diluted 
in 1 mL sterile water to the required concentration (17.25 mM) (DOX solubility in water 
is 10 mg/mL).  
Actinomycin D (ACT) stock solution of concentration 398 µM was prepared by dilution 
of Actinomycin D® powder (2 mg) (Sigma Life Sciences, Ireland) in 4 mL sterile water 
(ACT solubility in water is 0.5 mg/mL). 
2.2. Cell culture: 
In order to determine the best medium composition for each cell line and optimise the cell 
culture process, a variety of protocols were explored in the initial stages. 
A549 and Calu-1 cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) 
(with 2 mM L-glutamine) or RPMI. Both media contained 10 % foetal bovine serum 
(FBS) and cultures were examined with or without 1 % Hepes buffer (maintained at 
constant pH, independent of CO2 amount and usually used at 5 mM to 30 mM 
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concentration) (SIGMA-ALDRICH, 2015), 1 % sodium pyruvate (as a carbon source in 
addition to glucose) (SIGMA-ALDRICH, 2015) and 1 % non-essential amino acids 
(SIGMA-ALDRICH, 2015), at 37 °C in a humidified atmosphere containing 5 % CO2. 
After comparison of the two different media (by analysing the cell aspect and 
proliferation) with and without addition of amino acids, Hepes buffer and sodium 
pyruvate, it was determined that the A549 cell line grows better in DMEM with 2 mM L-
glutamine and 10 % foetal bovine serum, whereas the Calu-1 cell line develops better in 
RPMI with 10 % foetal bovine serum. The addition of other nutrients does not improve 
the cell culture in any way. 
2.3. Cytotoxicity assays: 
The MTT test is a colorimetric assay that measures the reduction of yellow 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) by mitochondrial 
succinate dehydrogenase into purple formazan crystals insoluble in aqueous solution (Al-
Nasiry et al., 2007; Hamid et al., 2004; SIGMA-ALDRICH, 2015). 
Alamar blue (AB) is a water-soluble dye which is a sensitive oxidation-reduction 
indicator employed for in vitro quantification of the cell viability. When added to cell 
cultures, the active dye, resazurin or 7-hydroxy-10-oxidophenoxazin-10-ium-3-one 
diffuses into the cytosol and acts as an intermediate electron acceptor, allowing the 
oxidised blue non-fluorescent form to be reduced by both mitochondrial and cytosolic 
enzymes activity to the fluorescent pink one, which is easily measured by its absorption 
or fluorescence (Al-Nasiry et al., 2007; Hamid et al., 2004; Rampersad, 2012; SIGMA-
ALDRICH, 2015). 
Alamar blue (1.5 mL of AB (10× ready to use working solution)) and MTT (3 mL of 
MTT stock solution (2.5 mg/mL, 25 mg MTT/10 mL PBS)) assays, (protocol developed 
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in Nanolab, DIT, Farhane et al., 2015), were performed in 96 well plates, three of each 
were seeded with a total number of cells of 1 x 105 (4 × 103 cells /mL) for 24 hrs, 1x104 
(400 cells /mL) for 48 hrs and 5x103 (200 cells /mL) for 72 hrs. 
After 24 hrs incubation, plates were washed with phosphate buffered saline solution 
(PBS) and 100 µL of DOX diluted in 1 mL sterile water to the required concentration, 
were added to each well starting with the test concentration at 50 µM (a range from 0 μM 
(as a control) to 50 μM (0, 0.198125, 0.396025, 0.78125, 1.5625, 3.125, 6.25, 12.5, 25, 
50 μM)). ACT was added in a concentration range from 0 µM (as a control) to 50 µM (0, 
0.198125, 0.396025, 0.78125, 1.5625, 3.125, 6.25, 12.5, 25, 50 μM) for 24 hrs and from 
0 to 0.5 µM (0, 0.015625, 0.03125, 0.0625, 0.125, 0.25, 0.5 µM) for 48 and 72 hrs. 
After the appropriate incubation time in DOX or ACT, plates were washed with PBS and 
100 μL of AB/MTT solution in 30 mL of fresh medium, were added to each well. Plates 
were then incubated for 3 hrs and AB fluorescence was measured in the plate reader using 
Soft Max® Pro6.2.2 as software at 540 nm excitation and 595 nm emission. The medium 
was then removed, the plates were washed with PBS and 100 μL of DMSO (dimethyl 
sulfoxide) were added in each well then MTT absorbance was read at 570 nm. 
All cytotoxicity assays were prepared in triplicate and repeated three times and all data 
was treated using SigmaPlot 10.0 and IC50 was calculated for each time exposure (24, 48 
and 72 hrs). 
2.3. Atomic Force Microscopy (AFM): 
The atomic force microscope is a scanning probe microscope given a high resolution and 
nanoscale images of complexes matrices allowing a various application especially in cell 
imaging and manipulating living cells to single-molecule resolution (Müller and Dufrêne, 
2011). AFM works by dragging a sharpened probe over the surface and using interactions 
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between the surface and probe to build up a map of the sample topography (Baró and 
Reifenberger, 2012). An ancestor of AFM was developed by Gustav Schmalz in 1929, 
and consisted of an instrument that worked by dragging a sharpened probe over a surface. 
Due to resistance from surface features, the resolution and fidelity of the resulting image 
was suspect (Wallace, 2012). 
In AFM, the force of the interaction between the probe and the sample is measured by a 
force transducer, the cantilever on which the probe is mounted and a feedback control 
system is used to maintain a desired force between the probe and the sample (Kuznetsov 
and McPherson, 2011). 
       
Figure 2.1: Asylum MFP-3D-BIO Atomic Force Microscope (DIT-FOCAS, 2015). 
The air dried samples on CaF2 substrates were profiled using a MFP-3D BIO AFM 
(Asylum Research) (Figure 2.1). The cantilevers used were Olympus silicon AC240. Tips 
were 160 nm long and had a typical resonant frequency of 70 kHz. The AFM was operated 
in AC or vibrating mode (the signal driving the feedback is the amplitude of the time 
varying deflection, rather than the quasistatic deflection, as used in contact mode) in order 
to minimize tip/sample interaction. Typical free air amplitudes were ~200mV and a high 
amplitude set-point relative to the set-point was maintained to minimize sample damage. 
45 
 
The images obtained, from 5 to 10 cells per cell line, contained 1024 pixels per scan line 
and only one representative image of typical cell for each cell line is shown. 
2.4. Flow Cytometry 
Flow cytometry is finding increasing uses in clinic and pathology. Flow cytometry 
measures optical and fluorescence characteristics of single cells, based on the light 
scattering and emission properties of the cells, giving information on cell cycle, and 
physical properties such as size and internal complexity (Darzynkiewicz and Zhao, 2001; 
Macey, 2007). 
Cells flow past the illumination of a light source (Figure 2.2), whereupon they scatter 
laser light, or, if intrinsically fluorescent or tagged with a fluorescent marker, they absorb 
and emit the light energy at higher wavelengths (Brown and Wittwer, 2000). The scattered 
and fluorescent light is collected by appropriately positioned lenses. A combination of 
beam splitters and filters steers the scattered and fluorescent light to the appropriate 
detectors which produce electronic signals proportional to the optical ones 
(BDBiosciences, 2000). No fluorescent labels were used for this study and only the 
cellular light scattering was measured. The light scattering depends on the physical 
properties of the particle, or in this case, cells, namely their size and surface area 
(Forward-scattered light (FSC)) and granularity and internal complexity (Side-scattered 
light (SSC)) (Marina, Sanders, and Mourant, 2012).    
Cells were cultured in T75 flasks over 48 hrs then trypsinised and centrifuged in 10 mL 
fresh medium at 4 °C and 1000 rpm for 5 min. After this, the cells were re-suspended 
with 5 mL PBS and only 2 mL was used for analysis. Samples were prepared in parallel 
and the two cell lines were analysed separately. A total number of 2x 104 cells was 
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analysed for each sample without any dyes. The experiments were conducted in triplicate 
(three independent experiments). 
 
Figure 2.2: Accuri C6 Flow Cytometer and hydrodynamic focusing of the sample 
through the laser (BDBiosciences, 2013, 2000). 
For bcl-2 protein expression, cells (3x 104/flasks) were cultured in T25 flasks over 24 hrs, 
and then exposed to a DOX dose corresponding to the inhibitory concentration, IC50, 
adjusted to the cell number, determined by cytotoxicity assays for each time point (from 
2 hrs to 72 hrs) and each cell line. After each incubation period, cells were trypsinised 
and centrifuged in 5 mL fresh medium at 4 °C and 1100 rpm for 5 min and they were then 
re-suspended in 1 mL Ice Cold Dulbecco's Phosphate-Buffered Saline (DPBS) buffer and 
centrifuged at 4 °C and 2500 rpm for 5 min. 
Cells were re-suspended in 750 µL ice cold DPBS buffer and transferred to Eppendorf 
tubes to which 250 µL of fixation buffer (ready to use solution which enables the fixation 
and permeabilisation of cells) were added. After 30 min incubation at 4 ºC, the fixed cells 
were washed twice in perm/wash buffer (1X solution obtained by dilution of 10X stock 
solution in distilled water), centrifuged (2500 Rpm for 5 min at 4 ºC) and then gently re-
suspended in 50 µL perm/wash buffer, after which 20 µL of the antibody (ready to use 
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clone bcl-2 conjugated with FITC) were added and the cells were incubated for 60 min 
in the dark at 4 ºC. The cells were then washed twice in perm/wash buffer, centrifuged 
(2500 Rpm for 5 min at 4 ºC) to remove unbound antibody and finally re-suspended in 1 
mL stain buffer (1X PBS with 2 % heat inactivated FBS and 0.09 % Na Azide). 
For γH2AX expression, cells (106/flask) were cultured in T25 flasks over 24 hrs, and then 
exposed to a DOX dose corresponding to the inhibitory concentration, IC50, adjusted to 
the cell number, determined by cytotoxicity assays for each time point (from 2 hrs to 72 
hrs) and each cell line. 
After each incubation period, cells were trypsinised and centrifuged in 5 mL fresh 
medium at 4 °C and 1100 rpm for 5 min, then were re-suspended with 1 mL PBS, 
transferred to an Eppendorf tube and centrifuged at 400 g for 5 min at 4 ºC. Cells were 
re-suspended in 200 µL of 2 % v/v formalin in PBS and incubated for 10 min. If not used 
immediately, cells can be kept in 1 mL ice-cold ethanol 70 % and samples and stored at 
-20 ºC for up to two weeks or overnight at 4 ºC. Cells were then re-suspended in 500 µL 
Triton X-100 0.25 % v/v in PBS and incubated at Room Temperature (RT) for 5 min or 
30 min at 4 ºC, after which cells were centrifuged at 400 g for 5 min at RT and re-suspend 
in 200 µL Bovine serum albumin (BSA) solution (2mg/100mL) and incubated at RT for 
30 min. After centrifugation at 400 g for 5 min at RT, cells were re-suspended in 150 µL 
antibody solution, Alexa Fluor® 647 anti H2AX phospho (Ser 139), diluted 1:500 (10 µL 
primary antibody in 5 mL blocking solution) in BSA solution and incubated at RT for 2 
hrs or overnight at 4 ºC. The cells were then washed thrice in PBS and finally re-
suspended in 1mL BSA solution. 
All Flow cytometry analysis was performed using a BD Biosciences Accuri C6 Flow 
Cytometer (10,000 events were recorded, settings are run with limits, fluidics slow, 
agitate before analysis, wash before and between samples and FL1 for bcl-2 analysis, FL2 
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for DOX and FL3 for γH2AX analysis) (Becton Dickinson, Oxford, UK) (Figure 2.2). 
The Accuri Flow Cytometry software was used for the analysis of Flow Cytometry 
samples and data processing, consisting of gating to eliminate dead cells and analysis of 
mean fluorescence. 
2.5. Confocal Laser Scanning Fluorescence Microscopy (CLSM) 
Confocal Laser Scanning Microscopy has become an invaluable non–invasive imaging 
technique in biological and medical fields for the investigation of cell morphology and 
physiological processes, using fluorophores that specifically target and identify 
subcellular structures and are excited by light provided by a laser at a specific wavelength. 
Its basic concept was originally developed by Marvin Minsky in the mid-1950s (Claxton, 
Fellers, and Davidson, 2006; Lange-Asschenfeldt et al., 2012). 
The light emitted by the laser system (excitation source) passes through an objective, a 
dichroic mirror, onto the sample. A pinhole aperture is used to eliminate the scattered 
light, the emitted fluorescence is collected only from the focal point and images of the 
scanned sample can then be reconstructed point by point (Figure 2.3) (Nwaneshiudu et 
al., 2012). 
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      A.       B. 
    
Figure 2.3: A. Zeiss LSM 510 Confocal Laser Scanning Microscope (DIT-FOCAS, 
2015) and B. Schematic illustrating the confocal principle (Zeiss-Training, 2011). 
In this study, samples were prepared on uncoated glass bottom Petri dishes (MatTek 
Corporation, USA). Approximately 104 cells were allowed to attach for two hrs, then 
covered with cell culture medium.  
After incubation, the medium was removed and cells were washed repeatedly (two or 
three times) with PBS and 1 mL of Calcien solution per Petri dish (50 µL of Calcien in 2 
mL medium (Calcien was reconstructed with 250 µL Dimethyl sulfoxide, DMSO to a 
concentration of 5 mM)) were added and samples were then incubated for 20 min. The, 
medium was then removed, samples were washed with PBS and 2 mL of Nucred® ready 
to use solution (2 drops of Nucred® stock solution into 1 mL of media) were added. 
Samples were then incubated for 15-30 min, rinsed twice with sterile PBS and cells were 
imaged in 0.9 % sodium chloride solution. 
Excitation and emission wavelengths were, respectively, 488/507 nm for Calcein and 
633/690 nm for Nucred®. However, this combination of stains did not work well, due to 
the fact that Calcein stains the whole cell. Thus, Sytox® green nucleic acid stain and 
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Wheat Germ Agglutinin conjugates were employed and reasonably good images were 
obtained. 
After incubation, the medium was removed and samples were rinsed twice with sterile 
PBS and fixed in formalin (4 %, 15 min). After fixation, samples were washed with 
Hank’s balanced salt solution (HBSS) and 7.5 µL of WGA solution (WGA of 1 mg/mL 
stock solution (prepared by dissolving 5 mg lyophilised WGA in 5 mL PBS) per 1 mL 
HBSS) was first added and cells were incubated for 20 min and then washed with HBSS. 
Sytox® green nucleic acid stain (2 µL of stock solution at 5 mM per 1 mL of HBSS) was 
thereafter added, cells were incubated for 30 min, washed with HBSS and then imaged in 
HBSS. 
Confocal Laser Scanning microscopic images were recorded using an inverted Zeiss LSM 
510 confocal laser scanning microscope equipped with a x60 oil immersion objective. 
(Figure 2.3) Excitation wavelengths used were 488 nm for Sytox® green nucleic acid stain 
(emission wavelength 523 nm) and 633/647 nm excitation/emission for WGA, using a 
band pass (BP) filter (detect only light between 505 and 530 nm) for the green dye and a 
long pass filter (>640 nm) and the channel ChS for the red dye. 
For DOX exposure, the same amount of cells was used in Petri dishes and, after 24 hrs 
incubation, the medium was removed and samples were rinsed twice with sterile PBS. 
New medium containing DOX, corresponding to the IC50 concentration (mean inhibitory 
concentration) which is the concentration that inhibits 50 % of cells (Neubig et al., 2003), 
was added and cells were further incubated for 2, 6, 12 , 24, 48 and 72 hrs. At the end, 
cells were washed twice with sterile PBS, fixed in formalin (4 %, 15 min) and kept in 
PBS for imaging. Control samples without exposure to DOX were also prepared in 
parallel, and incubated for the same period.  
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Confocal laser scanning fluorescence microscopic images were recorded using an 
inverted Zeiss LSM 510 confocal laser scanning microscope equipped with a x60 oil 
immersion objective. Doxorubicin fluorescence was excited with an argon ion laser at 
488 nm (Main Dichroic Beam Splitter HFT UV 488/543/633 nm), and the emission was 
collected at 530 nm (BP filter 505-530 nm).  
2.6. Raman micro-spectroscopy: 
Raman micro-spectroscopy is a non-invasive analytical tool which is increasingly being 
explored for its potential in clinical applications and especially in chemotherapeutic 
development. 
Basically, Raman is an optical spectroscopic technique, based on the transitions between 
vibrational levels of electronic states. In more detail, it is an inelastic scattering technique 
involving coupling of the incident photons or electromagnetic radiation with the 
molecular vibrations. When the frequency of the scattered light is less than the incident 
one due to the fact that the molecule absorbs energy from the incident photon and elevates 
itself from a lower energy state to an excited vibrational state, this is called Stokes Raman 
scattering. Conversely, anti-Stokes scattering occurs when the scattered photons are 
higher in energy than the incident photons, as a result of annihilation of a molecular 
vibration (Figure 2.4) (Tu and Chang, 2012).  
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Figure 2.4: Jablonski diagram, schematic representation of the energy transition in 
Raman micro-spectroscopy with h: Plank’s constant and ν0: excitation frequency ν: bond 
vibration frequency. 
The polarization P of the material depends on the polarizability, , of the material and on 
the electric field E (0) of the incident light at frequency 0: 
P () = ( )E()  
The polarisability () changes as a function of molecular vibration, 
k
, such that 
 

k
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k
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where R is the displacement of the atoms about their equilibrium position. k accounts 
for a random phase of the material vibrations. 
Thus, the polarisation can be written in the form: 
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Using the trigonometric relationship: 
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It can be seen that the polarisation now has the form: 
P = P (
0
) + P (
0
 - 
k
) + P (
0
 + 
k
) 
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An oscillating polarisation will re-emit light at its oscillation frequency, and thus light is 
reradiated at frequencies of 
0
 and 
0
  
k
.  
The first of these terms is the Rayleigh scattering, and the second is the Raman scattering. 
An increase in the frequency results in anti-Stokes Raman scattering, whereas a reduction 
in frequency results in Stokes Raman scattering. The efficiency of Raman-scattering of 
light depends on the Raman activity. If there is no change in the polarisability for a given 
vibrational transition, then the transition is not Raman-active. In three dimensions, change 
in the polarisability tensor determines the activity, and the vibration is Raman-active if 
any one of the polarisability tensor components is changed during the vibration (Ayars et 
al., 2001). 
As, at room temperature, it is easier to generate a vibrational quatum that do annihilate 
one, the Raman spectrum is commonly recorded as the Stokes line intensity as a function 
of wavenumber or Raman shift. Since the vibrations are characteristic of the molecular 
structure, the Raman spectrum provides a spectroscopic “fingerprint” of the material 
(Byrne et al., 2014). The laser (coloured in green in Figure 2.5) illuminates a sample 
through a microscope objective, and then the collected Raman-shifted light (coloured in 
red in Figure 2.5) is directed to a diffraction grating to disperse the Raman scattered beam 
into specific frequencies which are subsequently focused on an array of detectors, such 
as a high sensitivity charge coupled device (CCD). (Figure 2.5) The spectrometer is 
equipped with a notch or edge filter to eliminate the elastically scattered photons 
(Rayleigh photons) (Downes and Elfick, 2010; Notingher, 2007).  
In addition to the basic Raman Effect or spontaneous Raman, various phenomena were 
discovered over the last few years, among them Resonance Raman (RR), occurring when 
the laser frequency is close to an electronic transition in the material, surface enhanced 
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Raman scattering (SERS), which uses a nanoscale noble metal surface to enhance the 
signal, coherent anti-Stokes Raman scattering (CARS), involving two coherent lasers, 
and Fourier Transform Raman (FT-Raman) using the Michelson interferometer (Cîntǎ 
Pînzaru et al., 2004; Gala and Chauhan, 2015). 
Due to its non-invasive analytical capability, Raman micro-spectroscopy has seen an 
increase in applications in various fields, from environmental sciences, pharmaceutical 
development and drug discovery, to research and diagnostics (Paudel, Raijada, and 
Rantanen, 2015).  
 
Figure 2.5: Schematic of Raman spectrometer (reproduced with permission from G. 
Calado, PhD Transfer Report, Dublin Institute of Technology, 2017). 
For this work, ~5000 cells were seeded and incubated on CaF2 windows (Crystan Ltd, 
UK) for 48 hrs in order to achieve a final number of approximately 104 cells. Medium 
was removed and samples were rinsed twice with sterile PBS then fixed using formalin 
(4 %, 15 min). In order to optimise sample preparation protocols, spectra were recorded 
in immersion and after air drying in ambient atmosphere.  
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A Horiba Jobin-Yvon LabRAM HR800 spectrometer (Figure 2.6) with a 785 nm, 300 
mW diode laser as source, Peltier cooled 16-bit CCD (charge-coupled device), 300 
lines/mm grating and 100 μm confocal hole, was used. Spectra were acquired from three 
cell locations: cytoplasmic, nuclear and nucleolar, with an acquisition time of 30 s two 
times each, in the range from 400 cm-1 to 1800 cm-1 with an x100 objective (LCPlanN, 
Olympus N.A. 085) for dry samples and x100 objective (LUMPlanF1, Olympus N.A. 1) 
for immersed ones, to finally produce a data set of 90 points per cell location for each cell 
line (optimisation part) and 30 points per cell location for each cell line for the study.  
 
Figure 2.6: Dual Raman spectrometer, FOCAS Research Institute (DIT-FOCAS, 2015). 
As the formalin fixation process has been shown to have a negligible effect on the Raman 
spectra, and to best preserve the biochemical integrity of the cells compared to other 
fixation techniques (alcohol, desiccation, air drying, acetone, mixture of chloroform, 
methanol and acetic acid) (Draux et al., 2010; Kann et al., 2015; Mariani et al., 2009; 
Meade et al., 2010), this process was used and cells were fixed on CaF2 windows. To 
optimise the experimental conditions for Raman spectroscopic profiling, measurement in 
immersion was compared to measurement of dried samples in air. Measurement of tissue 
samples in immersion has been demonstrated to minimise background due to stray 
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scattered light (Bonnier et al., 2011). Spectra from nucleolus, nucleus and cytoplasm were 
recorded from the two cell lines, A549 and Calu-1, for both immersion and dry conditions. 
After data pre-processing, the average spectra were compared and principal component 
analysis (PCA), an unsupervised multivariate analysis which allows the reduction of the 
number of variables in a multidimensional dataset, was employed as supervised 
multivariate analysis approach to analyse the data from A549 and Calu-1 cells 
independently, and then to compare the two cell lines. 
 
Figure 2.7: Mean spectra of A. Nucleolus, B. Nucleus and C. Cytoplasm of A549 cell 
line. Highlighted regions correspond to DNA/RNA and lipids features. 
Figure 2.7 shows the three average spectra corresponding to each cellular region for A549 
cells. Visibly, it can be seen that the mean spectra of the nucleolar, nuclear and 
cytoplasmic regions are somewhat different, and discriminating peaks (indicated by 
shaded regions in Figure 2.4) at, for example, 1580, 1094 , 833 and 795 cm-1 can be 
allocated to nucleic acids which correspond respectively to vibrations of the DNA Base 
adenine and guanine, DNA PO2
- symmetric stretching, ribose phosphate and DNA 
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backbone O-P-O stretching (Oshima et al., 2010; Pijanka et al., 2013; Zhang et al., 2008), 
while others at ~1300 cm-1 (CH deformation) are associated with lipid compounds which 
are more intense in the cytoplasmic than the nuclear region. The DNA bands at 1095 cm-
1 and 833 cm-1 indicate that the DNA is predominantly in the B form (Notingher et al., 
2002). 
A. 
 
B. 
 
Figure 2.8: PCA nucleolus, nucleus and cytoplasm in immersion conditions A. A549 cell 
line and B. Calu-1 cell line. 
Cytoplasm    Nuclear     Nucleolar      
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Figure 2.8 shows that the three cellular regions are well differentiated by PCA and the 
same discriminants peaks were found in loading 1 of PCA of the nucleolus, nucleus and 
cytoplasm,). (For all PCA Figures, the loadings are off set for clarity, the dashed 
horizontal line indicating zero loading).  
Furthermore, Loading 2 (Figure 2.8), corresponding to PC2, which separates the 
nucleolar and nuclear regions, exhibits discriminating negative peaks related to nucleoli 
at 782 and 1336 cm-1 (Uracil, Cytosine and Thymine) corresponding to RNA (Hobro et 
al., 2007), 1242 cm-1 (Amide II), 1480 cm-1 (Guanine, Adenine) and 1578 cm-1 (proteins) 
due to the contribution of surrounded membrane, as well as positive ones at 728 
(Adenine), 830 cm-1 (O-P-O asymmetric stretching) and 1095 cm-1 (DNA PO2
- symmetric 
stretching), corresponding to the nuclear region, which is the primary location of DNA, 
while the nucleolar regions contain RNA and small quantities of DNA (Bonnier and 
Byrne, 2012; Movasaghi, Rehman, and Rehman, 2007).  
According to Figure 2.9, which shows the PCA of A549 and Calu-1 measured both in 
immersion and dry, it can be seen that there is differentiation of the spectra of nucleolar, 
nuclear and cytoplasmic regions under both experimental conditions, clearly illustrating 
that Raman is able to differentiate between the three cellular compartments.  
The important discrimination percentage is due to PC1 and, according to the 
corresponding loading (loading 1), the discriminant features derive from DNA, 795 cm-1 
and 1095 cm-1, related to DNA form and DNA PO2
- symmetric stretching, and lipids at 
1300 (CH2 stretching) and 1440 cm
-1 (CH stretching). 
Some studies have shown that the air drying step causes spectral distortions and 
deviations giving different results (Draux et al., 2010). In Figure 2.9, however, it is 
noticeable that there is similar spectral distribution of nucleolar, nuclear and cytoplasmic 
regions for both cells lines, and furthermore that the features in loading 1 corresponding 
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to DNA (negative ones) and lipids (positive ones) are the same for both cell lines, 
confirming that differentiation is based on cellular regions rather than on the basis of 
sample preparation conditions. 
A.                                                                
 
B. 
 
Figure 2.9: PCA immersion and dry A. A549 and B. Calu-1, (a) nucleolus, (b) nucleus 
and (c) cytoplasm. 
Cytoplasm    Nuclear      Nucleolar     immersion conditions 
Cytoplasm    Nuclear      Nucleolar      dry conditions 
In addition, PC2 clearly separates the two dry and immersion conditions, but the 
corresponding loading 2 is noisy and symmetric which means that the difference is 
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derived only from background due to the fact that different experimental conditions were 
employed.  
Moreover, it has been demonstrated that recording spectra in immersion conditions 
improves the signal to background ratio in Raman spectra (Bonnier et al., 2011). 
However, using a well-adapted pre-processing protocol for background subtraction can 
similarly improve the signal to background ratio (Beier and Berger, 2009; Bonnier and 
Byrne, 2012; Cadusch et al., 2013). Thus, seeing that immersion and dry conditions give 
comparable results, and due to the fact that immersion presents the inconvenience of 
contaminations (dust, bacteria…) and samples cannot be used for a long time in 
comparison to dry ones, dry conditions will be used for the rest of the experiments. 
For DOX experiments, cells (~ 1x 104/window) were seeded and incubated on CaF2 
windows (Crystan Ltd, UK) for 24 hrs for both control and exposure to DOX. The 
medium was then removed and samples were rinsed twice with sterile PBS and covered 
with DOX at each corresponding IC50 inhibitory concentration, adjusted to the cell 
number, for exposed cells and fresh medium for unexposed controls. After each 
incubation period, 2, 6, 12, 24, 48 and 72 hrs, cells were washed twice with sterile PBS 
and fixed in formalin (4 %, 15 min). 
Spectra were acquired in same experimental conditions as the optimisation part, in dry 
conditions, from three cell locations: cytoplasm, nucleus and nucleolus, visible under 
white light illumination. A final data set of 30 points per cell location for each time point, 
2, 6, 12, 24, 48 and 72 hrs was produced after DOX exposure and for control cells, for 
each cell line, amounting to a total of over 210 cells per cell line, corresponding to a total 
data set of 1260 spectra. 
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For ACT experiments, the same number of cells (~ 1x 104/window) as DOX experiments 
were seeded and incubated on CaF2 windows for 24 hrs for both control and exposure to 
ACT. The medium was then removed and samples were rinsed twice with sterile PBS and 
covered with ACT at each corresponding IC50 for exposed cells and fresh medium for 
unexposed controls. After each incubation period, 48 and 72 hrs, exposed and unexposed 
control cells were washed twice with sterile PBS and fixed in formalin (4 %, 15 min). 
Spectra were acquired using the same experimental conditions from three cell locations: 
cytoplasm, nucleus and nucleolus, identifiable under white light illumination. The final 
data set of a total of 720 spectra was thus derived from 30 cells, each measured in the 
nucleolus, nucleus and cytoplasm, for each exposure time (2) and control (2), for each 
cell line (2). 
For all Raman experiments, spectral pre-processing and analysis were performed in 
Matlab2013 using algorithms developed in house. Prior to data analysis, consisting of 
PCA, LDA (Linear Discriminant Analysis), ICA (Independent Component Analysis) and 
PLSR (Partial least Square Regression), background was subtracted using a NCLS (non-
negatively constrained least squares) algorithm using a CaF2 spectrum and spectra were 
smoothed (Savitsky-Golay filter 3th order, 11 points), baseline corrected (fifth order 
polynomial) and vector normalised. 
PCA, one of the most popular and oldest multivariate analysis technique (Abdi and 
Williams, 2010), allows the reduction of the number of variables in a multidimensional 
dataset, although it retains most of the variation within the dataset. It represents the 
spectra in data groupings of similar variability, allowing the identification and 
differentiation of different spectral groups. 
In order to examine the relationships among a set of correlated variables, the original set 
of variables is transformed into a new set of uncorrelated variables called principal 
62 
 
components. These new variables are linear combinations of the original variables and 
are derived in decreasing order of importance (Chatfield and Collins, 1980). 
Mathematically speaking, a data set is represented in terms of an m × n matrix, X, in 
which the n columns are the samples or observations and the m rows are the variables. 
This matrix is linearly transformed into another matrix Y, also of dimension m × n, so 
that for some m × m matrix, P, Y = PX. This equation represents a change of basis and 
the rows of P are considered to be the row vectors p1, p2, . . . , pm, and the columns of X 
to be the column vectors x1, x2, . . . , xn, such that it can then can be interpreted in the 
following way, where P become the principal component directions (Richardson, 2009): 
 
The loadings of the PCs represent the variance for each variable (wavenumber) for a given 
PC, and analysis of the loadings can give information about the source of the variability 
inside a dataset, derived from variations in the molecular components contributing to the 
spectra. It has been demonstrated that the PC loadings can be most simply understood 
when analysis of datasets is undertaken in a pairwise fashion (Bonnier and Byrne, 2012). 
PCA does not cluster the data, per se, in the same manner as for example Hierarchical or 
K-Means Cluster Analysis, whereby differential distribution of the data according to 
negative or positive loadings associates specific spectral features with that dataset. PCA 
was employed as an unsupervised multivariate approach to analyse data and the effects 
of ACT in each cell localisation by identification and differentiation of different spectral 
groups using scatter plots and loadings showing a representation of spectral features 
responsible for the variance between data groups according to wavenumbers. The order 
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of the PCs denotes their importance to the dataset and PC1 describes the highest amount 
of variation (Bonnier and Byrne, 2012; Brauchle and Schenke-Layland, 2013; Pavićević 
et al., 2012). 
ICA an unsupervised statistical technique, employed as an extension to PCA, which is 
able to identify latent variables called independent components in each data set separately. 
In the case of Raman micro spectroscopy, ICA can be used to identify spectral 
contributions such as those from a substrate, which can then be removed or studied in 
their own, using the same number of ICs (three components) as PCs, as estimated by 
PCA, explaining the majority of variance, and only the first component for each cellular 
compartment was plotted (Farhane, Bonnier, Maher, et al., 2017; Hyvärinen and Oja, 
2000; Lee, 1998).  
LDA was proposed by R. Fischer in 1936 (Xanthopoulos, Pardalos, and Trafalis, 2013) 
and is a well-known data analysis technique for feature extraction and dimension 
reduction, used mostly after dimension reduction by PCA (Ye, Janardan, and Li, 2005). 
In this study, LDA performed on each of the datasets scores independently and a 10-fold 
cross validation was performed to produce confusion matrices (Gutman et al., 2013; 
Riedl, Esslinger, and Fauhl-Hassek). LDA accuracy was calculated using a 10-fold cross 
validation on increasing numbers of latent variables (PC scores). The classification which 
resulted in the maximum accuracy while keeping the number of latent variables to a 
minimum was chosen for all successive models. 
PLSR, is a statistical regression technique, introduced in the early 1980s (Helland, 2004), 
which reduces the dimensionality of the data and correlates information in an X data set 
matrix to the matrix of a Y data according to the equation Y= XB + E, where B is a matrix 
of regression coefficients and E is the regression residual. In this work, the X-matrix is 
represented by the Raman spectra and the Y-matrix is consisted of values of the DOX 
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concentration inside the cells, and the time evolution (Keating et al., 2015; Muratore, 
2013; Nawaz et al., 2011). 
The percentage of variance explained as a function of the number of components was 
calculated using 10-fold cross validation. The regression coefficients obtained by PLSR 
of Raman data regressed against time were plotted and analysed. As a function of 
frequency, the co-efficients illustrate the spectral features which are influenced by the 
intracellular interaction of the chemotherapeutic drug and the resulting metabolic changes 
(Farhane, Bonnier, Howe, et al., 2017). 
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Abstract:  
Raman micro-spectroscopy has attracted considerable attention over the last few years to 
explore its possible clinical applications as a non-invasive powerful label-free in vitro 
screening tool in cancer diagnosis and monitoring, subcellular analysis of biochemical 
processes, drug uptake, mode of action and mechanisms of interaction as well as toxicity 
of, for example, chemotherapeutic agents. 
However, in order to evaluate accurately the potential of Raman micro-spectroscopy for 
such applications it is essential to optimise measurement and data processing protocols 
associated with subcellular analysis. To this end, in vitro differentiation of cell lines is a 
basic proof of concept for the potential of the technique, and although many studies have 
indicated successful differentiation based on Raman micro-spectroscopy, it is important, 
as the measurement and processing techniques are improved, to establish the biochemical 
and subcellular basis of that discrimination.  
In this study, Raman micro-spectroscopy is used to compare and differentiate normal and 
cancer cells from human lung origin, A549 adenocarcinoma cell line, Calu-1 epidermoid 
74 
 
non-small-cell and BEAS-2B normal immortalized bronchial epithelium cell line. Spectra 
were taken from the three subcellular compartments, cytoplasm, nucleus and nucleolus 
and Principal Component Analysis was used to compare the spectral profiles between the 
cell lines and, coupled to Linear Discriminant Analysis, to explore the optimum 
sensitivity and specificity of discrimination. To support the analysis, Raman micro-
spectroscopy was coupled with Flow Cytometry, Confocal Laser Scanning Microscopy 
and Atomic Force Microscopy.  
While all subcellular regions can be employed to differentiate the normal and cancer cell 
lines, optimum discrimination sensitivity and specificity is achieved using the spectra 
from the nucleolar region alone. Notably, only the nucleolar spectral profiles differentiate 
the two cancer cell lines. The results point to the importance of the nucleolar regions in 
diagnostic applications of Raman microscopy as well as further applications in 
subcellular analysis of cytological processes. 
 
Keywords: Raman micro-spectroscopy, cell nucleolus, cancer and normal cells, Flow 
Cytometry, Confocal Laser Scanning Microscopy, Atomic Force Microscopy. 
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3.1. Introduction: 
The recent decades have seen a notable expansion in exploration of biomedical 
applications of Raman micro-spectroscopy (Diem et al., 2012; Downes and Elfick, 2010; 
Krafft and Popp, 2015), due to the fact that it is a powerful, rapid and non-destructive 
label-free technique for studying biological systems such as tissue and cells (J Chan et 
al., 2008; Movasaghi, Rehman, and Rehman, 2007). 
Raman micro-spectroscopy can detect chemical, biological and physical changes of 
biomolecules, and the specific information contained in the cellular Raman spectrum 
provides a molecular fingerprint of the sample of interest, which allows Raman micro-
spectroscopy to differentiate between normal and abnormal cells and tissues, indicating 
possible applications for example in cancer research (J Chan et al., 2008; Kong et al., 
2015). Indeed, Raman micro-spectroscopy has been shown to provide high specificity 
and sensitivity, even for pre-cancer detection (Eikje, Aizawa, and Ozaki, 2005; Kallaway 
et al., 2013; Kendall et al., 2010; Rashid et al., 2014), and is non-invasive and potentially 
automatable, thus avoiding the disadvantages of many biomedical techniques used to 
identify and sort cancerous cells from normal ones, which exhibit low specificity and are 
destructive or perturb the cellular biology (J W Chan et al., 2006; Huser and Chan, 2015; 
Knipfer et al., 2014). 
As an optical microscopic technique, Raman micro-spectroscopy also has the potential to 
probe the molecular structure on a cellular and subcellular level (Bonnier et al., 2010; 
Miljkovic et al., 2010). In comparison to Infrared absorption spectroscopy; Raman micro-
spectroscopy offers the possibility to study biological matrices in an aqueous environment 
due to the weak contribution from water (Dorney et al., 2012; Notingher et al., 2002). 
Thus, the potential applications extend beyond disease diagnostics to the label free in 
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vitro screening of cytological processes, such as drug or nanoparticle uptake and 
mechanisms of interaction, and toxicology (Dorney et al., 2012; Ling et al., 2002; 
Matthäus et al., 2007; Romero et al., 2013). There has been a wide range of studies to 
date demonstrating the potential of Raman micro-spectroscopy to map live and fixed cells 
with subcellular resolution (Caponi et al., 2013; Draux et al., 2010; Krafft et al., 2005; 
Meade et al., 2010; Palonpon, Sodeoka, and Fujita, 2013), profile the distribution of 
anticancer agents (El-Mashtoly et al., 2014; Farhane et al., 2015; Feofanov et al., 2000; 
Nawaz et al., 2013; Wojcik et al., 2015) and nanoparticles in cells (Ahlinder et al., 2013; 
Bräutigam et al., 2014; Dorney et al., 2012) and monitor subcellular processes (Klein et 
al., 2012) and toxicological responses (Boyles et al., 2015; Casey et al., 2008; Knief et 
al., 2009; Wadhwa et al., 2011). 
Fundamental to the development of applications of Raman micro-spectroscopy for 
disease diagnostics as well as analysis of cytological processes is an understanding of the 
variability of the spectral signatures across the subcellular environment, their potential 
for differentiation of cell phenotype or diseased state, and their sensitivity to external 
perturbation, such as viral infection, radiation damage, or chemical stress due to, for 
example, toxic or chemotherapeutic agents. It is clear that the signatures for the 
cytoplasm, nucleus and nucleoli are distinct and differentiable (Bonnier and Byrne, 2012), 
but it is not clear which region has the best diagnostic potential or sensitivity to external 
insult. The current study examines the subcellular basis of differentiation of human cell 
lines in vitro, both normal and cancerous, using Raman micro-spectroscopy. 
Numerous studies over the last few years have investigated the capability of Raman 
micro-spectroscopy to differentiate between cancerous cell lines; Crow et al. (Crow et al., 
2005) used human prostate cancer cell lines, Pijanka et al. investigated lung cancer cell 
lines (Pijanka et al., 2013), and Chen et al. explored neoplastic hematopoietic cells (J W 
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Chan et al., 2006), while Krishna et al. were interested in mixed cell populations of human 
promyelocytic leukemia and breast cancer (Krishna et al., 2005). All those studies 
demonstrated that Raman micro-spectroscopy, coupled with multivariate statistics, is able 
to distinguish between different cell lines with a high specificity and sensitivity. However, 
the basis of the differentiation was not elucidated in terms of the subcellular regions. 
In this study, Raman profiles of three cell lines from same anatomical origin, the human 
lung, were compared and analysed. The first part is the investigation of the differentiation 
of a normal human bronchial epithelium cell line, BEAS-2B, from the adenocarcinoma 
human alveolar basal epithelial cell line, A549, and the non-small-cell lung cancer cell 
line Calu-1. Thereafter, the two cancer cell lines are compared to each other, using Raman 
micro-spectroscopy. The morphological and topographical characteristics of the two 
human lung cancer cell lines A549 and Calu-1, using Flow Cytometry, CLSM and AFM 
were also analysed and correlated to their Raman spectroscopic features.  
In all cases, spectral profiles of the cytoplasm, nucleus and nucleoli were independently 
acquired and analysed, and the study highlights the importance of the nucleoli in potential 
diagnostic and bioanalytical applications. 
3.2. Materials and Methods 
3.2.1. Materials: 
A549 human lung adenocarcinoma cells with the alveolar type II phenotype, and BEAS-
2B normal human bronchial epithelium (ATCC® CRL-9609™), virus transformed, 
infected with a replication-defective SV40/Adenovirus 12 hybrid and cloned, were all 
obtained from ATCC (Manassas, VA, USA). Calu-1 human lung epidermoid cells were 
obtained from the European Collection of Cell Cultures. 
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SYTOX® Green Fluorescent Nucleic Acid Stains and Wheat Germ Agglutinin conjugates 
(WGA), a cell membrane glycoconjugates binder, purchased from BioSciences (Ireland, 
suppliers for Life Technologies), were employed to image the nuclear compartment and 
cytoplasmic membrane of cells using Confocal Laser Scanning Microscopy. 
3.2.2. Cell culture: 
A549 and BEAS-2B cells were cultured in DMEM (with 2 mM L-glutamine) and Calu-
1 in RPMI, all with 10% foetal bovine serum (FBS) at 37°C in an humidified atmosphere 
containing 5% CO2 and cells were split every two days to maintain ~60% confluence. 
3.2.3. Sample preparation and measurement protocols: 
3.2.3.1. Raman micro-spectroscopy: 
Cells~5000 were seeded and incubated on CaF2 windows (Crystan Ltd, UK) for 48 hrs in 
order to achieve a final number of approximately 104 cells. Medium was removed and 
samples were rinsed twice with sterile PBS then fixed using formalin (4 %, 15 min) and 
spectra were recorded after air drying in ambient atmosphere.  
A Horiba Jobin-Yvon LabRAM HR800 spectrometer with a 785 nm, 300 mW diode laser 
as source, Peltier cooled 16-bit CCD, 300 lines/mm grating and 100 μm confocal hole, 
was used for this work. Spectra were acquired from the three cell locations: cytoplasm, 
nuclear and nucleolar in the range from 400 cm-1 to 1800 cm-1 with an x100 objective 
(LCPlanN, Olympus) for 30 s two times, to finally produce a data set of 30 points per cell 
location for each cell line, over a total of 90 different cells. 
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3.2.3.2. Confocal Laser Scanning Fluorescence Microscopy (CLSM): 
Samples were prepared on uncoated glass bottom Petri dishes (MatTek Corporation, 
USA). Approximately 104 Cells were allowed to attach for two hrs, then covered with 
cell culture medium. After incubation, the medium was removed and samples were rinsed 
twice with sterile PBS and fixed in formalin (4%, 15 min).  
After fixation, samples were washed with Hank’s balanced salt solution (HBSS) and 
WGA (7.5 µL of WGA per 1 mL HBSS) was first added and cells were incubated for 20 
min and washed with HBSS. Sytox® green nucleic acid stain (2 µL per 1 mL of HBSS) 
was thereafter added, cells were incubated for 30 min and washed with HBSS then imaged 
in HBSS. 
Confocal Laser Scanning microscopic images were recorded using an inverted Zeiss LSM 
510 confocal laser scanning microscope equipped with a x60 oil immersion objective. 
Excitation wavelengths used were 488nm for Sytox® green nucleic acid stain (emission 
wavelength 523 nm) and 633/647 nm excitation/emission for WGA. 
3.2.3.3. Flow Cytometry: 
Cells were cultured in T75 flasks over 48 hrs and then trypsinised and centrifuged in 10 
mL fresh medium at 4 °C and 1000 rpm for 5 min. After this, the cells were re-suspended 
with 5 mL PBS and only 2 mL was used for analysis. Samples were prepared in parallel 
and the two cell lines were analysed separately. A total number of 2x 104 cells was 
analysed for each sample. The experiments were conducted in triplicate (three 
independent experiments).  
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Flow cytometry analysis was performed using a BD Biosciences Accuri C6 Flow 
Cytometer (Becton Dickinson, Oxford, UK) without any dyes. 
3.2.3.4. Atomic Force Microscopy (AFM): 
The air dried samples on CaF2 substrates were profiled using a MFP-3D BIO AFM 
(Asylum Research). The cantilevers used were Olympus silicon AC240. Tips were 
160nm long and had a typical resonant frequency of 70 kHz. The AFM was operated in 
AC mode in order to minimize tip/sample interaction. Typical free air amplitudes were 
~200mV and a high amplitude set-point relative to the set-point was maintained to 
minimize sample damage. The images obtained, from 5 to 10 cells per cell line, contained 
1024 pixels per scan line and only one representative image of a typical cell for each cell 
line is shown. 
3.2.4. Data analysis: 
Raman spectra pre-processing and analysis were performed in Matlab 2013 using 
algorithms developed in house. 
Prior to analysis, spectra were smoothed (Savitsky-Golay filter 5th order, 7 points), 
baseline corrected, substrate background subtracted, using a polynomial method home 
developed, and vector normalised.  
After pre-processing, PCA (principal component analysis) and PCA-Linear Discriminant 
Analysis (PCA-LDA), powerful approaches commonly used for the analysis of large 
spectral data sets, were employed as supervised multivariate analysis tools to differentiate 
the data recorded from different subcellular localisations and cell lines. PCA allows the 
reduction of the number of variables in a multidimensional dataset, the order of the PCs 
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denoting their importance in the dataset where PC1 describes the highest amount of 
variation. While PCA identifies differences between the data sets, LDA maximizes these 
differences so as to group similar spectral sets. PCA performs a feature reduction of the 
data and LDA classifies the data into one of two or more classes. Thus, if a group of 
spectra have a similar correlation to the shape defined by PC1 and that defined by PC2; 
they are classified as same class. 
PCA was performed on each of the datasets independently (nucleoli, nucleus, and 
cytoplasm). LDA was then performed on each of the datasets scores independently and a 
10-fold cross validation was performed to produce confusion matrices (Gutman et al., 
2013; Riedl, Esslinger, and Fauhl-Hassek). LDA accuracy was calculated using a 10-fold 
cross validation on increasing numbers of latent variables (PC scores) for the 
classification of all cancer types and normal cells. The classification which resulted in the 
maximum accuracy while keeping the number of latent variables to a minimum was 
chosen for all successive models. In the case of the classification of all cancer cells and 
normal one, from a plot of accuracy as a function of increasing number of latent variables, 
the maximum accuracy was found when 4 principal components were used in the 
classification. Further addition of principal components only increased the complexity of 
the model without further improving the performance. 
The Accuri Flow cytometry software was used for the initial analysis of flow cytometry 
samples, but the Beckman Coulter Summit software and the FCS Express Research 
Edition have been used for the reanalysis of the samples. The QC control of the instrument 
was performed using Spherotech 6 and 8 peak beads. 
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3.3. Results and discussion: 
3.3.1. Raman micro-spectroscopy: 
Raman spectra were taken from the three cell compartments for all cell lines and Figure 
3.1 shows the average spectra corresponding to each cell region for Calu-1 cells. Visibly, 
it can be seen that the mean spectra of the nucleolar, nuclear and cytoplasmic regions are 
somewhat different, and discriminating peaks (indicated by highlighted regions in Figure 
3.1) at, for example, 1578, 1095 , 830 and 795 cm-1 can be allocated to nucleic acids 
which correspond respectively to vibrations of the DNA bases adenine and guanine, DNA 
PO2
- symmetric stretching, ribose phosphate and DNA backbone O-P-O stretching 
(Oshima et al., 2010; Zhang et al., 2008), while others at 1300 (CH deformation) and 717 
cm-1 (CN+(CH3)3 stretching)
 are associated with lipid components of the cell membrane, 
which are also observable in subsequent spectra of the nuclear and nucleolar regions, 
although more prominently in the spectra of the cytoplasmic region. The DNA bands at 
1095 cm-1 and 830 cm-1 indicate that the DNA is in B form and one at 813 cm-1 
corresponds to DNA A form (Notingher et al., 2002). 
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Figure 3.1: Mean spectra of Nucleolus (A), Nucleus (B) and Cytoplasm (C) of Calu-1 
cell line. Highlighted regions indicate discriminatory features. 
Similar profiles were obtained for the subcellular analysis of A549 cells. 
For a more detailed understanding of the differences in spectral profiles of the subcellular 
regions, a multivariate analysis is more informative, and therefore, PCA was employed 
to analyse and compare the spectral profiles of the subcellular regions as well as the 
differences between cancer and normal cell lines. Figures representing the differentiation 
of the spectra by PCA according to the corresponding PC loadings were plotted and, for 
clarity, in all PCA figures, the loadings are off set, the dashed horizontal line in all cases 
indicating zero loading. 
As an illustration of the analysis technique used throughout, Figure 3.2 A shows the PCA 
scatter plot of the cytoplasmic, nuclear and nucleolar spectra of the Calu-1 cell line, along 
with the corresponding loadings of PC1 and PC2. PC1 clearly differentiates between the 
cytoplasmic and integrated nuclear regions (nuclear and nucleolar) and, according to the 
corresponding loading (loading 1), the most visible discriminant features derive from 
DNA, 795 cm-1 and 1095 cm-1, related to DNA form and DNA PO2
- symmetric stretching, 
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and lipids at 717 cm-1 (CN+(CH3)3 stretching),
 1300 (CH2 stretching) and 1440 cm
-1(CH 
stretching). The differentiation of the subcellular regions according to PC1 is not 
unexpected, due to the significant biochemical differences between the combined nuclear 
and cytoplasmic regions which are similar for all cell lines. 
Although some degree of discrimination of the nuclear and nucleolar regions according 
to PC2 is evident in Figure 3.2 A, a better visualisation of this is achieved by a direct 
pairwise PCA of the two datasets, as shown in Figure 3.2 B. PC1 now clearly 
differentiates the nucleolar and nuclear regions. It exhibits discriminating negative peaks 
related to nucleoli at 782 and 1336 cm-1 (Uracil, Cytosine and Thymine) corresponding 
to RNA (Hobro et al., 2007), 1242 cm-1 (Amide II), 1480 cm-1 (Guanine, Adenine) and 
1578 cm-1 (proteins) due to the contribution of surrounded membrane, as well as positives 
ones at 728 (Adenine), 830 cm-1 (O-P-O asymmetric stretching) and 1095 cm-1 (DNA 
PO2
- symmetric stretching), corresponding to the nuclear region, which is the primary 
location of DNA, while the nucleolar regions contain RNA and a small quantities of DNA 
(Bonnier and Byrne, 2012; Movasaghi, Rehman, and Rehman, 2007). Similar 
differentiation can be achieved for the subcellular regions of A549 cells (data not shown). 
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Figure 3.2: A. PCA scatter plot of nucleolar, nuclear and cytoplasmic regions of Calu-1 
cells, with corresponding loadings of PC1 and PC2 B. PCA of nucleolar and nuclear 
regions of Calu-1 cells and corresponding loading of PC1. 
 Cytoplasm    Nucleus      Nucleolus 
In a similar fashion, PCA was employed to compare the spectral profiles of the normal 
lung human cell line BEAS-2B to the two lung cancer cell lines A549 and Calu-1. 
86 
 
 
Figure 3.3: PCA of nucleolar, nuclear and cytoplasmic regions of A. A549, Calu-1 and 
BEAS-2B with corresponding loadings of PC1 and PC2 B. PCA of each cell localisation 
for A549, Calu-1 and BEAS-2B and the corresponding loadings of PC1. 
Cytoplasm    Nucleus     Nucleolus     A549 cell line 
Cytoplasm    Nucleus     Nucleolus     Calu-1 cell line 
Cytoplasm    Nucleus     Nucleolus     BEAS-2B cell line 
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The PCA scatter plot of Figure 3.3 A compares the three subcellular regions of all three 
lung cell lines. PC1 largely differentiates between the cytoplasmic regions and the 
integrated nuclear and nucleolar regions of the cells, and the corresponding loading 
exhibit features related to nucleic acid (DNA and RNA) and lipids, similar to the loading 
of PC1 in Figure 3.2 A.  
Accounting for 21% of the explained variance, PC2 indicates a clear differentiation 
between the normal cell line and the two cancerous ones. Although the loading of PC2 
represents differentiating features of all three subcellular regions, identifiable features 
include negative peaks at 669 (Thymine and Guanine), 728 (Adenine), 1095 cm-1 (DNA 
PO2- symmetric stretching) and ones at 1005 (Phenylalanine), 1320 (Guanine), 1440 
(Guanine and Adenine), and 1665 cm-1 (Amide I), associated with the cancer cell lines. 
Positive peaks corresponding to lipids at 760 and 820 (tryptophan ring), 1115 (C-C 
stretching), 1250 and 1420 cm-1 (lipids C=C and C-H vibration) are associated with the 
normal cell line. A similar scatterplot and loadings profile, with separation between 
integrated nuclear region and cytoplasmic area according to PC1 and differentiation of 
normal and cancer cell line according to PC2 is observable when cell lines were analysed 
pairwise, A549 versus BEAS-2B and Calu-1 against BEAS-2B (Figure S.3.1, 
Supplemental Information). 
The PCA discriminating features between normal and cancer cells correspond to DNA 
and proteins for cancer cell lines and lipids for the normal one, which is consistent with 
the fact that cancerous cells have a more active metabolism and exhibits more proteins 
and more DNA than normal cells but present less cytoplasm and therefore lipids are 
positive discriminating features for normal cells.  
The differentiation of the cell lines is more evident when the subcellular regions are 
analysed independently using PCA, as shown in Figure 3.3 B. The normal and cancerous 
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cell lines are now largely discriminated by PC1 and almost the same discriminating 
features can be found in the loadings of PC1 for the nucleolar and nuclear regions, while 
additional peaks in the loading of PC1 for the cytoplasm of the normal versus cancerous 
cells are observed at 760 and 820 (tryptophan ring) and  1250 (Amide III), related to 
normal cells and ones at 717 (CN+ (CH3)3 stretching), 1400 (CH deformation) and 1578 
cm-1 (protein) 1661 cm-1 (lipids C=C stretching) related to cancerous cell lines (Farhane 
et al., 2015; Movasaghi, Rehman, and Rehman, 2007; Notingher, 2007; Notingher et al., 
2002). 
Thus using PCA allows a separation between normal and cancerous cell lines. Notably, 
however, no differentiation of the cancerous cell lines is evident. To investigate this 
further, the cancer cell lines were compared to each other and spectra from the nucleolus, 
nucleus and cytoplasm were similarly analysed. 
As shown in Figure 3.4 A, a scatter plot of the combined PCA of the nucleolar, nuclear 
and cytoplasmic regions of the A549, Calu-1 cancer cell lines, there is no clear separation 
between the two cells. As before, PC1 differentiates between the cytoplasmic and 
combined subcellular regions, but, in contrast to the comparison of the normal and 
cancerous cell line, there is no clear differentiation between the two cell lines. Indeed, 
PC1 discriminates between the cytoplasm and the combined nuclear region, for both cell 
lines and the corresponding loading exhibits features corresponding to lipids, 717 and 873 
cm-1 (CN+ (CH3)3, 1270 and 1303 cm
-1 (C–H vibrations) and 1450 (CH2 deformation) and 
ones related to DNA at 784 (Cytosine and Thymine), 1095 (DNA PO2− symmetric 
stretching) and 1578 cm-1 (Guanine, Adenine). PC2 partially discriminates the nucleolar 
and nuclear regions and exhibits discriminating negative peaks for the nucleolar region at 
784 and 1336 cm-1 (Uracil, Cytosine and Thymine) corresponding to RNA, 1242 cm-1 
(Amide II), 1480 cm-1 and 1578 cm-1 (Guanine, Adenine), as well as positives ones at 728 
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(Adenine), 830 cm-1 (O-P-O asymmetric stretching) and 1095 cm-1 (DNA PO2
- symmetric 
stretching), corresponding to the nuclear region(Bonnier and Byrne, 2012; Movasaghi, 
Rehman, and Rehman, 2007).  
Therefore, it appears that Raman micro-spectroscopy is unable to differentiate between 
cancerous cells, although it is able to distinguish the subcellular regions for all cell lines. 
Nevertheless, previous studies, have demonstrated the ability of Raman micro-
spectroscopy to distinguish between different cancer cell lines (J W Chan et al., 2006; 
Chen et al.; El-Mashtoly et al., 2014; Pijanka et al., 2013; Rashid et al., 2014; Tolstik et 
al., 2014). To explore the apparent discrepancy in results, the individual subcellular 
regions were further analysed (Figure 3.4 B, C and D). 
Results show no indication of discrimination between the two lung cancerous cells for 
the nuclear and cytoplasmic areas (Figure 3.4 C and D) although there is some degree of 
differentiation according to PC1 (35% of variation) for the nucleolar regions of A549 and 
Calu-1 (Figure 3.4 B). Discriminant features of the loading of PC1 include negative peaks 
at 1270 (RNA Uracil and cytosine ring stretching), 1320 and 1450 (CH2 deformation) and 
1661 cm-1 (Lipids C=C stretching). The same features are found to be higher in the mean 
spectra of nucleolar A549 compared to Calu-1 (Figure 3.5), indicating that there are more 
lipids in the former.   
Also prominent in the loading of PC1 are two strong positive peaks at 784 cm-1 (Uracil, 
Cytosine and Thymine) and 811 cm-1 (RNA O-P-O phosphodiester bond) as well as ones 
at 1240 (Amide III), 1480 and 1578 cm-1 (Guanine, Adenine), which indicate that there 
is a stronger RNA contribution in Calu-1 cells than A549. This can be clearly seen in the 
mean nucleolar spectra in Figure 3.5. 
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Figure 3.4: PCA scatterplots and corresponding loadings of PC1 and PC2 of A549 and 
Calu-1 cells: A. nucleolus, nucleus and cytoplasm B. nucleolus, C. nucleus D. cytoplasm. 
Cytoplasm    Nucleus     Nucleolus     A549 cell line 
Cytoplasm    Nucleus     Nucleolus     Calu-1 cell line 
A. 
 
B. 
 
C. 
 
D. 
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A.          
 
B.  
 
C. 
 
Figure 3.5: Mean spectra of A. nucleolus of A549 (green) and Calu-1 (black), B. nucleus 
of A549 (red) and Calu-1 (magenta) and C. cytoplasm of A549 (blue) and Calu-1 (cyan). 
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Moreover, according to the mean spectra, it seems that the most notable differences in 
nuclear and nucleolar regions between A549 and Calu-1 corresponds to the features at 
813 cm-1 (DNA A form) and at 830 cm-1 (DNA B form).  
The ratio between the two peaks (enlargement Figure 3.5) is inverted which signifies that 
there is more DNA B form in A549 than in Calu-1 and vice versa. 
To support Raman micro-spectroscopy observations, Confocal Laser Scanning 
Microscopy, Flow Cytometry and Atomic Force Microscopy were in their turn employed 
to compare the two human lung cancer cell lines. 
3.3.2. Confocal Laser Scanning Fluorescence Microscopy (CLSM): 
CLSM was employed in order to identify the morphological characteristics of the two cell 
lines, A549 and Calu-1. As shown in Figure 3.6, before and after nucleic and cytoplasmic 
staining, the two cell lines present a different shape and size, as well as numbers of 
nucleoli, which are clearly resolved within the nucleus and have diameters ~2-4 m. 
Indeed, WGA, a cytoplasmic membrane stain which delimits the cytoplasmic membrane, 
highlights the shape of cells and shows that Calu-1 are bigger and longer than A549 cells, 
while Sytox® green, a specific nuclear dye which has a high affinity for DNA, shows that 
Calu-1 cells present a higher density of nucleoli and a larger nuclear area than A549 cells.  
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A.  
    
B. 
   
Figure 3.6: Confocal fluorescence images of A. A549 and B. Calu-1 stained with Sytox® 
green nucleic acid stain and WGA. 
3.3.3. Flow Cytometry: 
As shown in Figure 3.7, the flow cytometry 2D scatter plots are different from one cell 
line to another, indicating that Calu-1 cells are more spread and bigger in size than A549. 
This is confirmed in the histograms; Calu-1 (red) and A549 (green) show a difference in 
cell surface and size (FSC forward scatter) and cell granularity and internal environment 
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(SSC side scattering) between the two cell lines, confirming that Calu-1 cells present 
larger size and dispersive granularity of the nucleus, which explains the most significant 
percentage of cellular side scattering (Marina, Sanders, and Mourant, 2012), than A549, 
consistent with the confocal microscopy results. 
 
Figure 3.7: Flow cytometry 2D scatter plots (FSC vs SSC) with debris excluded and 
histograms ((FSC vs cell number) and (SSC vs cell number)) for both cancer cell lines 
A549 (green) and Calu-1 (red). 
3.3.4. AFM: 
AFM shows that both cell lines have different topography. Indeed, according to Figure 
3.8 A549 cells are higher and more convex than Calu-1 (Height 1.4 µm for A549 
compared to 1.2 µm for Calu-1). Additionally, it can be seen from the structure of the 
height profiles that Calu-1 cells have more surface granularity, consistent with larger 
number of nucleoli, which confirms the CLSM and flow cytometry results.   
 
Calu-I A549 
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Figure 3.8: AFM images of A. A549 and B. Calu-1: 3D image, height scan and 
topographical profile generated for height scan; respectively. 
According to Flow Cytometry (SSC maximum 500,000 for A549 and 1,000,000 for Calu-
1) and AFM (Figure 3.7 and 3.8), A549 cells are thicker than Calu-1 but present fewer 
and smaller nucleoli, which is confirmed by CLSM. Nucleoli size for both cell lines is by 
the order of 2-4 µm, larger than the Raman laser spot (1 µm) and, according to Raman 
micro-spectroscopy; RNA is more prominent in Calu-1 nucleoli than those of A549. 
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3.3.5. PCA-LDA: 
Thus, CLSM, Flow Cytometry and AFM show that A549 and Calu-1 cells are different 
in size, morphology and topography. Raman micro-spectroscopy was unable to 
differentiate between them with high sensitivity according to the biochemical fingerprint 
of the cytoplasmic or nuclear regions alone. However, differentiation of cell lines is 
achievable according to the spectroscopic signature of the nucleoli. 
Nucleoli are non-membrane-bound nuclear compartments, well described and analysed 
in details since the last millennium (Jarboui et al., 2011; Visintin and Amon, 2000). They 
are responsible for ribosome biogenesis and diverse cellular functions and processes such 
as cell cycle control, cellular stress response, nuclear export and sequestration of key 
proteins regulators of cell-cycle activity and response to apoptosis and early stage cellular 
response to toxic such as chemotherapeutic drugs (Farhane et al., 2015). The size, number 
and organisation of nucleoli are cell-specific and nuclear proteins, notably histone, play 
an important role in the nucleoli stability and functions (Hinsby et al., 2006; Olson, 
Dundr, and Szebeni, 2000). 
The important role played by nucleoli and its cell specificity explain the fact that it is 
spectroscopically the discriminant factor between cancer cell lines. For confirmation, 
PCA was coupled with LDA and confusion matrices were generated using 4 principal 
components and, in the first instance, nucleolar and nuclear areas were analysed in 
combination. The results shown in Table 3.1 A indicate a sensitivity and specificity of 
between 40 and 60 % for the two cancerous cell lines and 91.8 % specificity and 93.2 % 
specificity for the normal cells, BEAS-2B, which confirms, along with the LDA plot in 
Figure 3.9, that poor discrimination between the cancerous cell lines is achievable. To 
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improve the specificity and sensitivity, the nucleolar and nuclear regions were analysed 
separately. 
It is notable that in the confusion matrix of Table 3.1 B, for the nucleolar regions of 
BEAS-2B, the sensitivity and specificity are 100 % (separation is obvious in Figure 3.9 
B). A clearly better separation for the two cancerous cell lines is achievable for the 
nucleolar region, and a similar amelioration can be observed for the nuclear region (Table 
3.1 C), although the specificity and sensitivity remain lower than that of the nucleolar 
region. Significantly lower sensitivities and specificities were obtained for the 
cytoplasmic regions of the cancer cell lines (Table 3.1 D). The results are supported by 
the PCA-LDA plot in Figure 3.9. 
In summary, Raman micro-spectroscopy coupled with both PCA and PCA-LDA 
highlights the critical importance of nucleoli in determining the biochemical identity of 
the cell. Recent studies using Raman micro-spectroscopy to investigate the nucleoli 
biochemical and molecular composition, and differences in this nuclear compartment 
between normal and cancer cell lines, highlighted the potential role of the nucleoli in cell 
differentiation (Kuzmin, Pliss, and Kachynski, 2013; Schulze et al., 2013). The current 
study confirms that this nuclear organelle, in addition to its essential cellular function, is 
also the primary source of the differentiating Raman spectroscopic fingerprint of the cell 
lines.  
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Table 3.1: Confusion matrix table for A549, Calu-1 and BEAS-2B A. Nucleolus + 
Nucleus B. Nucleolus C. Nucleus and D. Cytoplasm. 
A.  
 A549 Calu-1 BEAS-2B 
A549 40 18 2 
Calu-1 16 43 1 
BEAS-2B 2 3 55 
Sensitivity % 68.9 78.1 94.8 
Specificity % 52.3 52.7 91.9 
 
B. 
 A549 Calu-1 BEAS-2B 
A549 26 4 0 
Calu-1 1 29 0 
BEAS-2B 0 0 30 
Sensitivity % 96.2 87.8 100 
Specificity % 87.8 96.2 100 
 
C. 
 A549 Calu-1 BEAS-2B 
A549 19 9 2 
Calu-1 6 23 1 
BEAS2B 1 4 25 
Sensitivity % 73.1 63.8 89.2 
Specificity % 67.6 70.8 84.3 
 
D. 
 A549 Calu-1 BEAS-2B 
A549 23 7 0 
Calu-1 14 16 0 
BEAS-2B 4 1 25 
Sensitivity % 56.1 66.6 100 
Specificity % 63.1 61.1 83.3 
Notably, the improved differentiation of the cell lines based on the spectral profiles of the 
nucleoli alone does not consider the additional discriminating factor of the number and 
or density of nucleoli in the nucleus of different cell lines. In studies which compare an 
99 
 
integrated spectral analysis of the nucleus of the cell (Casey et al., 2008), this factor will 
amplify the intrinsic biochemical differences of the nucleoli of different cell lines.  
 
Figure 3.9: PCA - LDA of subcellular regions of A549, Calu-1, and BEAS-2B A. 
Nucleolar +Nuclear B. Nucleolar C. Nuclear D. Cytoplasm. 
The study points towards the importance of the nucleoli in the diagnostic potential of 
Raman micro-spectroscopy. The role of the nucleoli in the early stage response of cells 
to chemotherapeutic agents has also been demonstrated (Wojcik et al., 2015), indicating 
the sensitivity of the spectral profile of this subcellular region to cytological processes. 
 
A.                                                               B. 
 
C.                                                                D.                 
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3.4. Conclusion: 
While this study confirms the ability of Raman micro-spectroscopy to differentiate 
between normal and cancerous cell lines in vitro, as well as between cancer cell lines 
from the same anatomical site, it clearly demonstrates that the discriminating potential 
varies depending on the subcellular region analysed. As, typically, the sampled spot size 
in Raman micro-spectroscopy is less than the cell area, this has important implications 
for optimisation of diagnostic potential in cytopathology, but also for the sensitivity of 
analysis of cellular processes such as the action of chemotherapeutic agents. 
A comparison of normal and cancer cell lines indicates that all subcellular regions are 
differentiable. However, the classification sensitivities and specificities are lowest for the 
cytoplasmic regions. While somewhat improved classification is achievable using the 
spectra of the integrated nuclear region, classification based on the nucleolar regions 
alone is significantly superior. Notably, in the detailed spectral analysis, the cancer cell 
lines were only well differentiated on the basis of the nucleolar regions. 
The morphological analysis demonstrates that the cells differ significantly in their 
nucleolar content, while the spectroscopic study indicates significant differences in the 
individual nucleolar biochemical content. The study demonstrates the importance of the 
nucleoli in its contribution to the diagnostic potential of Raman micro-spectroscopy as 
well as further applications in subcellular analysis of cytological processes. 
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3.7. Supplemental Information:  
 
Figure S.3.1: PCA scatter plots and corresponding loadings of PC1 and PC2 of nucleolar, 
nuclear and cytoplasm regions of A. A549 and BEAS-2B B. Calu-1 and BEAS-2B PCA. 
Cytoplasm    Nucleus     Nucleolus     A549 cell line 
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Chapter 4: Raman micro-spectroscopy for in vitro drug 
screening: subcellular localisation and interactions of 
Doxorubicin 
 
The following chapter reproduces the journal article, Z. Farhane, F. Bonnier, A. Casey 
and H.J. Byrne Analyst, 2015, 140, 4212, in which section and figure numbers have been 
adapted to the prescribed thesis format. 
 
All experiments, data analysis and paper writing were performed by Z.F. 
A.C. and F.B. assisted in the experimental design.  
H.J.B. assisted in the project design and proofing of the manuscript.    
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Abstract: 
Vibrational spectroscopy, including Raman spectroscopy, has been widely used over the 
last few years to explore potential biomedical applications. Indeed, Raman spectroscopy 
has been demonstrated to be a powerful non-invasive tool in cancer diagnosis and 
monitoring. In confocal microscopic mode, the technique is also a molecularly specific 
analytical tool with optical resolution which has potential applications in subcellular 
analysis of biochemical processes, and therefore as an in vitro screening tool of the 
efficacy and mode of action of, for example, chemotherapeutic agents. 
In order to demonstrate and explore the potential in this field, established, model 
chemotherapeutic agents can be valuable. In study paper, Raman spectroscopy coupled 
with confocal microscopy were used for the localization and tracking of the commercially 
available drug, Doxorubicin (DOX), in the intracellular environment of the lung cancer 
cell line, A549.  
Cytotoxicity assays were employed to establish clinically relevant drug doses for 24hr 
exposure, and confocal laser scanning fluorescence microscopy was conducted in parallel 
with Raman spectroscopy profiling to confirm the drug internalisation and localisation.  
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Multivariate statistical analysis, consisting of PCA (principal component analysis) was 
used to highlight Doxorubicin interaction with cancer cells and spectral variations due to 
its effects before and after DOX spectral features subtraction from nuclear and nucleolar 
spectra, were compared to non-exposed control spectra.  
Results show that Raman micro-spectroscopy is not only able to detect Doxorubicin 
inside cells and profile its specific subcellular localisation, but, it is also capable of 
elucidating the local biomolecular changes elicited by the drug, differentiating the 
responses in different sub cellular regions. Further analysis clearly demonstrates the early 
apoptotic effect in the nuclear regions and the initial responses of cells to this death 
process, demonstrating the potential of the technique to monitor the mechanisms of action 
and response on a molecular level, with subcellular resolution.  
 
Keywords: Raman spectroscopy, Doxorubicin, confocal microscopy, in vitro screening, 
cancer cells 
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4.1. Introduction: 
Although the potential of vibrational spectroscopy, including infrared absorption and 
Raman spectroscopy, for biomedical applications has been well demonstrated, translation 
to the clinical environment has been slow, potentially due to the demands of 
standardisation, regulation and extensive clinical trials (Byrne et al., 2015; Rae et al., 
2014). Fundamentally, the techniques are analytical, with molecular specificity, and, in 
the case of Raman spectroscopy in the confocal microscopy mode, can achieve optical 
resolution enabling subcellular profiling in 3D, suggesting that an appropriate application 
would be in screening of biomolecular changes in vitro (Chan et al., 2006; Crow et al., 
2005; Notingher et al., 2002; Uzunbajakava et al., 2003). Regulatory requirements in both 
the EU and US (EU Directive-2010/63/EU and US Public Law 106-545, 2010, 16th 
Congress) have increasingly restricted the use of animal models for development of 
pharmaceuticals and cosmetics, and Raman micro-spectroscopy offers a potentially low 
cost, label free alternative to in vitro High Content Analysis for routine screening (Gordon 
and McGoverin, 2011; Tu and Chang, 2012). 
The potential of Raman micro-spectroscopy in this field has previously been 
demonstrated in a number of studies (Das and Agrawal, 2011; Kallaway et al., 2013). The 
use of model systems, with established modes of action is of particular benefit in this 
respect, and commercially available drugs such as cisplatin (an alkylating and DNA 
binding agent) (Nawaz et al., 2010; Nawaz et al., 2011) and vincristine (an alkaloid agent) 
(Nawaz et al., 2013) have been explored. In these specific studies, however, the drug itself 
was not detected, but rather the spectroscopic response profiles of the cells themselves 
were correlated with the cytotoxic responses measured in cells. Nawaz et al., postulated 
that the direct chemical interaction of the drug in the cell could be differentiated from the 
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resultant cytological response using multivariate regression, and this approach was 
recently validated by Keating et al (Keating et al., 2015). El-Mashtoly et al. (El-Mashtoly 
et al., 2014) utilised the distinct structure of Erlotinib, containing a carbon-carbon triple 
bond, to specifically detect the subcellular presence of the drug in vitro, while Cuisinier 
et al. used the C=O stretching band at 1740 cm-1 to monitor paclitaxel (a microtubule 
stabilizing agent) in cells and Vigny et al. (Feofanov et al., 2000) probed the resonance 
Raman response to detect and study nonfluorescent transition-metal complexes, 
Theraphtal, used as a chemotherapeutical combination. Raman spectroscopy has also 
been demonstrated as a suitable probe of subcellular localisation (Ahlinder et al., 2013; 
Bräutigam et al., 2014; Dorney et al., 2012) and toxicity of nanoparticles (Casey et al., 
2008; Knief et al., 2009; Thakor et al., 2011). 
One of the 10 most frequent drugs used in cancer chemotherapy and especially for the 
treatment of aggressive and metastatic tumours is doxorubicin.(Yokochi and Robertson, 
2004) Doxorubicin (DOX) is an anthracycline antibiotic extract from Streptomyces 
peucetius and a well-established anti-cancer drug (since 1960) (Hurley, 2002). It is widely 
used in chemotherapy for a varied range of cancers including breast carcinoma, 
haematological malignancies and lung cancer. Despite its known cardiotoxicity, it is 
currently one of the anticancer drugs most used in clinics (Cutts et al., 2005; Yang et al., 
2014). When taken up into cell nucleus, where it has high affinity for DNA and blocks 
topoisomerase II (Hurley, 2002; Woods and Turchi, 2013), DOX induces genotoxicity 
and inhibits the process of DNA replication and macromolecular biosynthesis, leading to 
tumour cell apoptosis (Kaufmann and Earnshaw, 2000). As this interaction is dependent 
on the level of protein, cells with high levels of topoisomerase II are more susceptible to 
DOX, which explains its selectivity to cancer cells (Hurley, 2002). In addition to the 
formation of complex drug-DNA-topoisomerase II, DOX also induces the formation of 
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DNA adducts (Cutts et al., 2005; Swift et al., 2006), hydrogen peroxide (Mizutani et al., 
2005) and inhibits DNA methyltransferase (Yokochi and Robertson, 2004) and 
Transforming Growth Factor-β1 (TGFβ1) (Filyak et al., 2008). 
Despite the wide range of cytotoxicity that DOX elicits, its complete mechanism of action 
still not fully understood and much research has been undertaken to elucidate more clearly 
how DOX works, its uptake and intracellular delivery and resistance of cancer cells 
(Hurley, 2002; Lee et al., 2004; Moritz et al., 2010; Romero et al., 2013; Shen et al., 
2008). In this context, the technique of Raman spectroscopy could add additional insight, 
in vitro. The anthracycline structure of DOX, consisting of a conjugated anthraquinone 
ring structure banded to an aminoglycoside (Cutts et al., 2005), renders it fluorescent and 
gives it a strong Raman scattering efficiency even off resonantly, (Figure 4.1 A). It can 
therefore potentially be simultaneously tracked inside cells by confocal fluorescence 
microscopy and Raman spectroscopy, and therefore is an ideal candidate to probe the 
sensitivity of the latter to not only monitor the intracellular interactions of drugs, but also 
the mechanisms of interaction and the progression of subsequent cellular responses.  
A number of studies over the last few years have investigated either the cellular uptake 
and nuclear accumulation (Majzner et al., 2015), cytotoxicity or the interaction of free or 
nanoformulations of DOX in different cancer cell lines or isolated DNA (Guo et al., 2009; 
Lee et al., 2004; Minati et al., 2012; Romero et al., 2013; Wojcik et al., 2015; Xiao et al., 
2013).  
In this study, Raman micro-spectroscopy is used as a tool, complemented by parallel 
cytotoxicity assays and confocal fluorescence microscopy, to both monitor DOX within 
the cellular environment, to detect its biochemical effects and fingerprint the 
physiological responses in the cancer cell line, A549, a non-small cell lung 
adenocarcinoma. The study thus explores the capability of the technique to screen the 
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uptake and mechanisms of interaction of chemotherapeutic agents in vitro in a truly label 
free manner. 
    
 
Figure 4.1: A. chemical structure of Doxorubicin B. Raman spectrum of doxorubicin in 
aqueous solution (785 nm as source, background subtracted, vector- normalised and 
baseline corrected). 
4.2. Materials and Methods: 
4.2.1. Cell culture: 
A549 human lung adenocarcinoma cells with the alveolar type II phenotype were 
obtained from ATCC (Manassas, VA, USA).  
A549 cells were cultured in DMEM (with 2 mM L-glutamine) with 10% foetal bovine 
serum (FBS) at 37 °C in a humidified atmosphere containing 5 % CO2 and cells were split 
every two days to maintain ~60 % confluence. 
For confocal fluorescence and Raman spectroscopic analysis, cell number was 
determined using a Beckman Coulter Particle Count and Size Analysis® Z2 Cell Counter.  
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4.2.2. Cytotoxicity assays: 
Alamar blue (AB) and 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide 
(MTT) assays were performed in 96 well plates and a total number of 1x105 cells were 
used to seed three plates (4x103 cells/mL).  
Doxorubicin hydrochloride® powder (Sigma Life Sciences, Ireland) was diluted in 1mL 
sterile water to the required concentration. After 24 hrs incubation, plates were washed 
with phosphate buffered saline solution (PBS) and doxorubicin wase added in a range 
from 0 µM (as a control) to 50 µM. 
A solution of 1.5 mL of AB (10X ready to use solution) and 3 mL of MTT stock solution 
(2.5 mg/mL, 25 mg MTT/10 mL PBS) in 30 mL of fresh medium were prepared. AB and 
MTT assays were both measured with a Cytotox SpectraMax®M3 plate reader using Soft 
Max® Pro6.2.2 as software and data was treated using SigmaPlot 10.0. After 24 hrs 
incubation in DOX, plates were washed with PBS and 100 µL of AB/MTT solution were 
added to each well. Plates were then incubated for 3 hrs and AB fluorescence was 
measured before in the plate reader using 540 nm excitation and 595 nm emission. The 
medium was then removed, the plates were washed with PBS and 100 µL of DMSO 
(Dimethyl sulfoxide) were added in each well. MTT absorbance was read at 570 nm. All 
cytotoxicity assays were made in triplicate and repeated three times. 
4.2.3. Confocal Laser Scanning Fluorescence Microscopy:  
Approximately 1 x 104 cells were allowed to attach on uncoated glass bottom Petri dishes 
(MatTek Corporation, USA) for approximately two hours, after which they were covered 
with cell culture medium. After 24 hrs incubation, the medium was removed and samples 
were rinsed twice with sterile PBS, new medium containing DOX corresponding to the 
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IC50 concentration (inhibitory concentration) which is the concentration that inhibits 50% 
of cells (Neubig et al., 2003), was added and cells were incubated for 24 hrs more. At the 
end, cells were washed twice with sterile PBS, fixed in formalin (4 %, 15 min) and kept 
in PBS for imaging. Control samples without exposure to DOX were also prepared in 
parallel, and incubated for 24 hrs.  
Confocal laser scanning fluorescence microscopic images were recorded using an 
inverted Zeiss LSM 510 confocal laser scanning microscope equipped with a x60 oil 
immersion objective. Doxorubicin fluorescence was excited with an argon ion laser at 
488 nm, and the emission was collected at 530 nm.  
4.2.4. Raman micro-spectroscopy: 
Cells (~ 1x 104/window) were seeded and incubated on CaF2 windows (Crystan Ltd, UK) 
for 24 hrs for both control and exposure to DOX. Medium was then removed and samples 
were rinsed twice with sterile PBS and covered with DOX at the IC50 concentration. After 
24 hrs incubation, cells were washed twice with sterile PBS and fixed in formalin (4 %, 
15 min). 
A Horiba Jobin-Yvon LabRAM HR800 spectrometer with a 785 nm, 300 mW diode laser 
as source, Peltier cooled 16-bit CCD, 300 lines/mm grating and 100 μm confocal hole, 
was used for this work. Spectra were acquired in the range from 400 cm-1 to 1800 cm-1 
using a x100 objective (LCPlanN, Olympus), in dry conditions, for 30s two times, from 
three cell locations: cytoplasm, nucleus and nucleolus, to finally produce a data set of 30 
points per cell location for each control and exposure to DOX, over a total of 60 cells. 
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4.2.5. Data analysis:  
Raman spectral pre-processing and analysis were performed in Matlab 2013 using 
algorithms developed in house. Prior to analysis, spectra were smoothed (Savitsky-Golay 
filter 5th order, 7 points), vector normalised, baseline corrected (fifth order polynomial) 
and background was subtracted using a NCLS (non-negatively constrained least squares) 
algorithm. 
Principal components analysis (PCA) was employed as an unsupervised multivariate 
approach to analyse data and the effects of doxorubicin in each cell localisation. The order 
of the PCs denotes their importance to the dataset and PC1 describes the highest amount 
of variation (Bonnier and Byrne, 2012; Bonnier et al., 2010). 
4.3. Results and discussion: 
4.3.1. Cytotoxicity assays: 
 
 
Figure 4.2: AB and MTT 24 hrs dose dependent cytotoxicity of DOX to A549. 
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Figure 4.2 shows the dose dependent cytotoxicity of DOX after 24 hrs according to the 
AB and MTT in vitro cytotoxicity assays. Viability is expressed as % compared to 
control, and the error bars indicate the standard deviation of six independent replicate 
measurements. Both assays indicate a systematic dose dependent response. Neither of the 
assays indicates a complete loss of viability of the cell populations over the concentration 
range and exposure periods, and this viability cures were fitted with Equation 1 (Black 
and Leff, 1983). 
V = Vmin + (Vmax - Vmin)/ (1 + (C/IC50)
 n)   Equation 1 
Where V is the % viability, Vmin is the minimum viability, Vmax is the maximum viability, 
C is the DOX concentration, n is the Hill slope, and IC50 is the concentration which elicits 
50% of the maximum response. The IC50 values were determined to be 0.42±0.06 M 
and 0.55±0.16M for AB and MTT, respectively. Although the values overlap within 
experimental error, any slight difference in IC50 between AB and MTT may be because 
the AB assay is a measure of overall cell metabolism whereas the MTT assay is the 
reflection of mitochondrial activity within the cell. Mitochondria exist within the cells in 
all stages of their DNA replication, and are first targeted by DOX which explains its 
earlier response and higher sensitivity (Maher et al., 2014; Mukherjee, Davoren, and 
Byrne, 2010; Owen et al., 2006). Since cells will be analysed after 24 hrs exposure, the 
IC50 determined using the MTT assay was used for the rest of the study. 
4.3.2. Confocal Laser Scanning Fluorescence Microscopy: 
Confocal laser scanning fluorescence microscopy was used to confirm intracellular DOX 
localization and accumulation. Figure 4.3 illustrates that DOX, after 24 hrs incubation, is 
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predominantly accumulated in the cell nuclei, and no trace amounts are evident in the 
cytoplasm.  
The absence of DOX in the cytoplasm after 24 hrs, confirms also that A549 cells do not 
present any resistance to the drug (Shen et al., 2008). It is also notable that fragmentation 
of nucleoli within the nucleus is observed upon DOX treatment for 24 hrs, confirming 
that cells are going under apoptosis  (Nasser et al., 2008). 
A.                                                 B. 
  
          
Figure 4.3: In vitro confocal fluorescence images of A549 A. control and B. 24 hrs 
doxorubicin exposure. 
4.3.3. Raman micro-spectroscopy:  
The Raman spectrum of DOX powder dissolved in sterile water at the concentration of 
17.25 mM (Figure 4.1 B) clearly shows peaks at 1445 and 1570 cm-1, related to skeletal 
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ring vibrations, specific bands corresponding to C-O, C-O-H and C-H in the region 
between 1200 and 1300 cm-1 and ones attributed to C-C-O and C-O at 440 and 465 cm-1 
respectively (Eliasson et al., 2001; Strekal et al., 2001). The same peaks are clearly visible 
in the spectra of Figure 4.4, which shows the mean spectra of the nucleolar (A), nuclear 
(B) and cytoplasmic (C) regions of 30 A549 cells before and after 24 hrs exposure to the 
MTT IC50 concentration of DOX. Grey shading in the respective spectra indicates regions 
of interest, which are discussed further below. 
Indeed, a first observation is that, in both the nucleolar and nuclear spectra, there are 
discernible peaks at 440, 465, 1085, 1215 and 1245 cm-1 corresponding to DOX (indicated 
by the blue shaded regions). These peaks are not evident in the mean cytoplasmic 
spectrum, however, consistent with the absence of any fluorescence in the confocal 
fluorescence microscopic images of Figure 4.3. Thus, the conjugated structure of DOX 
renders it easily visible and therefore traceable intracellularly using Raman spectroscopy, 
even without the application of more complex data mining methods. 
Furthermore, it is obvious that many DNA peaks, for example 669, 728, 782, 830, 1095, 
1340 and 1425 cm-1 in the spectra of nucleus and nucleoli of treated cells (Figure 4.4 A 
and B) are diminished compared to non-treated ones. Note that the feature at 1425 cm-1 
is increased because of the contribution of the DOX peak at the same wavenumber but 
after DOX subtraction it can be clearly seen that this peak is diminished (see Figure 4.8). 
These results are in accordance with the expected changes in cell nuclei, related to the 
DOX mechanism of action, by which DNA synthesis is blocked by intercalation causing 
changes in DNA conformation (decrease of DNA B form) (Nawaz et al., 2013) inducing 
early cell apoptosis (Brauchle et al., 2014; Lin et al., 2012). (Full details of cellular peak 
assignments are given in Table 4.1). 
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A. 
 
B.  
 
C.  
 
Figure 4.4: Mean spectra of A549 cells A. nucleolus (green; control, black; exposed) B. 
nucleus (red; control, magenta; exposed) C. cytoplasm (blue; control, cyan; exposed).  
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A shift towards lower wavenumbers is observed for the peak at 1095 cm-1, corresponding 
to O-P-O stretching, (shown in the expanded section of Figure 4.4 A and B) which may 
indicate that DOX is also able to bind to DNA externally, although it is also influenced 
by the close proximity of the DOX peak at 1086 cm-1 (Nawaz et al., 2013). 
Table 4.1: Raman bands observed in spectra of the nucleolus, nucleus and cytoplasm 
(Movasaghi, Rehman, and Rehman, 2007; Nawaz et al., 2013; Notingher, 2007; 
Notingher et al., 2004; Notingher et al., 2002; Yao et al., 2009). 
Raman shift (cm-1) Assignment 
669 Thymine and guanine 
720 and 1158 C-C-N+ symmetric stretching in phosphatidylcholine 
728 Adenine  
765 Tryptophan ring 
855 Tyrosine vibration 
782 Uracil, Cytosine and Thymine 
784_795 Cytosine and thymine, DNA backbone O-P-O stretching 
813 RNA O-P-O phosphodiester bond, DNA A form 
828_830 O-P-O asymmetric stretching, DNA B form 
847 Ribose phosphate 
881 Deoxyribose ring breathing 
936 C-C protein skeleton stretching, helix 
1005 phenylalanine 
1047 RNA P–O stretch, sugar phosphate –C–O– stretching 
1095 DNA PO2
- symmetric stretching 
1176 Tyrosine and phenylalanine 
1246 Amide III 
1252 Adenine  
1270 RNA Uracil and cytosine ring stretching  
1300 RNA cytosine and adenine ring stretching 
1303 Lipids C-H vibrations 
1340 ,1425 and 1578 Adenine and guanine 
1320, 1450 CH2 deformation 
1578 proteins 
1661 Lipids C=C stretching 
1665 Amide I 
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In addition to effects on DNA related spectral features, small decreases in protein peaks 
at 1005, 1320, 1578 and 1665 cm-1 observed, relative to those of control (further 
confirmed in the PCA in Figure 4.8). The decrease in intensity of DNA and protein 
features is consistent with the onset of apoptosis, which in turn is consistent with a DOX 
mechanism of action by induction of cell apoptosis, consisting of programmed and 
intrinsic cell death, DNA fragmentation, membrane blebbing and consequently 
interrupted cancer cell growth (Nasser et al., 2008; Notingher et al., 2004; Yao et al., 
2009). 
In the case of the cytoplasm, a similar spectrum is obtained before and after exposure to 
DOX, although subtle changes of some of the spectral features are apparent (indicated by 
grey shaded regions in Figure 4.4 C), such as a decrease in the 720 cm-1 peak and a 
discrete increase in that at 1158 cm-1, both corresponding to phosphatidyl choline, one of 
the major cellular membrane constituents. A notable decrease is also apparent in the 
features at 1303 and 1665 cm-1. These small decreases in lipid and protein peaks can be 
explained by the fact that, although apoptotic cells exhibit major changes in the structure 
of DNA, cytoplasmic biochemistry and cell volume, the cellular membrane and plasma 
can remain almost intact for more prolonged periods. The small increase in the feature at 
1158 cm-1 may derive from the initial production of membrane vesicles synthetized by 
cells as a way to remove waste and toxins by exocytosis. As this synthesis starts at a later 
time, no substantial increase in lipid constituents is observed at this stage (Notingher et 
al., 2004; Owen et al., 2006). 
Although some spectral changes resulting from DOX exposure are discernible by eye, a 
more detailed picture is elucidated through multivariate analysis. PCA is therefore 
employed to analyse in more detail the effects of DOX exposure on the spectral profiles 
of the subcellular regions and, for this, control and exposed cells were compared and 
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analysed, after which the raw spectrum of DOX was subtracted using NCLS and the 
spectra obtained were compared to those of control. 
Figures representing the differentiation of the different spectra by PCA according to the 
corresponding PCs were plotted and, for clarity, the loadings are off set, the dashed 
horizontal line in all cases indicating zero loading. 
A. 
 
B. 
 
Figure 4.5: A. PCA of A549 cytoplasm, nucleus and nucleolus non-exposed cells B. PCA 
A549 cytoplasm, nucleus and nucleolus for both exposed and control cells. 
Cytoplasm   , Nuclear    and Nucleolar     non-exposed cell  
Cytoplasm   , Nuclear     and Nucleolar     exposed cell 
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As an illustration, Figure 4.5 shows (A) PCA of control and (B) exposed and control 
A549 cells. For control A549 cells, there is a clear differentiation between the nuclear 
(including nucleolar) region and the cytoplasm by PC1 and, according to the loading, the 
discriminant peaks correspond predominantly to DNA and lipids. There is no 
discrimination of the nuclear/nucleoli regions according to PC2, which is an indication of 
the intrinsic point to point spectral variability. 
PCA of both exposed and control cells (Figure 4.5 B), shows a separation between control 
cells (negative) and DOX exposed cells (positive) according to PC1 and the 
corresponding loading is dominated by features of the pure DOX spectrum (Figure 4.6). 
Notice also that there is a discrimination between the nuclear region and the cytoplasm 
for both exposed and non-exposed cells according to PC2 and the corresponding loading 
2 exhibits the same peaks as the loading of PC1 for PCA control cells only (Figure 4.5 
A), namely those at 1300 and 1440 cm-1 for lipids, 795 and 1095 cm-1 for DNA. 
 
Figure 4.6: Loading of PC1 (PCA of control cells vs exposed) in blue and doxorubicin 
spectrum in cyan. 
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To further elucidate the differences between exposed and control cells and to better 
understand the effects of DOX exposure on the spectral profiles of the different 
subcellular regions, PCA was employed for each cell compartment separately. 
Significant discrimination can be seen between the spectra of each subcellular region of 
control and exposed cells, whose origin is represented by the loadings of PC1. In the case 
of both the nucleolar and nuclear regions (Figure 4.7 A and B), the discriminating peaks 
correspond to DOX (440, 465, 1215 and 1245 cm-1), whereas for the cytoplasm (Figure 
4.7 C) there are no DOX features evident and the only difference is a decrease in protein 
and lipid features (1303, 1450 and 1665 cm-1). 
In addition to prominent DOX peaks, in the loadings of PC1 for the nucleolar and nuclear 
regions of exposed and control cells, there are a number of smaller discriminants peaks 
which may provide further indications of the mode of interaction. In order, to better 
visualise these peaks, the spectrum of raw DOX powder in aqueous solution, was 
subtracted using NCLS, and the resultant spectra were again subjected to PCA (Figure 
4.8). 
As seen in Figure 4.8A and B, the loading of PC1 for the nucleolar and nuclear spectra of 
exposed (DOX subtracted) and control cells shows on one hand, negatives bands at 830, 
881 and 1095 cm-1 and positive one at 813 cm-1 indicating a decrease and a 
conformational changes (B-form DNA into A-form) (Nawaz et al., 2013; Yao et al., 2009) 
caused by the DOX intercalation and, on the other hand, negative discriminants peaks at 
1005, 1320, 1450, 1578 and 1665 cm-1, corresponding to protein and lipids and 1340, 782 
and 728 cm-1 related to DNA which again is consistent with the intercalative mechanism 
of DOX, inducing a cell apoptosis traduced by a starting depletion of all three principal 
cell constituents: DNA, protein and lipids.  
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A. 
 
 
B. 
 
C.  
 
Figure 4.7: PCA of exposed and control A549 cells A. nucleolus B. nucleus C. 
cytoplasm. 
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In addition, there is a discernible increase of the amide III peaks at 1245 cm-1 (positive 
peak in loading 1) which may be explained by the initial mobilisation of a protein group 
to the intercalation site to prevent DNA repair. 
A. 
 
B. 
 
Figure 4.8: A. PCA of exposed nucleolar regions after DOX subtraction (black) versus 
control cells (green), B. PCA of exposed nuclear regions after DOX subtraction (yellow) 
versus control cells (red). 
To better elucidate any differences in the interaction of DOX in the nucleus compared to 
nucleoli, PCA of only nuclear and nucleolar regions was carried out for cells exposed to 
DOX then after DOX subtraction and compared to PCA of control cells. 
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Figure 4.9 A clearly shows differentiation between control nuclear and nucleolar regions. 
The loading of PC1 presents positive discriminant peaks corresponding to RNA at 1300, 
1270, 1047 and 847 cm-1 and negative ones at 1440 and 830, 1450, 1578 cm-1 attributed 
to DNA and lipids (Table 4.1), consistent with the predominance of DNA in the nuclear 
regions with lipids from the membrane and RNA in the nucleoli.  
PCA of exposed nuclear and nucleolar regions (Figure 4.9 B) shows a similar 
differentiation between these two cellular compartments, but the loading of PC1 is 
dominated by spectral features of DOX. This is consistent with DOX localisation in both 
nucleolar and nuclear regions, but more so in the latter, indicating that DOX is rapidly 
absorbed in the nuclear region, intercalated into DNA, and only residual amounts are free 
to progress to the nucleoli.  
PCA of nucleolar and nuclear regions of control cells (Figure 4.9 A) indicates that the 
differences between these two compartments, according to the loading of PC1, 
correspond to DNA and RNA. But in the PCA of the same two localisations after DOX 
exposure and subtraction, additional discriminant peaks are evident at 765, 1005, 1320, 
1665 cm-1, corresponding to proteins, although the separation is not so evident. In addition 
to DNA depletion, there are also changes in the profile of nuclear proteins. These features 
are negative with respect to PC1, consistent with an increased protein activity in the 
nucleoli. The decrease of the feature at 1450 cm-1, corresponding to lipids, may indicate 
that there is a denaturation of the cytoplasmic membrane surrounding the nucleus. 
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A.   
 
B. 
 
C. 
 
Figure 4.9: PCA of nucleolar (green) and nuclear (red) regions A. control B. after DOX 
exposure C. after DOX subtraction. 
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4.4. Discussion:  
In the present study, the chemotherapeutic agent DOX could clearly be detected and 
tracked intracellularly within A549 cells using Raman spectroscopy. Results for both 
Raman micro-spectroscopy and confocal microscopy show that this anthracycline 
molecule, after 24 hrs exposure, is completely localised inside the cell nucleus, in which 
DNA is abundant, consistent with its established mechanism of action by DNA 
intercalation. 
This nuclear localisation is manifest in the Raman nuclear and nucleolar spectra by the 
clear presence of DOX peaks at 465, 445 1200, 1300, 1440 and 1570 cm-1 and the absence 
of those peaks in cytoplasm spectra, and in confocal images by the red fluorescence in 
nucleus and nucleoli.  
More in depth investigations using multivariate analysis revealed that not only DOX can 
be detected inside cells, but also both its biochemical effects and the physiological 
responses of the cells to exposure can be seen. 
DOX is a known DNA intercalator, and the decrease in the nuclear spectral features at 
669 (thymine and guanine), 728 (adenine), 782 (cytosine and thymine), 1340 and 1425 
cm-1 (adenine and guanine) peaks are signatures of intercalation in the DNA duplex 
between two neighbouring base pairs, resulting in a decrease in the levels of B 
conformation DNA (830 cm-1) (Agudelo et al., 2014; Lei, Wang, and Wu, 2012). Similar 
results were found for vincristine, a microtubule binder and mitotic inhibitor, but which 
was also observed to intercalate with nuclear DNA in a similar in vitro exposure of A549 
cells, resulting in a diminution of thymine (669 cm-1), guanine (1317 cm-1), cytosine (782 
cm-1) and adenine (728 cm-1) bands, in addition to a decrease in DNA B form (827 cm-1) 
(Nawaz et al., 2013). 
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A decrease in thymine (669 cm-1) and guanine (1336 cm-1) bands and to a lesser extent a 
reduction of the band associated with DNA conformation (833 cm-1), were also found 
with cisplatin, a well-established chemotherapeutic “groove binding” agent which binds 
with DNA forming inter-strand and intra-strand crosslinks at 1, 2-GG and 1,3-GTG sites, 
leading to cell cycle arrest and apoptosis (Nawaz et al., 2010). For these chemotherapeutic 
drugs, Raman signatures of the chemical interaction with nuclear DNA have therefore 
been established. 
Moreover, changes in nuclear proteins are also observed in the studies related to cisplatin 
and vincristine, as observed in the current study of DOX. However, a more notable 
increase in some protein peaks, amide III α-helix (1302 cm-1) and β-sheet (1250-1259 cm-
1), CH2 deformation (938 cm
-1), interpreted as a physiological response of the cell to the 
chemotherapeutic exposure, was apparent for both cisplatin and vincristine, although it 
should be stressed that the time exposure for the cisplatin and vincristine studies was 96 
hrs, as compared to the 24 hrs exposure employed in the current study, making a direct 
comparison of the responses impossible. 
Comparing the spectral changes in exposed nucleoli to those of nucleus, it is clear that 
the dominant interaction with DNA occurs in the nucleus, as expected. However, the 
spectral changes in the nucleoli, associated with increased protein activity may provide 
additional insight into the early stage cellular response to toxic insult in which the cell 
nucleoli have been proposed to play a central role (Horky et al., 2002). 
In the case of the cytoplasm, distinct decreases in spectral features associated with lipids 
and proteins peaks are observed after DOX exposure, consistent with an apoptotic cell 
death mechanism, along with an increase of phosphatidyl choline, a marker of a vesicle 
membrane synthesis as a means to remove the cytotoxic agent by exocytosis. These 
results are different from those obtained for cisplatin, exposure to which results in a 
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conformational change in cytoplasmic protein, resulting from the binding of cisplatin, 
along with a modification in lipids as a direct chemical effect (disintegration of lipids) 
and physiological response (decrease in lipids due to the reduction of cell viability). 
In summary, distinct Raman spectroscopic markers of chemotherapeutic agents which 
interact with nuclear DNA can be established which can be used to help elucidate the 
mode of action of the drug. Changes in nuclear protein features can give indications of 
early cellular responses to the toxic insult. Raman markers for cytoplasmic biochemical 
effects are also evident, including decrease in both proteins and lipids, and subtle 
differences in the responses to exposure to different chemical agents can shed further light 
on the mechanisms of cellular response. 
4.5. Conclusion: 
This study further demonstrates the potential of Raman spectroscopy as a truly label free, 
in vitro screening tool to monitor the interaction of molecular chemotherapeutic agents 
on a cellular level. In confocal microscopic mode, the technique offers the same spatial 
resolution as confocal laser scanning fluorescence microscopy, enabling tracking of the 
subcellular localisation of the drug.  
The conjugated structure of the chosen model drug, doxorubicin, presents a strong Raman 
scattering cross section, which renders its spectral profile easily discernible at 
toxicologically relevant doses, even at non resonant wavelengths, above the intrinsic 
cellular spectrum. As a model system to explore the potential of the technique, the 
conjugated structure also results in a strong fluorescence such that the measurements can 
be supported by conventional, confocal microscopy.  
Notably, Raman micro-spectroscopy can also elucidate and differentiate the changes in 
the biomolecular structure within the subcellular regions, in this study, the cytoplasm, 
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nucleus and nucleoli, and potentially shed further light on the mechanisms of interaction 
of the drug.  
Given the drive for a reduction in the use of animal models, there is currently much 
promotion of the development of in vitro models for drug and toxicity screening. 
Ultimately, with improved screening sensitivities and speeds, Raman spectroscopy could 
be employed to monitor in quasi real time, in a label free manner, the efficacy and mode 
of action of, for example chemotherapeutic agents and other exogenous agents, laying the 
basis for improved quantitative structure activity relationships to guide drug development 
or chemical regulation strategies. 
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Chapter 5: Differentiating responses of lung cancer cell lines to 
Doxorubicin exposure: in vitro Raman micro-spectroscopy, 
oxidative stress and bcl-2 protein expression 
 
The following chapter reproduces the journal article, Z. Farhane, F. Bonnier, M.A. Maher, 
J. Bryant, A. Casey and H.J. Byrne, J. Biophotonics 10, No. 1, 151–165 (2017) / DOI 
10.1002/jbio.201600019, in which the section and figure numbers have been adapted to 
the prescribed thesis format. 
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PCA of nucleolar, nuclear and cytoplasmic regions of A549 and Calu-1 with 
corresponding loadings of PC1 and PC2. 
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Abstract:  
 
The potential of Raman micro-spectroscopy as an in vitro, non-invasive tool for clinical 
applications has been demonstrated in recent years, specifically for cancer research. To 
further illustrate its potential as a high content and label free technique, it is important to 
show its capability to elucidate drug mechanisms of action and cellular resistances. In this 
study, cytotoxicity assays were employed to establish the toxicity profiles for 24 hrs 
exposure of lung cancer cell lines, A549 and Calu-1, to the commercially available drug, 
Doxorubicin (DOX). Raman-spectroscopy, coupled with Confocal Laser Scanning 
Microscopy and Flow Cytometry, was used to track the DOX mechanism of action, at a 
subcellular level, and to study the mechanisms of cellular resistance to DOX. Biomarkers 
related to the drug mechanism of action and cellular resistance to apoptosis, namely 
reactive oxygen species (ROS) and bcl-2 protein expression, respectively, were also 
measured and correlated to Raman spectral profiles. Calu-1 cells are shown to exhibit 
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spectroscopic signatures of both direct DNA damage due to intercalation in the nucleus 
and indirect damage due to oxidative stress in the cytoplasm, whereas the A549 cell line 
only exhibits signatures of the former mechanism of action.  
 
Keywords: Raman micro-spectroscopy, Doxorubicin, Cytotoxicity, Confocal Laser 
Scanning Microscopy, Flow Cytometry, bcl-2 protein, ROS, drug resistance. 
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5.1. Introduction:  
The potential of Raman micro-spectroscopy as a non-destructive, label free, analytical 
technique in clinical, pharmaceutical development and biomedical applications, based on 
its ability to monitor the chemical, bio-physiological and physical changes at the 
molecular level, has been demonstrated (Byrne et al., 2015; Cîntǎ Pînzaru et al., 2004; 
Paudel, Raijada, and Rantanen, 2015). 
Among the possible applications of Raman micro-spectroscopy in the clinical setting, 
cancer research and diagnostics remain among the most promising, including cancer 
detection and typing, for example oral (Carvalho et al., 2015; Knipfer et al., 2014), gastric 
(Feng et al., 2011; Yao et al., 2009), breast (Abramczyk et al., 2012; Lee et al., 2014), 
cervical (Ramos, Malkin, and Lyng, 2015; Rashid et al., 2014), skin (Legesse et al., 2015) 
cancers as well as therapeutic follow up and response to chemotherapeutic drugs 
(Farhane, Bonnier, Casey, and Byrne, 2015; Kann et al., 2015).  
Indeed, Raman micro-spectroscopy has been used not only to detect and monitor drugs 
inside cells at a subcellular level but also to fingerprint the cellular response to this 
exposure and the adverse drug effect (Owen et al., 2006). Therefore, it can be developed 
as a companion diagnostic tool, providing details about drug efficacy and safety, as 
detailed in the US FDA guidance document issued in August 2014, which defines such a 
tool as an in vitro diagnostic device that provides information that is essential for the safe 
and effective use of a corresponding therapeutic product (Jorgensen, 2015; Trusheim and 
Berndt, 2015). The use of in vitro models is also consistent with EU and US policies to 
reduce the use of animals for scientific testing (EU Directive-2010/63/EU and US Public 
Law 106-545, 2010, 106th Congress) and thus the demonstration of Raman micro-
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spectroscopy as a companion diagnostic for screening and analysis of commercial 
chemotherapeutic agents could be of significant importance in cancer research.   
To this end, Doxorubicin (DOX), which belongs to the anthracycline family, 
commercially known as Adriamycin, and widely prescribed as a chemotherapeutic 
antibiotic, was employed as a model compound. Despite its extensive clinical use, DOX 
has many toxic and chronic side effects, notably cardiotoxicity (Hrelia et al., 2002), and 
therefore it is important to understand how it effects cancer cells and the sources of 
cellular resistance in order to optimise its clinical efficacy and reduce its toxicity to the 
surrounding environment. 
Routinely used clinically to treat aggressive and metastatic tumours, including lung 
cancers, DOX involves different mechanisms of action, not fully understood. Although 
originally thought to inhibit tumour cell proliferation by DNA intercalation, over the 
years, many other mechanisms of action have been identified, such as topoisomerase II 
inhibition, the formation of DNA adducts (Cutts et al., 2005; Yang et al., 2014), inhibition 
of DNA methyltransferase (Yokochi and Robertson, 2004) and Transforming Growth 
Factor-β1 (TGFβ1) (Filyak et al., 2008) and oxidative stress by generation of reactive 
oxygen species (ROS). The latter relates to its cytosolic metabolism and reduction to the 
doxorubicin semiquinone radical, leading to generation of superoxide and hydrogen 
peroxide, increased intracellular oxidative stress (Majzner et al., 2015; Rogalska et al., 
2011), changes in the mitochondrial permeability, a release of cytochrome C which 
activate caspase effectors causing DNA damage (Wolf and Baynes, 2006; Yang et al., 
2014). All these mechanisms of action lead to apoptosis, a programmed cell death or 
“cellular suicide”, as a way to remove unwanted cells exhibiting dangerous anarchic 
development as tumour cells, initiated extrinsically by the engagement of receptors at 
cytoplasmic membrane or intrinsically by, for example, DNA damage, resulting from 
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chemotherapy or oxidative stress or growth factor withdrawal (De Bruin and Medema, 
2008; Elmore, 2007; Haikerwal et al., 2015; Moldoveanu et al., 2014). 
The mitochondrial or intrinsic apoptosis pathway is controlled by two groups of proteins; 
pro-apoptotic and anti-apoptotic. Among the latter category, the bcl-2 (B cell lymphoma) 
family, an intracellular membrane protein generated as a direct result of DNA damage, 
represents the most important anti-apoptotic protein, which binds to almost all pro-
apoptotic proteins (Hardwick and Soane, 2013) and so regulates the mitochondrial 
apoptosis pathways by mediating the mitochondrial outer membrane permeability 
(MOMP) and by local inhibition of free radical production suggesting an anti-oxidant 
mechanism, inhibiting cell apoptosis as a results including drug-induced (Correia et al., 
2015; Gimenez-Cassina and Danial, 2015; Hussar, Žuravskaja, and Kärner, 2013; Makin 
and Dive, 2001; Rae et al., 2014; Sotiropoulou et al., 2010). 
Any alteration, resistance or failure in apoptosis, due for example, to a higher expression 
of anti-apoptotic protein bcl-2, allows tumour cells to survive and proliferate, leading to 
resistance to chemotherapy and a poor clinical prognosis (Caponi et al., 2013; Johnstone, 
Ruefli, and Lowe, 2002; Mohammad et al., 2015). The cytological mechanisms of drug 
resistance in cancer cells can be an increased detoxification of anticancer drugs by the 
glutathione system, a defective apoptotic pathway, enhanced DNA damage repair or 
increased tolerance to DNA damage leading to suppression of apoptosis, elevated 
expression of anti-apoptotic genes and proteins, decreased uptake of water-soluble drugs 
and enhanced drug efflux from cancer cells mediated by ATP-binding cassette (ABC) 
transporters (Poornima et al., 2014; Qiu et al., 2013). 
Understanding the relative contributions of this array of potential contributing 
mechanisms is a challenging task, requiring a manifold of parallel analytical techniques 
and assays, which are costly and time consuming. Previous studies have shown that 
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Raman micro-spectroscopy is not only able to discriminate between cancer cells 
according to nucleolar region (Farhane, Bonnier, Casey, Maguire, et al., 2015) but also 
to detect drugs inside cells, their effects on cell biology and the physiological response of 
the cell to this exposure (Farhane, Bonnier, Casey, and Byrne, 2015). The aim of the 
current study is to extend the previous investigations to fingerprint the DOX mechanism 
of action in two non-small cell lung cancer cell lines A549 and Calu-1 and the different 
cellular response using Raman micro-spectroscopy and to investigate its ability to 
differentiate the effect of the chemotherapeutic drug in the two different lung cancer cell 
lines. To support this spectroscopic analysis, Confocal Laser Scanning Fluorescence 
Microscopy was employed to monitor the subcellular DOX localisation and bcl-2 
expression due to DNA damage was measured using Flow Cytometry and correlated to 
cellular levels of ROS, in relation to DOX mechanism of action. All observations were 
related to changes in Raman features for the three cellular compartments nucleolus, 
nucleus and cytoplasm. 
5.2. Materials and methods:  
5.2.1. Materials: 
A549 human lung adenocarcinoma cells with the alveolar type II phenotype were 
obtained from ATCC (Manassas, VA, USA) and Calu-1 human lung epidermoid 
carcinoma cell line, was kindly provided by Dr. Josep Sulé-Suso, Institute for Science & 
Technology in Medicine, Keele University, Guy Hilton Research Centre UK and Cancer 
Centre, Royal Stoke University Hospital, University Hospitals of North Midlands, UK.  
Doxorubicin hydrochloride® powder (Sigma Life Sciences, Ireland) was diluted in 1mL 
sterile water to the required concentration (17.25 mM). 
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Alamar blue (AB) (10X ready to use solution) and 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl tetrazolium bromide (MTT) were obtained from Sigma Aldrich, Ireland.  
For cytotoxicity assays an AB/MTT solution, 1.5 mL of AB and 3 mL of MTT stock 
solution (2.5 mg/mL, 25 mg MTT/10 mL PBS) in 30mL of fresh medium was prepared. 
Fixation/permeabilization kit, BD Cytofix/Cytoperm (BD 554714), and FITC Mouse 
Anti-Human bcl-2 set with an IgG1 isotype control (BD 556357) were purchased from 
BD Biosciences, Ireland.  
Nucred® live 647 ReadyProbes® Reagent, used to image the cellular nucleus, and [5(6)-
Carboxy-2',7'-dichlorodihydrofluorescein diacetate] (Carboxy-H2DCFDA) dye, used for 
the detection of Reactive oxygen species (ROS), were both purchased from BioSciences, 
Ireland (suppliers for Life Technologies).  
5.2.2. Cell culture: 
A549 cells were cultured in DMEM (with 2 mM L-glutamine) with 10 % foetal bovine 
serum (FBS) and Calu-1 cells in RPMI with 10 % FBS, both at 37 °C in a humidified 
atmosphere containing 5% CO2 and cells were split every two days to maintain ~60 % 
confluence. 
For Confocal Laser Scanning Fluorescence Microscopy (CLSM) and Raman micro 
spectroscopic analysis, cell number was determined using a Beckman Coulter Particle 
Count and Size Analysis® Z2 Cell Counter. 
5.2.3. Cytotoxicity assays: 
AB and MTT assays were performed in 96 well plates and a total number of 1x105 cells 
were used to seed three plates (4x103 cells/mL). After 24 hrs incubation, plates were 
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washed with phosphate buffered saline solution (PBS) and DOX was added in a 
concentration range from 0 µM (as a control) to 50 µM. 
AB and MTT assays were both measured with a Cytotox SpectraMax®M3 plate reader 
using Soft Max® Pro6.2.2 software. After 24 hrs incubation in DOX, plates were washed 
with PBS and 100 µL of AB/MTT solution were added to each well. Plates were then 
incubated for 3 hours and AB fluorescence and MTT absorbance were measured in the 
plate reader using, respectively, 540 nm excitation, 595 nm emission for AB and 570 nm 
for MTT. All cytotoxicity assays were made in triplicate and repeated three times and 
viability data was fitted by a four parameter Hill equation analysis using SigmaPlot 10.0, 
to yield values of the mean inhibitory concentration, IC50. 
5.2.4. Confocal Laser Scanning Fluorescence Microscopy:  
Approximately 1 x 104 cells were allowed to attach on uncoated glass bottom Petri dishes 
(MatTek Corporation, USA) for two hours, after which they were covered with cell 
culture medium. After 24 hrs incubation, the medium was removed and samples were 
rinsed twice with sterile PBS, new fresh medium containing DOX corresponding to the 
median inhibitory concentration, IC50, determined by cytotoxicity assays, was added and 
cells were incubated for a further 24 hrs. After incubation, old medium was removed and 
2mL of Nucred® solution in medium was added and, after 15 to 30 min incubation, 
samples were rinsed twice with sterile PBS, fixed in formalin (4 %, 15 min) and kept in 
PBS for imaging. Control samples without exposure to DOX were also prepared in 
parallel, and incubated for 24 hrs.  
CLSM images were recorded using an inverted Zeiss LSM 510 confocal laser scanning 
microscope equipped with a x60 oil immersion objective. DOX fluorescence was excited 
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with an argon ion laser at 488 nm, and the emission was collected at 530 nm, while 
Nucred® excitation and emission were respectively measured using 633 and 690 nm.  
5.2.5. Flow Cytometry:  
Cells (3x 104/flasks) were cultured in T25 flasks over 24 hrs, and then exposed to a range 
of DOX concentration (from 0.25x IC50 to 3.5x IC50). After 24 hrs incubation, cells were 
trypsinised and centrifuged in 5 mL fresh medium at 4 °C and 1100 rpm for 5 min, 
whereupon, they were re-suspended with 1mL ice cold Dulbecco's Phosphate-Buffered 
Saline (DPBS) buffer and centrifuged at 4 °C and 2500 rpm for 5 min. 
Cells were re-suspended in 750 µL ice cold DPBS buffer and transferred to Eppendorf 
tubes to which 250 µL of fixation buffer were added. After 30 min incubation at 4 ºC, the 
fixed cells were washed twice in perm/wash buffer, centrifuged (2500 Rpm for 5 min at 
4 ºC) and then gently re-suspended in 50 µL perm/wash buffer, after which 20 µL of the 
antibody were added and the cells were incubated for 60 min in the dark at 4 ºC. The cells 
were then washed twice in perm/wash buffer, centrifuged (2500 Rpm for 5 min at 4 ºC) 
to remove unbound antibody and finally re-suspended in 1mL stain buffer. 10,000 cells 
were analysed by Flow Cytometry using a BD Biosciences Accuri C6 Flow Cytometer 
(Becton Dickinson, Oxford, UK). The Accuri Flow cytometry software was used for the 
analysis of flow cytometry samples and data processing. 
5.2.6. Reactive oxygen species (ROS) expression:  
Carboxy-H2DCFDA dye was employed for the detection and quantification of ROS 
production in the intracellular environment. A solution at 10 µM of Carboxy-H2DCFDA 
was made up in PBS and added to the cells for 1hr incubation. After incubation, cells 
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were washed three times with PBS, then exposed to DOX for 24 hrs. Fluorescence was 
measured in the plate reader using 488 nm excitation and 535 nm emission. 
Negative controls, consisting of healthy cells, untreated with DOX, analysed with or 
without Carboxy-H2DCFDA and DOX treated cells analysed without Carboxy-
H2DCFDA, as well as positive controls of healthy cells exposed to a solution of hydrogen 
peroxide at 1 µM, were prepared in parallel. 
5.2.7. Raman micro-spectroscopy: 
Cells (~ 1x 104/window) were seeded and incubated on CaF2 windows (Crystan Ltd, UK) 
for 24 hrs for both control and exposure to DOX. Medium was then removed and samples 
were rinsed twice with sterile PBS and covered with DOX at the IC50. After 24 hrs 
incubation, cells were washed twice with sterile PBS and fixed in formalin (4 %, 15 min). 
A Horiba Jobin-Yvon LabRAM HR800 spectrometer with a 785 nm, 300 mW diode laser 
as source (~100mW at the sample), Peltier cooled 16-bit CCD, 300 lines/mm grating and 
100 μm confocal hole, was used to record spectra from the two cell lines, in the range 
from 400 cm-1 to 1800 cm-1 using a x100 objective (LCPlanN, Olympus N.A. 0,85)), in 
dry conditions from three cell locations: cytoplasm, nucleus and nucleolus, for 30 s two 
times , to finally produce a data set of 30 points per cell location (one spectrum from each 
cell compartment per cell) for each control and exposure to DOX, over a total of 120 
different cells. 
5.2.8. Data analysis:  
Raman spectral pre-processing and analysis were performed in Matlab 2013 using 
algorithms developed in house. Prior to analysis, spectra were smoothed (Savitsky-Golay 
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filter 5th order, 7 points), vector normalised, baseline corrected (fifth order polynomial) 
and background and DOX spectral features were subtracted using a non-negatively 
constrained least squares (NCLS) algorithm (Byrne et al., 2016).  
After pre-processing, principal components analysis (PCA) was employed as an 
unsupervised multivariate approach to analyse data and the effects of doxorubicin in each 
cell localisation and in each cell line. The order of the PCs denotes their importance in 
the dataset, whereby PC1 describes the highest amount of variation (Bonnier and Byrne, 
2012). 
Independent component analysis (ICA) was also employed as an extension to PCA. ICA 
is an unsupervised statistical technique able to identify latent variables called independent 
components. In case of Raman micro-spectroscopy, ICA can be used to identify spectral 
contributions such as those from substrate, using the same number of ICs as PCs, which 
can then be removed or studied in their own right (Boiret et al., 2014; Vrabie et al., 2007). 
5.3. Results and discussion:  
5.3.1. Cytotoxicity assays: 
Figure 5.1 shows the dose dependant cytotoxicity of DOX after 24 hrs exposure, for both 
cell lines, A549 and Calu-1, according to the AB and MTT in vitro cytotoxicity assays. 
Viability is expressed as % compared to control (non-exposed healthy cells), and the error 
bars indicate the standard deviation of six independent replicate measurements.  
For both in vitro assays, a partial loss of cell population viability is observed. However, 
whereas the AB and MTT for the A549 cell line and the MTT assay for the Calu-1 cell 
line show similar responses, the AB assay is relatively insensitive to the Calu-1 exposure. 
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A.                                                       B. 
 
Figure 5.1: AB and MTT 24 hrs in vitro dose dependent cytotoxicity assays of DOX A. 
A549 and B. Calu-1. Viability is expressed as % compared to control, and the error bars 
indicate the standard deviation of six independent replicate measurements. 
The differences in the responses between AB and MTT in the two cell lines, as 
demonstrated by Figure 5.1, suggest different sensitivities and/or resistances of the 
respective cell-lines to the drug, and should be analysed in terms of the mode of response 
of the assays. 
The MTT test is a colorimetric assay that measures the reduction of yellow 3-(4, 5-
dimethythiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) by mitochondrial 
succinate dehydrogenase into purple formazan crystals, insoluble in aqueous solution (Al-
Nasiry et al., 2007; Hamid et al., 2004). Succinate dehydrogenase or succinate-coenzyme 
Q reductase (SQR) or respiratory Complex II is an enzyme complex, bound to the inner 
mitochondrial membrane of mammalian mitochondria and many bacterial cells. It is the 
only enzyme that participates in both the citric acid cycle and the electron transport chain, 
so the MTT assay is the reflection of mitochondrial activity. Alamar blue (AB), on the 
other hand, is a water-soluble dye and one of the most highly used cytotoxicity assays for 
in vitro quantification of the cell viability (Fields and Lancaster, 1993). 
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When added to cell cultures, the active dye, resazurin or 7-hydroxy-10-oxidophenoxazin-
10-ium-3-one, diffuses into the cytosol and acts as an intermediate electron acceptor 
allowing the oxidised blue non-fluorescent form to be reduced by both mitochondrial and 
cytosolic enzyme activity to the fluorescent pink one which is easily measured by its 
absorption or fluorescence (Al-Nasiry et al., 2007; Hamid et al., 2004; Rampersad, 2012).  
Its response is thus considered the expression of general cellular metabolism. Therefore, 
although reduced conversion compared to controls is used as a measure of reduced 
cellular viability for both AB and MTT assays; the MTT response is more specifically 
sensitive to mitochondrial enzymes while AB is related to both mitochondrial and 
cytosolic activities. 
As illustrated by Figure 5.2, A549 cells and Calu-1 exhibit somewhat different IC50 
values, as measured using the MTT cytotoxicity assay, determined to be 0.55±0.16 µM 
and 0.90 ±0.24 µM for the A549 and Calu-1 cell lines respectively. The most notable 
differences observed, however, are in the AB cytotoxicity profiles, which are 
characterised by IC50 values of 0.42 ±0.06 µM and 0.69±0.13 µM for the A549 and Calu-
1 cell lines respectively. For the same DOX dosage, although similar changes in 
mitochondrial activity (as recorded by the MTT assay) and the overall cellular 
metabolism (as recorded by the AB assay) are observed for the A549 cell line, the overall 
dose dependent change in cellular metabolism, as recorded by the AB assay, is 
considerably less in the Calu-1 cell line. 
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Figure 5.2: MTT 24 hrs dose dependent cytotoxicity of DOX to A549 and Calu-1. 
The differing cytotoxic profiles for the two cell lines, is consistent with the contribution 
of multiple mechanisms to the toxic response, and a greater intrinsic resistance of the 
Calu-1 cell line to one or more of these mechanisms. The underlying mechanisms will be 
studied in more detail in the following sections. Since cells will be analysed after 24 hrs 
exposure, the IC50 determined using the MTT assay was used for the rest of the study, for 
both cell lines. 
5.3.2. Confocal Laser Scanning Fluorescence Microscopy: 
CLSM was employed to visualise the DOX intracellular internalisation and localisation 
in both cell lines. Figure 5.3 illustrates the images for A549 and Calu-1 cells after 24 hrs 
DOX exposure, at the respective MTT IC50 concentration for each cell line, and Nucred
® 
staining. DOX is predominantly localised on the nuclear area and, for both cell lines after 
exposure, cells appear smaller in size and round or oval in shape and exhibit noticeable 
nucleoli fragmentation, known as karyorrhexis, and membrane blebbing. The cytoplasm 
is more tightly packed as a result of cellular shrinkage. All these morphological changes 
161 
 
indicate that cells are going under apoptosis (Brauchle et al., 2014; De Bruin and 
Medema, 2008; Elmore, 2007; Kaufmann and Earnshaw, 2000; Kroemer et al., 2009; 
Pietkiewicz, Schmidt, and Lavrik, 2015) . 
A.   B.  
  
Figure 5.3: Confocal Laser Scanning Fluorescence images of A. A549 and B. Calu-1 
after 24 hrs DOX exposure and Nucred® staining confirming the DOX nuclear 
localisation. 
Using ImageJ software, after fluorescence background subtraction, the mean fluorescence 
intensity of the nuclear area was measured for 10 cells for each cell line. The average 
DOX fluorescence intensity was determined to be, respectively 644±29 AU for the A549 
cell line and 725±11 AU for Calu-1, indicating that a larger amount of DOX is present in 
the Calu-1 nucleus, despite the fact that the IC50 value for Calu-1 is almost twice that of 
A549 and the global nuclear volume is slightly higher for A549 than Calu-1 (Farhane, 
Bonnier, Casey, Maguire, et al., 2015). 
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5.3.3. Flow Cytometry and bcl-2 expression: 
Bcl-2 is an intracellular nuclear membrane anti apoptotic protein synthetised in direct 
response to DNA damage, in this case due to intercalation of DOX. As shown in Figure 
5.4, a similar expression profile of up regulation followed by down regulation of the bcl-
2 protein, as a function of DOX concentration, was observed for the two cell lines and 
this expression profile has been reported to be responsible for the resistance to apoptosis 
up to certain doses, above which DNA damage becomes prominent and bcl-2 levels 
decrease as cells enter apoptosis (Stephanova, Topouzova-Hristova, and Konakchieva, 
2008). 
The differences between the two bcl-2 expression profiles for each cell line, as a function 
of MTT IC50 are manifest in the maximum level of bcl-2, and the dose at which this is 
reached. It is notable that the bcl-2 level in Calu-1 cells is consistently higher over the 
dose range than A549, with a maximum expression at 2 IC50 for A549 (1.1 M) and 3 
IC50 for Calu-1 (2.7 M).  
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A. 
 
B. 
 
Figure 5.4: Expression level of bcl-2 due to DOX exposure and control healthy cells for 
A. A549 and B. Calu-1 determined by Flow Cytometry.  
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5.3.4. ROS production monitored by DCFDA: 
In addition to the mode of action of DNA intercalation, internalised DOX can also lead 
to the generation of intracellular ROS in the cytosol by redox activation in the presence 
of NADPH, forming a quinone radical via one electron transfer and generating peroxide 
and superoxide (Gewirtz, 1999; Mizutani et al., 2005), resulting in DNA, mitochondrial 
and cell membrane damage by oxidation, responsible for its most significant chronic side 
effect, cardiotoxicity (Costa, Scholer-Dahirel, and Mechta-Grigoriou, 2014; Wang et al., 
2002). 
ROS were measured by the DCFDA dye, a highly fluorescent compound in presence of 
ROS which can be detected by fluorescence. As detailed in Table 5.1, and illustrated 
schematically in Figure 5.5, significantly higher ROS levels are present in Calu-1 cells 
than A549 (Test (DOX+DCFDA)), after 24 hrs exposure to the DOX IC50 concentration, 
as measured by the MTT assay. In fact, Calu-1 has higher ROS levels compared to A549 
even without any DOX exposure and this expression becomes even higher after DOX 
exposure, emphasising the difference between the two cell lines. ROS are usually 
generated through a cascade of reactions resulting from the distinct oxidation status of 
O2, including its radical forms, such as the superoxide radical, and non-radical forms such 
as hydrogen peroxide, H2O2 (Halliwell, 2006).  
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Table 5.1: ROS production in A. A549 cell line and B. Calu-1 cell line, negative controls 
using healthy cells and no DCFDA, exposed cells and no DCFDA and healthy cells with 
DCFDA and H2O2 1 µM solution as positive control. 
A. 
 Negative controls (Arb.Units) Positive 
control  
(Cells+H2O2+ 
DCFDA) 
(Arb. Units) 
Test 
(DOX+DCFDA) 
(Arb. Units) 
 
Healthy 
cells 
+PBS (no 
DCFDA) 
DOX + 
PBS (no 
DCFDA) 
Negative 
control 
(healthy cells 
+DCFDA) 
Average 70.85706 254.6403 80.57879 190.1014 279.9507 
STD 10.88444 12.0606 6.892106 28.31797 25.60829 
Ave %  87.93512 316.014 100 235.9199 347.4248 
STD % 13.50783 14.96746 8.55325 35.14321 31.78044 
B. 
 Negative controls (Arb.Units) Positive 
control 
(Cells+H2O2+ 
DCFDA) 
(Arb.Units) 
Test 
(DOX+DCFDA) 
(Arb.Units) 
 
Healthy 
cells 
+PBS (no 
DCFDA) 
DOX + 
PBS (no 
DCFDA) 
Negative 
control 
(healthy cells 
+DCFDA) 
Average 47.589 312.8539 309.0865 356.7716 1214.652 
STD 10.91059 23.91193 21.34131 24.93965  63.87997 
Ave %  15.39666 101.2189 100 115.4277 392.9813 
STD % 3.529947 7.736324 6.90464 8.068825 20.66734 
Cancer cells have a high level of ROS, recognized to be signalling molecules in various 
biological processes, eliciting proliferation, genomic instability and inflammation 
(Schumacker, 2006) but a considerable increase of ROS level induces damage and 
promotes apoptosis (Costa, Scholer-Dahirel, and Mechta-Grigoriou, 2014; Schumacker, 
2006). Although the relationship between DNA mutations, ROS generation, and drug 
sensitivity remains unclear, the ROS mediated apoptosis mechanism appears to be 
activated in the Calu-1 cell line to a significantly greater extent than in A549.  
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Figure 5.5: Reactive oxygen species generation expressed on percentage of control for 
Calu-1 and A549 cell lines. 
5.3.5. Raman micro-spectroscopy:  
Raman spectrosopy has previously demonstrated that A549 and Calu-1 cells are 
distinguishable, based on the spectral profile of their nucleoli (Farhane, Bonnier, Casey, 
Maguire, et al., 2015). Furthermore, it has previously been employed to profile the 
interactions of DOX within the nuclear and nucleolar regions of A549 cells (Farhane, 
Bonnier, Casey, and Byrne, 2015).  In order to further elucidate the subcellular differences 
of the responses and potential resistance mechanisms of the A549 and Calu-1 cell lines 
to DOX exposure, Raman spectra, for both A549 and Calu-1 cells, were taken from the 
three cellular compartments after 24 hrs exposure to the MTT IC50 concentration of DOX 
corresponding to each cell line. For PCA analysis, figures corresponding to spectral 
differentiation according to PC1 and PC2 were plotted and, for clarity, the corresponding 
loadings are off set, and the dashed horizontal line in all cases indicating zero loading. 
167 
 
Figure 5.6 shows the mean spectra of nucleolus, nucleus and cytoplasm for Calu-1 cell 
lines along with the spectrum of DOX powder dissolved in sterile water. Nucleolar size 
for both control cell lines is of the order of 2-4 μm, although it reduces to ~ 1-2 μm due 
to DOX exposure inducing fragmentation (Figure 5.3) (Farhane, Bonnier, Casey, 
Maguire, et al., 2015). Nevertheless, it remains larger than the Raman laser spot (1 μm), 
allowing Raman spectra acquisition specifically from the nucleoli. Points were chosen 
randomly from the cytoplasmic and nuclear areas of the cells. The variability of the 
spectra from each cellular region of each cell line is indicated by the spread of data points 
for each region in the PCA scatter plot of, for example, Figure 5.8.  
 
Figure 5.6: Spectrum of Doxorubicin (A) and mean spectra of Nucleolus (B), Nucleus 
(C) and Cytoplasm (D) of the Calu-1 cell line, highlighted regions indicating 
discriminating Doxorubicin features.  
As shown in previous study of the A549 cell line by Farhane et al. (Farhane, Bonnier, 
Casey, and Byrne, 2015), and as seen in Figure 5.6 for the Calu-1 cell line, obvious DOX 
features (indicated by highlighted regions) at 440 and 465 cm−1 respectively C–C–O and 
C–O and 1085, 1215 and 1245 cm−1 related to C–O, C–O–H and C–H are observed in the 
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nucleolar and nuclear region for both cell lines, confirming the predominant localisation 
of the drug in these regions.  
 
Figure 5.7: Mean spectra of the nucleoli of Calu-1 cells highlighting the spectroscopic 
changes after DOX exposure; control (brown) and after DOX exposure (black).  
Additionally, in the mean spectra of the nucleolus of Calu-1, before and after DOX 
exposure, an evident diminishment of peaks at 847 and 960 cm-1 can be seen (highlighted 
in Figure 5.7), indicating a modification of ribose phosphate backbone due to DOX 
intercalation. Moreover, obvious decreases of DNA peaks at 669, 728, 782 and 830 cm-1 
in the spectra of the nucleolus of treated cells compared to non-treated ones are observed, 
due to DOX-DNA interactions inducing DNA synthesis interruption (Gewirtz, 1999) and 
changes in DNA conformation (decrease of DNA B form) (Nawaz et al., 2013) inducing 
early cell apoptosis (Brauchle et al., 2014; Lin et al., 2012) (Similar results were found 
for nuclear spectra, data not shown). In addition to the decrease in DNA peaks, a shift 
towards lower wavenumbers is observed for the peak at 1095 cm-1, corresponding to O-
P-O stretching, which indicates that DOX is also able to bind to DNA externally (Nawaz 
et al., 2013). Besides the effects on DNA related spectral features, it appears that proteins 
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and lipids are also affected, as evidenced by the decrease of their corresponding peaks, 
for example, respectively at 1450 and 1665 cm-1. The peak at 1450 cm-1 is influenced by 
DOX peak proximity but, after DOX subtraction, it can be clearly seen that this peak is 
diminished (data not shown) (Huser and Chan, 2015). 
A more detailed analysis of the changes in the spectral features as a result of DOX 
exposure and comparison between the responses of the two cell lines is facilitated by 
PCA. Figure 5.8, showing PCA of nucleolar, nuclear and cytoplasmic regions, for A549 
and Calu-1 cells after exposure to DOX, exhibits a separation between the three cellular 
compartments and the corresponding loading of PC1, differentiating the combined 
nuclear region from the cytoplasmic one, is dominated on the positive side by DOX 
features, confirming once again its predominantly nuclear and nucleolar subcellular 
localisation, for both cell lines. The negative side is dominated by lipidic features at 1450 
cm-1 (CH2 deformation) and 1661 cm
-1 (Lipids C=C stretching), corresponding to 
biochemical changes in the cytoplasmic region (Downes and Elfick, 2010; Draux et al., 
2009; Kann et al., 2015). 
A pairwise PCA of the three cellular regions was performed, and it is notable in Figure 
5.8 B, that PC1 clearly differentiates the nucleolar and nuclear regions between the two 
cell lines and the corresponding loading of PC1 clearly exhibits positive DOX features, 
indicating that there is more DOX in Calu-1 than in A549 cells, supporting the ImageJ 
analysis of the CLSM images. Negatives features at 1320 and 1450 cm-1 (CH2 
deformation) and 1661 cm-1 (Lipid C=C stretching) are also observed in the loading of 
PC1 for nucleolar, nuclear and cytoplasmic areas, indicating that there is higher lipidic 
content in A549 cells than in Calu-1. 
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A. 
 
B. 
 
Figure 5.8: PCA of nucleolar, nuclear and cytoplasmic regions of A. A549 and Calu-1 
with corresponding loadings of PC1 and PC2 B. PCA of each cell localisation for A549 
and Calu-1 and the corresponding loadings of PC1 and PC2. 
Nucleolus     Nucleus     Cytoplasm     A549 cell line 
Nucleolus     Nucleus     Cytoplasm     Calu-1 cell line 
The differing cellular responses, in the subcellular regions, can be better visualised after 
subtraction of the DOX spectral signature from the cellular spectra (Farhane, Bonnier, 
Casey, and Byrne, 2015). Figure 5.9 shows the PCA of the nucleolus of A549 and Calu-
171 
 
1 after subtraction of DOX spectral features. Although the differentiation is not absolute, 
the A549 data is predominantly distributed with positive loadings of PC1, and vice versa 
for Calu-1. The loading of PC1 indicates that there is a more pronounced increase in some 
protein features in Calu-1 cells, than in A549. These include those at 645 cm-1 (C–C twist 
Tyrosine), 936 cm-1 (C–C stretching), 1176 cm-1 (Tyrosine), 1450 cm-1 (C-H) and 1665 
cm-1 (Amide I). Similar changes are apparent in these protein related features in the mean 
spectra of Figure 5.6, although they are less pronounced in the mean spectra of A549 
(Farhane, Bonnier, Casey, and Byrne, 2015). 
 
Figure 5.9: PCA of nucleolar compartment of Calu-1 and A549 after DOX spectral 
features subtraction and corresponding loadings of PC1 and PC2. 
Nucleolus    A549 cell line after DOX subtraction 
Nucleolus    Calu-1 cell line after DOX subtraction 
A further notable difference in the Raman profiles of Calu-1 compared to A549 cells is 
seen in the cytoplasmic region. Figure 5.6 reveals traces of DOX features for Calu-1, most 
apparent in the region from ~440-465 cm-1, which suggests the presence of a small 
amount of DOX in the cytoplasm, undetectable by CLSM. These are completely absent 
in the case of A549 (Farhane, Bonnier, Casey, and Byrne, 2015). The same DOX features 
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are obvious in the loading of PC2, separating the two cytoplasmic regions, in Figure 5.8 
B, further indicating the presence of DOX in the cytoplasm of Calu-1 cells, while it is not 
detectable in A549. This observation highlights the sensitivity of Raman spectroscopic 
profiling to even small quantities of drugs inside cells and indicates that the sub-cellular 
distribution of DOX after 24 hrs exposure differs between the two cell lines. 
In order, to investigate the DOX mechanism of action in more details, and to support and 
complement the PCA observations, ICA was performed using three components, as 
estimated by PCA, explaining the majority of variance, and only the first conponent for 
each cellular compartment was plotted and off set for clarity.  
 
Figure 5.10: A. DOX spectrum and A549 ICA component B. Nucleolus C. Nucleus and 
D. Cytoplasm. 
Figures 5.10 and 5.11 represent the ICA signals for the nucleolar, nuclear and cytoplasmic 
regions, respectively for the A549 and Calu-1 cell lines, plotted with the raw DOX 
spectrum for comparison. It is notable that the nucleolar and nuclear components exhibit 
DOX features at 440, 465 cm−1, 1085, 1215 and 1245 cm−1 for both cell lines, while these 
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features are only strongly observed (Figure 5.11) in the cytoplasm of Calu-1, confirming 
the PCA results.  
 
Figure 5.11: A. DOX spectrum and Calu-1 ICA component B. Nucleolus C. Nucleus and 
D. Cytoplasm. 
In both Figure 5.10 and 5.11, the peak at 795 cm-1 in the IC for both the nucleolus and 
nucleus (absent in the cytoplasm) corresponds to nucleic acid and confirms the nucleic 
DOX intercalation, while the negative peak at 1665 cm-1 represents a decrease in the 
protein Amide I response, consistent with the analysis of the mean spectrum of nucleolus 
and nucleus before and after DOX exposure. The IC for both the nucleolus and nucleus 
also exhibit obvious features at 1430-1456 cm-1. These peaks are not visible in mean 
spectra, due to the proximity of lipid peaks and are absent in ICA of the control cells 
before exposure to DOX (data not shown). While these signatures could be attributed to 
DOX, they also correspond to signatures of Guanine and Cytosine (Notingher et al., 
2002). The increase in these nucleic acid signatures could be due to DOX-DNA 
intercalation. DOX intercalates preferentially between two adjacent GC bases (Yang et 
174 
 
al., 2014), inducing changes in DNA conformation, damage of the DNA double helix 
structure and the observed spectral changes may therefore be evidence of DOX 
intercalation between Guanine and Cytosine bases. There is also a hyperchromic effect 
observed for the peak at 1376 cm-1 corresponding to Thymine, Adenine, Guanine (ring 
breathing modes of the DNA/RNA bases) (Pravin and Raman, 2013; Rafique et al., 2013). 
 
Figure 5.12: A. Spectrum DOX and B. Cytoplasm Calu-1 cell line ICA component.   
In the ICA of the cytoplasm of DOX exposed Calu-1 cells (Figure 5.12), DOX features 
are clearly evident, confirming DOX localisation in the cytoplasm. However, the spectral 
profile of the IC is considerably different than that of pristine DOX, and the IC of the 
nuclear and nucleolar regions. This is consistent with a metabolisation of the DOX 
molecules within the cytoplasm, and the resultant cellular interaction is manifest as the 
spectral features at 720 and 877 cm-1 corresponding to C–C–N+ stretching, ones at 1024, 
1343 cm-1 and 1456 cm-1, related to C-H vibrations and 1661 cm-1, corresponding to 
lipidic C=C stretching (Farhane, Bonnier, Casey, and Byrne, 2015; Notingher, 2007).  
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5.4. Discussion: 
The analysis of the dose dependent cytotoxic response of the two cell lines to DOX 
exposure, after 24 hrs shows a notably different profile, particularly for the case of the 
Alamar Blue assay. The results are consistent with an increased resistance of the Calu-1 
cell line to the drug, compared to A549. The traditional cytotoxic assays shed little light 
on the origin of the different cellular responses, in terms of the cellular pharmacokinetics, 
however. The flow cytometric analysis indicates that DOX exposure elicits significantly 
higher upregulation of the anti-apoptotic protein bcl-2 in the Calu-1 cell line, while 
analysis of the induced oxidative stress reveals substantially higher levels of ROS in Calu-
1. DOX is reported to induce cell death by two principle modes of action, and the results 
are consistent with different relative contributions to the cytotoxic response in the two 
cell lines. DOX is rapidly trafficked to the cell nucleus (and mitochondria), where it binds 
with the DNA by intercalation, inducing DNA damage and initiating an apoptotic 
cascade, registered by the MTT assay. The MTT assay registers similar cytotoxicity 
profiles for the two cell lines, and the somewhat higher IC50 value for Calu-1 is consistent 
with the observation from CLSM that there is a higher uptake of DOX in the nuclei of 
Calu-1. The DNA damage in cell nuclei triggers the upregulation of the anti-apoptotic 
protein bcl-2, which inhibits the apoptotic process. This response is significantly stronger 
in the Calu-1 cell line, and this greater resistance to apoptosis is consistent with the 
substantially lower loss of cell viability as registered by the AB assay. Concomitantly, a 
significantly higher degree of oxidative stress in the Calu-1 cell line is observable. ROS 
generation in the cytosol, resulting in DNA damage in the nucleus, is the second reported 
mode of action of DOX. The process is the result of a complex cascade initiated by the 
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reduction of DOX in the presence of NADPH and, in comparison to the direct interaction 
of DOX with the nuclear DNA, is a relatively slow process. 
The combination of the cytotoxic assays, Flow Cytometry and CLSM can help to 
understand the underlying mechanisms of the different responses of the two cell lines to 
DOX exposure, and the apparent higher resistance one to cell death. As a label free, high 
content analysis technique, Raman spectroscopy can provide similar insights in a single 
measurement. Notably, Raman spectroscopy gives a clear indication of the presence of 
DOX and/or its semiquinone metabolite in the cytoplasm of Calu-1 cells, whereas it is 
not apparent in A549 cells. This observation is indicative of a retarded transport of the 
drug to the nuclei of Calu-1 cells, and an increased contribution of oxidative stress to the 
cellular response mechanism. Contained in the spectral changes of the cytoplasm are also 
signatures of cell damage, characteristic of the response mechanism. In the cell nuclei, 
DOX exposure produces clear signatures of DNA intercalation, as well as external groove 
binding, in both cell lines. In the nuclei of Calu-1 cells, there is a significantly higher 
increase in protein activity, consistent with the upregulation of the cellular anti-apoptotic 
resistance mechanism. 
The results of the Raman micro spectroscopic investigation therefore clearly demonstrate 
signatures of the interaction of the DOX with the two cell lines, and the mechanisms of 
cellular response. The differences in response are consistent with the differences observed 
through the combination of established techniques of cytotoxic assays, flow cytometry 
and CLSM.  
However, the spectroscopic signatures are obtained in a single, label free measurement. 
It is noted that the chemotherapeutic agent chosen here, DOX, is a relatively strong 
Raman scatter, due to its -conjugated anthracycline structure, and much is already 
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known about its mechanisms of interaction. Nevertheless, the study serves as a further 
illustration of the potential of Raman spectroscopy as an in vitro companion diagnostic 
tool. Although the screening was performed at a single time point, ongoing technological 
developments such as in nonlinear Raman techniques promise significantly enhanced 
signals, and therefore reduced sampling times, and ultimately real-time monitoring of 
cellular uptake of drugs and other external agents such as nanoparticles, and the 
subsequent cellular responses.  
5.5. Conclusion: 
The study further demonstrates the potential of Raman micro-spectroscopy as a high 
content, label free in vitro tool, not only to localise drugs within cells, but also to monitor 
their interactions in the cytoplasm and nucleus of the cells at a molecular level, and to 
characterise the subsequent cellular responses on a subcellular level. Spectroscopic 
signatures of DNA intercalation, binding and damage are clearly identifiable in the cell 
nucleus, and cellular responses such as the upregulation of anti-apoptotic proteins and 
cytoplasmic damage can be monitored. The technique has previously been employed to 
differentiate the two cancer cell lines, A549 and Calu-1 based on the spectroscopic 
signatures of their nucleoli, and in this study the differences of the responses of the two 
cell lines to DOX exposure are clearly identifiable in their post exposure spectroscopic 
signatures. Notably, due to the sensitivity of the detection system, Raman spectroscopy 
can detect the presence of the drug in the cytoplasm in the Calu-1 cell line, but not in 
A549, which is a key to understanding the difference in the cytotoxic responses, and 
therefore in cell resistance to the drug, coupled with the increased upregulation of anti-
apoptotic proteins in the nucleus. The technique corroborates the results of classic 
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cytotoxicity assays, bcl-2 monitoring using flow cytometry, ROS monitoring using 
confocal microscopy, but does so in a single, label free measurement, clearly indicating 
the benefits of the technique for high content screening and in vitro companion 
diagnostics. 
5.6. Acknowledgement: 
This work was supported by Science Foundation Ireland Principle Investigator Award 
11/PI/1108. 
  
179 
 
5.7. References: 
Abramczyk, H, Brozek-Pluska, B, Surmacki, J, Jablonska-Gajewicz, J and Kordek, R 
(2012) Raman ‘Optical Biopsy’ of Human Breast Cancer. Prog. Biophys. Mol. 
Biol., 108(1–2), 74-81. 
Al-Nasiry, S, Geusens, N, Hanssens, M, Luyten, C and Pijnenborg, R (2007) The Use of 
Alamar Blue Assay for Quantitative Analysis of Viability, Migration and Invasion 
of Choriocarcinoma Cells. Hum Reprod, 22(5), 1304-9. 
Boiret, M, Rutledge, D N, Gorretta, N, Ginot, Y M and Roger, J M (2014) Application of 
Independent Component Analysis on Raman Images of a Pharmaceutical Drug 
Product: Pure Spectra Determination and Spatial Distribution of Constituents. J 
Pharm Biomed Anal, 90, 78-84. 
Bonnier, F and Byrne, H J (2012) Understanding the Molecular Information Contained 
in Principal Component Analysis of Vibrational Spectra of Biological Systems. 
Analyst, 137(2), 322-32. 
Brauchle, E, Thude, S, Brucker, S Y and Schenke-Layland, K (2014) Cell Death Stages 
in Single Apoptotic and Necrotic Cells Monitored by Raman Microspectroscopy. 
Sci. Rep., 4, 4698. 
Byrne, H J, Baranska, M, Puppels, G J, Stone, N, Wood, B, Gough, K M, Lasch, P, 
Heraud, P, Sule-Suso, J and Sockalingum, G D (2015) Spectropathology for the 
Next Generation: Quo Vadis? Analyst, 140(7), 2066-73. 
Byrne, H J, Knief, P, Keating, M E and Bonnier, F (2016) Spectral Pre and Post 
Processing for Infrared and Raman Spectroscopy of Biological Tissues and Cells. 
Chem.Soc.Rev., 45(7), 1865-78. 
180 
 
Caponi, S, Liguori, L, Giugliarelli, A, Mattarelli, M, Morresi, A, Sassi, P, Urbanelli, L 
and Musio, C (2013) Raman Micro-Spectroscopy: A Powerful Tool for the 
Monitoring of Dynamic Supramolecular Changes in Living Cells. Biophys Chem, 
182, 58-63. 
Carvalho, L F, Bonnier, F, O'Callaghan, K, O'Sullivan, J, Flint, S, Byrne, H J and Lyng, 
F M (2015) Raman Micro-Spectroscopy for Rapid Screening of Oral Squamous 
Cell Carcinoma. Exp. Mol. Pathol., 98(3), 502-9. 
Correia, C, Lee, S H, Meng, X W, Vincelette, N D, Knorr, K L, Ding, H, Nowakowski, 
G S, Dai, H and Kaufmann, S H (2015) Emerging Understanding of Bcl-2 
Biology: Implications for Neoplastic Progression and Treatment. Biochim 
Biophys Acta, 1853(7), 1658-71. 
Costa, A, Scholer-Dahirel, A and Mechta-Grigoriou, F (2014) The Role of Reactive 
Oxygen Species and Metabolism on Cancer Cells and Their Microenvironment. 
Semin Cancer Biol, 25, 23-32. 
Cutts, S M, Nudelman, A, Rephaeli, A and Phillips, D R (2005) The Power and Potential 
of Doxorubicin-Dna Adducts. IUBMB Life, 57(2), 73-81. 
Cîntǎ Pînzaru, S, Pavel, I, Leopold, N and Kiefer, W (2004) Identification and 
Characterization of Pharmaceuticals Using Raman and Surface-Enhanced Raman 
Scattering. J. Raman Spectrosc., 35(5), 338-46. 
De Bruin, E C and Medema, J P (2008) Apoptosis and Non-Apoptotic Deaths in Cancer 
Development and Treatment Response. Cancer Treat. Rev., 34(8), 737-49. 
Downes, A and Elfick, A (2010) Raman Spectroscopy and Related Techniques in 
Biomedicine. Sensors (Basel, Switzerland), 10(3), 1871-89. 
181 
 
Draux, F, Jeannesson, P, Beljebbar, A, Tfayli, A, Fourre, N, Manfait, M, Sule-Suso, J and 
Sockalingum, G D (2009) Raman Spectral Imaging of Single Living Cancer Cells: 
A Preliminary Study. Analyst, 134(3), 542-8. 
Elmore, S (2007) Apoptosis: A Review of Programmed Cell Death. Toxicol Pathol, 35(4), 
495-516. 
Farhane, Z, Bonnier, F, Casey, A and Byrne, H J (2015) Raman Micro Spectroscopy for 
in Vitro Drug Screening: Subcellular Localisation and Interactions of 
Doxorubicin. Analyst, 140(12), 4212-23. 
Farhane, Z, Bonnier, F, Casey, A, Maguire, A, O'Neill, L and Byrne, H J (2015) Cellular 
Discrimination Using in Vitro Raman Micro Spectroscopy: The Role of the 
Nucleolus. Analyst, 140(17), 5908-19. 
Feng, S, Chen, R, Lin, J, Pan, J, Wu, Y, Li, Y, Chen, J and Zeng, H (2011) Gastric Cancer 
Detection Based on Blood Plasma Surface-Enhanced Raman Spectroscopy 
Excited by Polarized Laser Light. Biosens. Bioelectron., 26(7), 3167-74. 
Fields, R D and Lancaster, M V (1993) Dual-Attribute Continuous Monitoring of Cell 
Proliferation/Cytotoxicity. Am Biotechnol Lab, 11(4), 48-50. 
Filyak, Y, Filyak, O, Souchelnytskyi, S and Stoika, R (2008) Doxorubicin Inhibits Tgf-
Beta Signaling in Human Lung Carcinoma A549 Cells. Eur J Pharmacol, 590(1-
3), 67-73. 
Gewirtz, D A (1999) A Critical Evaluation of the Mechanisms of Action Proposed for the 
Antitumor Effects of the Anthracycline Antibiotics Adriamycin and 
Daunorubicin. Biochem Pharmacol, 57(7), 727-41. 
Gimenez-Cassina, A and Danial, N N (2015) Regulation of Mitochondrial Nutrient and 
Energy Metabolism by Bcl-2 Family Proteins. Trends Endocrinol Metab, 26(4), 
165-75. 
182 
 
Haikerwal, S J, Hagekyriakou, J, MacManus, M, Martin, O A and Haynes, N M (2015) 
Building Immunity to Cancer with Radiation Therapy. Cancer Lett., 368(2), 198-
208. 
Halliwell, B (2006) Oxidative Stress and Neurodegeneration: Where Are We Now? J 
Neurochem, 97(6), 1634-58. 
Hamid, R, Rotshteyn, Y, Rabadi, L, Parikh, R and Bullock, P (2004) Comparison of 
Alamar Blue and Mtt Assays for High through-Put Screening. Toxicol In Vitro, 
18(5), 703-10. 
Hardwick, J M and Soane, L (2013) Multiple Functions of Bcl-2 Family Proteins. Cold 
Spring Harb Perspect Biol, 5(2). 
Hrelia, S, Fiorentini, D, Maraldi, T, Angeloni, C, Bordoni, A, Biagi, P L and Hakim, G 
(2002) Doxorubicin Induces Early Lipid Peroxidation Associated with Changes 
in Glucose Transport in Cultured Cardiomyocytes. BBA-REV BIOMEMBRANES, 
1567, 150-6. 
Huser, T and Chan, J (2015) Raman Spectroscopy for Physiological Investigations of 
Tissues and Cells. Adv Drug Deliv Rev, accepted manuscript 26 June 
2015 DOI: 10.1016/j.addr.2015.06.011. 
Hussar, P, Žuravskaja, M and Kärner, M (2013) Apoptosis Regulator Bcl-2. Papers on 
Anthropology XXII, 22, 63-7. 
Johnstone, R W, Ruefli, A A and Lowe, S W (2002) Apoptosis: A Link between Cancer 
Genetics and Chemotherapy. Cell, 108(2), 153-64. 
Jorgensen, J T (2015) Clinical Application of Companion Diagnostics. Trends Mol Med, 
21(7), 405-7. 
183 
 
Kann, B, Offerhaus, H L, Windbergs, M and Otto, C (2015) Raman Microscopy for 
Cellular Investigations — from Single Cell Imaging to Drug Carrier Uptake 
Visualization. Adv. Drug Deliv. Rev., 89, 71-90. 
Kaufmann, S H and Earnshaw, W C (2000) Induction of Apoptosis by Cancer 
Chemotherapy. Exp Cell Res, 256(1), 42-9. 
Knipfer, C, Motz, J, Adler, W, Brunner, K, Gebrekidan, M T, Hankel, R, Agaimy, A, 
Will, S, Braeuer, A, Neukam, F W and Stelzle, F (2014) Raman Difference 
Spectroscopy: A Non-Invasive Method for Identification of Oral Squamous Cell 
Carcinoma. Biomed. Opt. Express, 5(9), 3252-65. 
Kroemer, G, Galluzzi, L, Vandenabeele, P, Abrams, J, Alnemri, E S, Baehrecke, E H, 
Blagosklonny, M V, El-Deiry, W S, Golstein, P, Green, D R, Hengartner, M, 
Knight, R A, Kumar, S, Lipton, S A, Malorni, W, Nunez, G, Peter, M E, Tschopp, 
J, Yuan, J, Piacentini, M, Zhivotovsky, B and Melino, G (2009) Classification of 
Cell Death: Recommendations of the Nomenclature Committee on Cell Death 
2009. Cell Death Differ, 16(1), 3-11. 
Lee, S, Chon, H, Lee, J, Ko, J, Chung, B H, Lim, D W and Choo, J (2014) Rapid and 
Sensitive Phenotypic Marker Detection on Breast Cancer Cells Using Surface-
Enhanced Raman Scattering (Sers) Imaging. Biosens. Bioelectron., 51, 238-43. 
Legesse, F B, Medyukhina, A, Heuke, S and Popp, J (2015) Texture Analysis and 
Classification in Coherent Anti-Stokes Raman Scattering (Cars) Microscopy 
Images for Automated Detection of Skin Cancer. Comput Med Imaging Graph, 
43, 36-43. 
Lin, H H, Li, Y C, Chang, C H, Liu, C, Yu, A L and Chen, C H (2012) Single Nuclei 
Raman Spectroscopy for Drug Evaluation. Anal Chem, 84(1), 113-20. 
184 
 
Majzner, K, Wojcik, T, Szafraniec, E, Lukawska, M, Oszczapowicz, I, Chlopicki, S and 
Baranska, M (2015) Nuclear Accumulation of Anthracyclines in the Endothelium 
Studied by Bimodal Imaging: Fluorescence and Raman Microscopy. Analyst, 
140(7), 2302-10. 
Makin, G and Dive, C (2001) Apoptosis and Cancer Chemotherapy. TRENDS CELL 
BIOL, 11(11), S22-S6. 
Mizutani, H, Tada-Oikawa, S, Hiraku, Y, Kojima, M and Kawanishi, S (2005) 
Mechanism of Apoptosis Induced by Doxorubicin through the Generation of 
Hydrogen Peroxide. Life Sci, 76(13), 1439-53. 
Mohammad, R M, Muqbil, I, Lowe, L, Yedjou, C, Hsu, H Y, Lin, L T, Siegelin, M D, 
Fimognari, C, Kumar, N B, Dou, Q P, Yang, H, Samadi, A K, Russo, G L, 
Spagnuolo, C, Ray, S K, Chakrabarti, M, Morre, J D, Coley, H M, Honoki, K, 
Fujii, H, Georgakilas, A G, Amedei, A, Niccolai, E, Amin, A, Ashraf, S S, 
Helferich, W G, Yang, X, Boosani, C S, Guha, G, Bhakta, D, Ciriolo, M R, 
Aquilano, K, Chen, S, Mohammed, S I, Keith, W N, Bilsland, A, Halicka, D, 
Nowsheen, S and Azmi, A S (2015) Broad Targeting of Resistance to Apoptosis 
in Cancer. SEMIN CANCER BIOL, 35, Supplement, S78-S103. 
Moldoveanu, T, Follis, A V, Kriwacki, R W and Green, D R (2014) Many Players in Bcl-
2 Family Affairs. Trends Biochem Sci, 39(3), 101-11. 
Nawaz, H, Garcia, A, Meade, A D, Lyng, F M and Byrne, H J (2013) Raman Micro 
Spectroscopy Study of the Interaction of Vincristine with A549 Cells Supported 
by Expression Analysis of Bcl-2 Protein. Analyst, 138(20), 6177-84. 
Notingher, I (2007) Raman Spectroscopy Cell-Based Biosensors. Sensors, 7(8), 1343-58. 
185 
 
Notingher, I, Verrier, S, Romanska, H, Bishop, A E, Polak, J M and Hench, L L (2002) 
In Situ Characterisation of Living Cells by Raman Spectroscopy. SPECTROSC-
INT J, 16(2), 43-51. 
Owen, C A, Selvakumaran, J, Notingher, I, Jell, G, Hench, L L and Stevens, M M (2006) 
In Vitro Toxicology Evaluation of Pharmaceuticals Using Raman Micro-
Spectroscopy. J Cell Biochem, 99(1), 178-86. 
Paudel, A, Raijada, D and Rantanen, J (2015) Raman Spectroscopy in Pharmaceutical 
Product Design. Adv Drug Deliv Rev, 89, 3-20. 
Pietkiewicz, S, Schmidt, J H and Lavrik, I N (2015) Quantification of Apoptosis and 
Necroptosis at the Single Cell Level by a Combination of Imaging Flow 
Cytometry with Classical Annexin V/Propidium Iodide Staining. J Immunol 
Methods, 423, 99-103. 
Poornima, P, Kumar, V B, Weng, C F and Padma, V V (2014) Doxorubicin Induced 
Apoptosis Was Potentiated by Neferine in Human Lung Adenocarcima, A549 
Cells. Food Chem Toxicol, 68, 87-98. 
Pravin, N and Raman, N (2013) Dna Interaction and Antimicrobial Activity of Novel 
Tetradentate Imino-Oxalato Mixed Ligand Metal Complexes. Inorg. Chem. 
Commun., 36, 45-50. 
Qiu, T, Zhou, L, Wang, T, Xu, J, Wang, J, Chen, W, Zhou, X, Huang, Z, Zhu, W, Shu, Y 
and Liu, P (2013) Mir-503 Regulates the Resistance of Non-Small Cell Lung 
Cancer Cells to Cisplatin by Targeting Bcl-2. Int J Mol Med, 32(3), 593-8. 
Rae, A, Stosch, R, Klapetek, P, Hight Walker, A R and Roy, D (2014) State of the Art 
Raman Techniques for Biological Applications. Methods, 68(2), 338-47. 
186 
 
Rafique, B, Khalid, A M, Akhtar, K and Jabbar, A (2013) Interaction of Anticancer Drug 
Methotrexate with Dna Analyzed by Electrochemical and Spectroscopic Methods. 
Biosens. Bioelectron., 44, 21-6. 
Ramos, I R, Malkin, A and Lyng, F M (2015) Current Advances in the Application of 
Raman Spectroscopy for Molecular Diagnosis of Cervical Cancer. Biomed Res 
Int, 2015, 561242. 
Rampersad, S N (2012) Multiple Applications of Alamar Blue as an Indicator of 
Metabolic Function and Cellular Health in Cell Viability Bioassays. Sensors 
(Basel), 12(9), 12347-60. 
Rashid, N, Nawaz, H, Poon, K W C, Bonnier, F, Bakhiet, S, Martin, C, O'Leary, J J, 
Byrne, H J and Lyng, F M (2014) Raman Microspectroscopy for the Early 
Detection of Pre-Malignant Changes in Cervical Tissue. Experimental and 
Molecular Pathology, 97(3), 554-64. 
Rogalska, A, Gajek, A, Szwed, M, Jozwiak, Z and A, M (2011) The Role of Reactive 
Oxygen Species in Wp 631-Induced Death of Human Ovarian Cancer Cells: A 
Comparison with the Effect of Doxorubicin. Toxicol In Vitro, 25(8), 1712-20. 
Schumacker, P T (2006) Reactive Oxygen Species in Cancer Cells: Live by the Sword, 
Die by the Sword. Cancer Cell, 10(3), 175-6. 
Sotiropoulou, P A, Candi, A, Mascre, G, De Clercq, S, Youssef, K K, Lapouge, G, Dahl, 
E, Semeraro, C, Denecker, G, Marine, J C and Blanpain, C (2010) Bcl-2 and 
Accelerated Dna Repair Mediates Resistance of Hair Follicle Bulge Stem Cells to 
Dna-Damage-Induced Cell Death. Nat Cell Biol, 12(6), 572-82. 
Stephanova, E, Topouzova-Hristova, T and Konakchieva, R (2008) Mitochondria Are 
Involved in Stress Response of A549 Alveolar Cells to Halothane Toxicity. 
Toxicol In Vitro, 22(3), 688-94. 
187 
 
Trusheim, M R and Berndt, E R (2015) The Clinical Benefits, Ethics, and Economics of 
Stratified Medicine and Companion Diagnostics. Drug Discov Today, 20(12), 
1439-50. 
Vrabie, V, Gobinet, C, Piot, O, Tfayli, A, Bernard, P, Huez, R and Manfait, M (2007) 
Independent Component Analysis of Raman Spectra: Application on Paraffin-
Embedded Skin Biopsies. Biomed Signal Process Control, 2(1), 40-50. 
Wang, S, Kotamraju, S, Konorev, E, Kalivendi, S, Joseph, J and Kalyanaraman, B (2002) 
Activation of Nuclear Factor-Kappab During Doxorubicin-Induced Apoptosis in 
Endothelial Cells and Myocytes Is Pro-Apoptotic: The Role of Hydrogen 
Peroxide. Biochem J, 367(Pt 3), 729-40. 
Wolf, M B and Baynes, J W (2006) The Anti-Cancer Drug, Doxorubicin, Causes Oxidant 
Stress-Induced Endothelial Dysfunction. Biochim Biophys Acta, 1760(2), 267-71. 
Yang, F, Teves, S S, Kemp, C J and Henikoff, S (2014) Doxorubicin, Dna Torsion, and 
Chromatin Dynamics. Biochim Biophys Acta, 1845(1), 84-9. 
Yao, H, Tao, Z, Ai, M, Peng, L, Wang, G, He, B and Li, Y (2009) Raman Spectroscopic 
Analysis of Apoptosis of Single Human Gastric Cancer Cells. Vib. Spectrosc, 
50(2), 193-7. 
Yokochi, T and Robertson, K D (2004) Doxorubicin Inhibits Dnmt1, Resulting in 
Conditional Apoptosis. Mol Pharmacol, 66(6), 1415-20. 
 
 
188 
 
Chapter 6: Monitoring Doxorubicin cellular uptake and 
trafficking using in vitro Raman micro-spectroscopy: short and 
long time exposure effects on lung cancer cell lines  
 
The following chapter reproduces the journal article, Z. Farhane, F. Bonnier and H.J. 
Byrne, Anal Bioanal Chem (2017) 409:1333-1346/DOI 10.1007/s00216-016-0065-0, in 
which the section and figure numbers have been adapted to the prescribed thesis format. 
 
All experiments, data analysis and paper writing were performed by Z.F.  
F.B. assisted in the experimental design.  
H.J.B. assisted in the project design and proofing of the manuscript. 
 
 
 
 
 
 
 
 
 
189 
 
Monitoring Doxorubicin cellular uptake and trafficking using in 
vitro Raman micro-spectroscopy: short and long time exposure 
effects on lung cancer cell lines  
Z.Farhane1*, F.Bonnier2 and H.J.Byrne1 
1FOCAS Research Institute, Dublin Institute of Technology, Kevin Street, Dublin 8, 
Ireland. 
2Université François-Rabelais de Tours, Faculty of Pharmacy, EA 6295 
Nanomédicaments et Nanosondes, 31 avenue Monge, 37200 Tours, France 
*Correspondingauthor: zeineb.farhane@mydit.ie 
 
Abstract:  
 
Raman micro-spectroscopy is a non-invasive, in vitro analytical tool which is being 
increasingly explored for its potential in clinical applications and monitoring the uptake, 
mechanism of action and cellular interaction at a molecular level of chemotherapeutic 
drugs, ultimately as a potential label-free preclinical screening and companion diagnostic 
tool.  
In this study, Doxorubicin (DOX), a “gold standard” chemotherapeutic drug, is employed 
as a model in the in vitro lung cancer cell line, A549, in order to demonstrate the potential 
of Raman micro-spectroscopy to screen and identify spectroscopic markers of its 
trafficking and mechanism of action. Confocal Laser Scanning Microscopy (CLSM) was 
used in parallel to illustrate the uptake and subcellular localisation, and cytotoxicity 
assays were employed to establish the toxicity profiles for early and late exposure times 
of A549 to DOX. Multivariate statistical analysis, consisting of principal components 
analysis (PCA), partial least squares regression (PLSR) and independent component 
190 
 
analysis (ICA) was used to elucidate the spectroscopic signatures associated with DOX 
uptake and subcellular interaction.  
Raman spectroscopic profiling illustrates both drug kinetics and its pharmacodynamics 
in the cell and associated biochemical changes, demonstrating that DOX is mainly 
localised in the nuclear area, saturating the nucleolus first, within ~6 hrs of exposure, 
before the surrounding nuclear areas after ~12 hrs, and only accumulates in the cytoplasm 
after 48 hrs. PLSR over varying time intervals enables identification of DOX-DNA 
binding at early stages of exposure (0-12 hrs), while regression over the longer time 
periods (24-72 hrs) reveals spectroscopic signatures associated with the metabolic cellular 
response. 
 
Keywords: Raman micro-spectroscopy, Confocal Laser Scanning Microscopy, 
Doxorubicin, cytotoxicity, long and short time exposure, Multivariate Analysis. 
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6.1. Introduction: 
Doxorubicin (DOX), a cell cycle non-specific chemotherapeutic agent, is one of the two 
first anthracycline antibiotics isolated from Streptomyces peucetius (Carvalho et al., 
2009) and among the most widely used chemotherapeutic agents, despite its numerous 
side effects, (Carvalho et al., 2014; Mitry and Edwards, 2016) and is highly effective in 
treating different types of cancers, from leukaemia, thyroid, and lung to many other 
neoplasia, especially metastatic and invasive ones (Carvalho et al., 2014; Hofman et al., 
2015; Schiller et al., 2013; Umsumarng et al., 2015). The accepted mechanisms of action 
of DOX are complex and not fully understood, and include the interaction (i) with the 
cellular nuclear area, consisting of DNA intercalation, cross-linking, binding and 
alkylation, inhibition of topoisomerase I and II and RNA polymerase, all inducing DNA 
damage, inhibition of DNA replication and protein synthesis (rRNA transcription 
inhibition), as a consequence, leading to nucleolar disruption and cellular apoptosis 
(Tacar, Sriamornsak, and Dass, 2013) and (ii) with the cell membrane and mitochondria, 
resulting in generation of reactive oxygen species leading to direct membrane damage 
and oxidative stress, responsible for the major DOX side effect, cardiomyopathy (Akhter 
and Rajeswari, 2014; Burger et al., 2010; Carvalho et al., 2014; Golunski et al., 2016). 
DNA remains the main target of cancer therapeutics, whereby induction of DNA damage 
initiates a cascade of events that determines cellular apoptosis. DNA damage level and 
repair, by expression of anti-apoptotic proteins such as bcl-2 and resistance to apoptosis, 
are the main processes involved in carcinogenesis and in the response of cancer cells to 
cancer chemotherapy (El-Awady et al., 2016; Farhane et al., 2016). Apoptosis, known as 
programmed cell death, plays an important role in the internal environmental homeostasis 
and is closely associated with the development of cancer and in chemotherapy, by 
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implication, of drug-induced cell apoptosis (Yadav et al., 2014). One of the pathways 
leading to apoptosis disruption and tumour development is the nucleolar stress pathway 
(Quin et al., 2014). In fact, the nucleolus, known also as a ribosome factory, is the most 
prominent structure inside the nucleus, acting as a central integration of signalling 
pathways and performing numerous functions such as production of ribosome subunits, 
RNA editing and cell cycle and playing an important role in cancer development by 
dysregulation of its functions (Hein et al., 2013; Lo, Lee, and Lai, 2006; Orsolic et al., 
2016). Due to its fundamental contribution in cancer proliferation, the nucleolus is the 
target for chemotherapeutic drugs such as Actinomycin D, which inhibits rRNA 
synthesis, Cisplatin which interferes with RNA Polymerase I in the nucleolus decreasing 
rDNA transcription, 5-fluoruracil which targets rRNA processing, DNA/RNA synthesis 
and DNA repair and DOX, which is known to disrupt nucleolar morphology and decrease 
rDNA transcription (Quin et al., 2014; Woods et al., 2015). 
It has also been shown in previous Raman spectroscopic studies that this sub-nuclear 
region is responsible for the discrimination between cancer cell lines (Farhane, Bonnier, 
Casey, Maguire, et al., 2015). 
Among the most common cancers worldwide, lung cancer is by far the highest cause of 
cancer-related death and has a 5-year survival of 15 %. The main treatments of lung 
cancer are chemotherapy and radiotherapy, but these approaches have serious side effects 
and drug resistance is often developed during treatment (Bolukbas and Meiners, 2015). 
Thus, a better understanding of the mechanism of drug action and the cellular responses 
at the pre-clinical step is crucial to improve patient survival. To this end, Raman micro-
spectroscopy, a non-invasive powerful label-free in vitro screening tool, is presented as 
the ideal candidate due to its ability to detect chemical, biological and physical changes 
of biomolecules at subcellular level and provide a molecular fingerprint of the sample of 
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interest, in this case cancer cell physiology, at a sub-cellular level, during 
chemotherapeutic treatment (Byrne et al., 2014; Gala and Chauhan, 2015; Huser and 
Chan, 2015; Notingher, 2007). 
Raman micro-spectroscopy has attracted considerable attention in recent years for 
applications in areas such as the drug discovery process, quality control during industrial 
manufacturing and detection of counterfeit products in the pharmaceutical industry 
(Bhumika and Priti, 2010; Gala and Chauhan, 2015; Vankeirsbilck et al., 2002). 
Biomedical and clinical applications have also been explored extensively (Kallaway et 
al., 2013; Pence and Mahadevan-Jansen, 2016) and its potential as a screening technique 
either for normal/cancer cell discrimination or in chemotherapeutic and cellular process 
screening have been demonstrated (Farhane, Bonnier, Casey, and Byrne, 2015; Farhane, 
Bonnier, Casey, Maguire, et al., 2015). 
Therefore, it can be developed as a companion diagnostic tool, providing details about 
drug efficacy and safety, as detailed in the US FDA guidance document issued in August 
2014, which defines such a tool as an in vitro diagnostic device that provides information 
that is essential for the safety and efficacy of a corresponding therapeutic product 
(Trusheim and Berndt, 2015). 
The demonstration of Raman micro-spectroscopy as a companion diagnostic for 
screening and analysis of commercial chemotherapeutic agents could be of significant 
importance in cancer research and especially in pre-clinical in vitro screening, a concept 
introduced by the US National Cancer Institute (NCI) in 1955 and providing screening 
models and supports to research, as a model which accurately predicts drug efficacy 
accurately at a molecular level, clinical activity and pharmacodynamics and kinetics 
(Suggitt and Bibby, 2005; Zhang et al., 2012). 
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Previously, DOX, routinely used for lung cancer therapy, was employed with A549, a 
non-small lung cancer cell line, and Raman analysis of the distribution of the drug in the 
cell, and the changes in the cellular spectroscopic signatures was performed, at a fixed 
point in time (24 hrs) (Farhane, Bonnier, Casey, and Byrne, 2015). 
In the present paper, investigations were extended to look at the evolution of the 
responses, in order to track the drug reactions for early and late stages exposure, globally 
understand the mechanism of action and monitor the subsequent cellular behaviour using 
Raman micro-spectroscopy. The study demonstrates the potential of Raman Spectroscopy 
to monitor the drug uptake and the cellular responses at a subcellular level, but also 
elucidate details of the pharmacodynamics and drug cellular kinetics of the clinically 
prescribed drug. 
6.2. Materials and methods:  
6.2.1. Materials: 
A549 human lung adenocarcinoma cells with the alveolar type II phenotype were 
obtained from ATCC (Manassas, VA, USA).  
Doxorubicin hydrochloride® powder (Sigma Life Sciences, Ireland) was diluted in1mL 
sterile water to the required concentration (17.25 mM). 
Alamar blue (AB) (10X ready to use solution) and 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl tetrazolium bromide (MTT) were obtained from Sigma Aldrich, Ireland. For 
cytotoxicity assays, an AB/MTT solution, 1.5 mL of AB and 3 mL of MTT stock solution 
(2.5 mg/mL, 25 mg MTT/10 mL PBS) in 30 mL of fresh medium was prepared prior to 
the tests. 
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6.2.2. Cell culture: 
A549 cells were cultured in DMEM (with 2 mM L-glutamine) with 10% foetal bovine 
serum (FBS) at 37 °C in a humidified atmosphere containing 5% CO2 and cells were split 
every two days to maintain ~60 % confluence. 
For Confocal Laser Scanning Fluorescence Microscopy (CLSM) and Raman-micro 
spectroscopic analysis, cell number was determined using a Beckman Coulter Particle 
Count and Size Analysis® Z2Cell Counter. 
6.2.3. Cytotoxicity assays: 
AB and MTT assays were performed in 96 well plates and a total number of 1x105/25 
mL, 1x104/25 mL and 5x103/25 mL cells, respectively for 0-24 hrs, 48 hrs and 72 hrs 
DOX exposure, were used to seed three plates each. After 24 hrs incubation, plates were 
washed with phosphate buffered saline solution (PBS) and DOX was added in a 
concentration range from 0 µM (as a control) to 50 µM. 
AB and MTT assays were both measured with a Cytotox SpectraMax®M3 plate reader 
using Soft Max® Pro6.2.2 software. After incubation in DOX, plates were washed with 
PBS and 100µL of AB/MTT solution were added to each well. Plates were then incubated 
for 3 hrs and AB fluorescence was measured first in the plate reader using 540 nm 
excitation and 595 nm emission, then the medium was removed, the plates were washed 
with PBS and 100 µL of DMSO (Dimethyl sulfoxide) were added in each well. MTT 
absorbance was read at 570 nm. 
All cytotoxicity assays were made in triplicate and repeated three times and viability data 
was fitted by a four parameter Hill equation analysis using SigmaPlot 10.0, to yield values 
of the mean inhibitory concentration, IC50. 
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6.2.4. Confocal Laser Scanning Fluorescence Microscopy:  
Approximately 1 x 104 cells were allowed to attach on uncoated glass bottom Petri dishes 
(MatTek Corporation, USA) for two hours, after which they were covered with cell 
culture medium. After 24 hrs incubation, the medium was removed and samples were 
rinsed twice with sterile PBS, new fresh medium containing DOX corresponding to the 
inhibitory concentration, IC50, determined by cytotoxicity assays for each time point (48 
and 72 hrs) and adjusted to the cell number (Table 6.1), was added and cells were 
incubated for a further 48 hrs and 72 hrs separately. For short time exposure, cells were 
incubated with the inhibitory concentration, IC50 determined previously for 24 hrs, and 
samples corresponding to each time point, 2, 6, 12 and 24 hrs were prepared separately. 
After incubation, samples were rinsed twice with sterile PBS, fixed in formalin (4%, 15 
min) and kept in PBS for imaging. Control samples without exposure to DOX were also 
prepared in parallel, and incubated for 2, 6, 12, 24, 48 and 72 hrs. 
CLSM images were recorded using an inverted Zeiss LSM 510 confocal laser scanning 
microscope equipped with a x60 oil immersion objective. DOX fluorescence was excited 
with an argon ion laser at 488 nm, and the emission was collected at 530 nm. 
6.2.5. Raman micro-spectroscopy: 
Cells (~ 1x 104/window) were seeded and incubated on CaF2 windows (Crystan Ltd, UK) 
for 24 hrs for both control and exposure to DOX. Medium was then removed and samples 
were rinsed twice with sterile PBS and covered with DOX at each corresponding IC50 
inhibitory concentration (IC50 (24 hrs) for 2, 6, 12, 24 hrs exposure, IC50 (48 hrs) and IC50 
(72 hrs)) which is normalised according to the cell number used (~1x 104/window) (Table 
6.1). The 24 hrs IC50 dose was initially chosen, based on previous studies, in order to 
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monitor the kinetics of the uptake of DOX at earlier times. This dose was reduced at 
longer times, as it would be too toxic at the longer exposure periods.    
After each incubation period (2, 6, 12, 24, 48 and 72 hrs), cells were washed twice with 
sterile PBS and fixed in formalin (4 %, 15 min). 
A Horiba Jobin-YvonLabRAM HR800 spectrometer with a 785 nm, 300 mW diode laser 
as source (~100 mW at the sample), Peltier cooled 16-bit CCD, 300 lines/mm grating and 
100 μm confocal hole, was used for this work. Spectra were acquired in the range from 
400 cm-1 to 1800 cm-1 using a x100 objective (LCPlanN, Olympus), in dry conditions, for 
30s twice, from three cell locations: cytoplasm, nucleus and nucleolus, to finally produce 
a data set of 30 points per cell location for each time point, 2, 6, 12, 24, 48 and 72 hrs 
after DOX exposure and for control cells, over a total of 210 cells corresponding to a total 
data set of 630 spectra. 
6.2.6. Data analysis:  
Raman spectral pre-processing and analysis were performed in Matlab 2013 using 
algorithms developed in house. Prior to analysis, background was subtracted using a 
NCLS (non-negatively constrained least squares) algorithm and spectra were 
subsequently smoothed (Savitsky-Golay filter 3th order, 11 points), baseline corrected 
(fifth order polynomial) and vector normalised. 
Principal components analysis (PCA) was employed as an unsupervised multivariate 
approach to analyse data and the effects of doxorubicin in each cell localisation. The order 
of the PCs denotes their importance to the dataset and PC1 describes the highest amount 
of variation (Bonnier and Byrne, 2012). 
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Partial least squares regression (PLSR) was employed to track the temporal and dose 
dependent evolution of the spectral signatures in the subcellular regions. PLSR is a 
statistical regression technique which reduces the dimensionality of the data and 
correlates information in an X data set matrix to the matrix of a Y data according to the 
equation Y= XB + E, where B is a matrix of regression coefficients and E is the regression 
residual. In this work, the X-matrix is represented by the Raman spectra and the Y-matrix 
is consisted of values of the DOX concentration inside the cells, and the time evolution 
(Keating et al., 2015; Muratore, 2013; Nawaz et al., 2011). 
The percentage of variance explained in the response variable (Y) as a function of the 
number of components was calculated using 10-fold cross validation and from a plot of 
the percent of variance explained function of number of components, the majority 
percentage of variance (above 90%) was found to be explained by the first 3 components. 
The regression coefficients obtained by PLSR of Raman data regressed separately against 
DOX cellular concentration and time evolution were plotted and analysed. As a function 
of frequency, the co-efficients illustrate the spectral features which are influenced by the 
intracellular interaction of the DOX and the resulting metabolic changes. 
Independent component analysis (ICA), a signal-processing technique, was also 
employed as an extension to PCA. ICA is an unsupervised statistical technique able to 
identify latent and statistically independent variables called independent components and 
corresponding to the pure signal underlying the observed signal and to interpret their 
different contributions.  In the case of Raman micro-spectroscopy, ICA can be used to 
identify and extract principal spectral contributions such as those from substrate, using 
the same number of ICs (independent components) as PCs which is three components, 
which can then be removed or studied in their own right (Boiret et al., 2014; Farhane et 
al., 2016; Parastar, Jalali-Heravi, and Tauler, 2012; Wang, Ding, and Hou, 2008). The 
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first independent component (IC1) explains the highest percentage of variance and was 
used to further examine the temporal evolution of the spectral signatures. 
6.3. Results: 
6.3.1. Cytotoxicity assays: 
The cytotoxicity of A549 cells to DOX exposure using both the AB and MTT assays for 
24 hrs has been previously reported (Farhane, Bonnier, Casey, and Byrne, 2015), 
indicating an IC50 of 0.42 ± 0.06 μM and 0.55 ± 0.16 μM for AB and MTT, respectively. 
Figure S1 of the supplementary information shows the dose dependant cytotoxicity of 
DOX after 48 hrs (Figure S.6.1 A) and 72 hrs (Figure S.6.1 B) exposure, for the A549 
cell line, according to the AB and MTT in vitro cytotoxicity assays. Viability is expressed 
as % compared to control (non-exposed healthy cells), and the error bars indicate the 
standard deviation of six independent replicate measurements. For both in vitro assays 
and for all times exposure, a partial loss of cell population viability is observed. 
The AB and MTT assays for the A549 cell line show similar responses for late time 
exposure (48 and 72 hrs) but slightly different ones for 24 hrs. However, the IC50 values 
for 48 hrs exposure for A549 cells are comparable and were determined to be 0.30± 0.04 
μM and 0.31± 0.05 μM for AB and MTT, respectively. Similar behaviour was found after 
72 hrs treatment, characterised by IC50 values of 0.29± 0.02 M and 0.27± 0.02 M, 
respectively for AB and MTT. 
The MTT assay is a reflection of mitochondrial activity while the AB assay is the 
expression of general cellular metabolism. The somewhat greater sensitivity of MTT 
compared to AB at the early stages is consistent with a mechanism of interaction which 
induce an early apoptosis (Berthiaume and Wallace, 2007; Green and Leeuwenburgh, 
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2002). Nevertheless, since the mechanisms and cellular effects for the long time 
exposures of 48 and 72 hrs will be compared to those for shorter exposures 0-24 hrs, the 
IC50 determined by the MTT assay was used throughout the study for comparability 
purposes and Figure 6.1 shows the dose dependant cytotoxicity for those time points. 
 
Figure 6.1: MTT in vitro dose dependent cytotoxicity assays of DOX to A549 cell line 
for short (0-24 hrs) and long exposure times (48 hrs, 72 hrs).  
 
Viability is expressed as % compared to control, and the error bars indicate the standard 
deviation of six independent replicate measurements. 
For Raman micro-spectroscopy and Confocal Laser Scanning Fluorescence Microscopy, 
the DOX dose used was scaled to cell numbers, according to a linear relationship between 
MTT response and cell number, using each corresponding IC50 and Table 6.1 shows the 
different concentrations used (Akbari and Javar, 2013; Sieuwerts et al., 1995; Twentyman 
and Luscombe, 1987). 
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Table 6.1: IC50 determined by the MTT and corresponding dose used for 10
4 cells. 
Exposure time (hrs) 0-24 48 72 
IC50 (μM) 0.55± 0.16 0.31± 0.05 0.27± 0.02 
DOX Concentration (μM) 13.75 77.5 135 
6.3.2. Confocal Laser Scanning Fluorescence Microscopy: 
Confocal Laser Scanning Fluorescence Microscopy (CLSM) was employed to visualise 
and confirm the DOX intracellular internalisation and subcellular localisation. Figure 6.2 
illustrates the images for different DOX exposure times, from 2 hrs to 72 hrs; clearly 
demonstrating that DOX is predominantly accumulated in the nuclear region at all time 
points. The DOX nuclear accumulation is obvious even after only 2 hrs, suggesting that 
this commercial drug is trafficked straight to the nuclear area without any accumulation 
in the cytoplasm up to 24 hrs. Some trace amounts do appear in the cytoplasm at 48 and 
72 hrs, consistent with the onset of a late cytoplasmic DOX mechanism of action 
associated with oxidative stress as a result of reactive oxygen species production (Farhane 
et al., 2016). 
Compared to healthy control cells, exposed cells appear smaller in size and round or oval 
in shape and exhibit noticeable fragmentation of nucleoli within the nucleus, with tightly 
packed cytoplasm and membrane blebbing. All these morphological changes confirm that 
cells are undergoing apoptosis (Farhane, Bonnier, Casey, and Byrne, 2015; Hein et al., 
2013; Sardao et al., 2009; Woods et al., 2015). 
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1.     2.       3.        4.         5.          6. 
 
Figure 6.2: Confocal Laser Scanning Fluorescence images of A549 cells after DOX 
exposure and corresponding controls: 1. 2 hrs DOX exposure, 2. 6 hrs DOX exposure, 3. 
12 hrs DOX exposure, 4. 24 hrs DOX exposure, 5. 48 hrs DOX exposure and 6. 72 hrs 
DOX exposure. 
6.3.3. Raman micro-spectroscopy: 
Raman micro spectrosopy has previously been demonstrated to be capable of tracking 
DOX inside the cellular compartments and differentiating between its different 
mechanisms of action and the cellular responses due to drug treatment at a fixed timepoint 
of 24 hrs exposure. In order to further investigate the subcellular responses and to track 
the drug pathway, Raman profiles from the three subcellular compartments, nucleolus, 
nucleus and cytoplasm, were analysed at shorter timescales of 2, 6 and 12 hrs at the 24 
hrs IC50 concentration, and at the longer exposure times of 48 hrs and 72 hrs, at the IC50 
concentration, adjusted to the cell number, of these time points, as determined using the 
MTT assay (Figure 6.1, Table 6.1).  
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A. 
 
B. 
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C. 
 
D. 
 
Figure 6.3: Raman spectra after background subtraction, baseline correction and vector-
normalisation of A. Doxorubicin dissolved in sterile water and mean spectra of A549 cell 
line for 0, 2, 6, 12, 24, 48 and 72 hrs of B. nucleolus C. nucleus and D. cytoplasm. 
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Figure 6.3 shows the mean spectra for each time point of the three cellular localisations, 
namely the nucleus, the primary location of DNA, the nucleolus, a sub-compartment of 
the nucleus, which contains RNA and small amount of DNA, and the surrounding 
cytoplasm containing the cytoskeleton, a framework of protein filaments, all protected by 
the plasma membrane (Glitsch, 2016; Olson, Dundr, and Szebeni, 2000). 
In general, nucleic acids can be identified by peaks characteristic of nucleotide and sugar-
phosphate backbone vibrations (Notingher, 2007) and the main bands are for example at 
785 cm-1, assigned to cytosine and thymine (DNA/RNA) and DNA backbone O–P–O 
stretching, 813 cm-1, related to RNA O–P–O stretching, 830 cm-1, corresponding to DNA 
B form O-P-O asymetric stretching and 1095 cm-1, assigned to DNA PO2
− symmetric 
stretching. Protein signatures are dominated by peaks related to Amide III and Amide I 
vibrations, between 1230-1280 cm-1 and 1640-1695 cm-1, respectively, and amino acids 
containing phenyl groups, such as phenylalanine peaks at for example 1005 and 1030 cm-
1, tryptophan at 760 cm-1 and tyrosine at 645, 853 and 877 cm-1. Lipids are predominatly 
represented by peaks at 700-720 cm-1, related to C–C–N+ symmetric stretching in 
phosphatidylcholine, 1303 cm-1 assigned to C-H vibration and between 1410 and 1495 
cm-1 corresponding to C-H deformation (Farhane, Bonnier, Casey, and Byrne, 2015; 
Notingher, 2007; Verrier et al., 2004). 
Since the Raman spectra are characteristic of the molecular structure, any changes to that 
structure, for example after chemotherapeutic treatment, can be detected and monitored. 
As an illustration, for both nucleolar and nuclear regions (Figure 6.3 B and C), an obvious 
shift towards lower wavenumbers of the band at 1095 cm-1 confirms again that DOX is 
able to bind to DNA externally, starting from the early stages of exposure (Farhane, 
Bonnier, Casey, and Byrne, 2015), and a decrease of the band at 785 cm-1 indicates a 
progressive DNA/RNA denaturation, while in the nuclear region, there is a decrease in 
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the features at 830 cm-1 and, in the nucleolar area, an almost complete disappearance of 
the band at 813 cm-1, potentially due to cessation of DNA replication as a consequence 
of DNA denaturation and fragmentation (Guo et al., 2009; Notingher et al., 2003). In the 
cytoplasmic area (Figure 6.3 D), a slight increase in features at 1065 and 1080 cm-1 is 
observed, corresponding to protein C-N stretching, which may correspond to an increase 
of signaling proteins in cells going under apoptosis. 
It is notable that, for all cellular regions and over the time course, there is an increase in 
the principle DOX features (Figure 6.3 A, indicated by the highlighted regions in Figure 
6.3 B, C and D) at 440 and 465 cm−1, respectively corresponding to C–C–O and C–O 
vibrations, and at 1215 and 1245 cm−1, related to C–O–H and C–O. Notice, however, that 
DOX features only appear in the cytoplasm starting from 48 hrs exposure. Similar 
observations were found in CLSM images (Figure 6.2), confirming the primary 
localisation of DOX in the combined nuclear area for all time points before 48 hrs 
treatment.  
In order to examine further the DOX cellular pathway, PCA of exposed cells versus 
control was employed and a clear separation occured according to PC1 for all time points 
compared to control, as previously demonstrated for 24 hrs exposure (Farhane, Bonnier, 
Casey, and Byrne, 2015) (data not shown). The evolution of DOX peak intensities at 440, 
465, 1215 and 1245 cm-1, corresponding respectively to C-C-O, C-O, C-O-H and C-O 
vibrations of the DOX molecule, in the loading of PC1 was analysed, as shown in Figure 
6.4. The intensity is expressed as a percentage of the highest value of each respective 
band in the three subcellular regions. 
It is obvious that there is a progressive increase of DOX intracellular concentration until 
a plateau is reached after 6-12 hrs exposure and DOX is seen to accumulate in the 
nucleolus first, then the nucleus and after 48 hrs appears in the cytoplasm. Since the bands 
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at 1215 and 1245 cm-1 can be influenced by the proximity of protein features, further 
analysis was focused on the two bands at 440 and 465 cm-1. 
 
Figure 6.4: Evolution of DOX Raman bands at 440, 465, 1215 and 1245 cm-1 as a 
function of time for the A549 cell line for each cellular compartment, nucleolus, nucleus 
and cytoplasm. Intensities are expressed in percentage according to the maximum value 
for each band over the three cellular compartments and standard deviation corresponds to 
the spectral variations of each band. 
Notably, according to these two DOX Raman bands, there is more DOX in the nucleolus 
than the nucleus for 2, 6 and 12 hrs exposure, with a maximum at 6 hrs. These 
observations are consistent with a mechanism of DOX being trafficked straight to the 
combined nuclear area, after a passive diffusion to the cells due to its high lipophilicity, 
binds to proteasomal then translocates into the nuclear area, via nuclear pores, where it 
dissociates from the proteasome complex and binds to DNA with hight affinity (Carvalho 
et al., 2009; Tacar, Sriamornsak, and Dass, 2013), a larger amount accumulating in the 
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denser nucleolar area, which saturates more rapidly. Accumulation in the cytoplasm is 
only evident after 48 hrs, confirming previous studies showing that the intracellular DOX 
is primarily accumulated in the nuclear area, at short exposure times, and that the main 
mechanism of action is one of DNA intercalation, interfering with both DNA and RNA 
polymerase and inducing in consequence DNA replication and RNA transcription 
blockage (Tacar, Sriamornsak, and Dass, 2013; Wallace, 2003). The observed plateau in 
the nuclear and nucleolar regions is more notable, given that the doses for 48 and 72 hrs 
were increased to the respective doses of 77.5 M and 135 M, respectively, compared 
to 13.75 M for 24 hrs (Table 6.1). Nevertheless, it is clear that the DOX concentration 
inside the combined nuclear regions becomes approximately constant after ~24 hrs 
exposure, after which DOX begins to accumulate in the cytoplasm due to nuclear 
membrane loss of integrity (Eom et al., 2005; Sardao et al., 2009).  
The behaviour is consistent with saturation of nuclear binding sites after a certain time 
and any additional drug taken up by cells accumulates in the cytoplasm (El-Kareh and 
Secomb, 2005; Zenebergh, Baurain, and Trouet, 1984). 
In order to track the cellular changes associated with the progressive uptake of DOX in 
the subcellular regions, PLSR was employed, and spectra were regressed against time, 
progressively increasing the time interval from 0-6 to 0-72 hrs. The resultant regression 
co-efficients for the nucleolar and nuclear region are shown in Figure 6.5. 
In the case of the regression as a function of time for the nuclear region (Figure 6.5 B), 
the co-efficients over the period 0-6 hrs and 0-12 hrs are almost identical, whereas 
regression beyond this period results in significant changes to the regression co-efficients. 
In the case of the nucleolar spectral data (Figure 6.5 A), such significant changes in the 
regression co-efficients are evident on progressing from 0-6 hrs to 0-12 hrs, and beyond. 
For both cellular regions, the time points after which the regression co-efficients begin to 
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change significantly co-incide with those of the onset of saturation of the DOX related 
spectral features in Figure 6.4, indicating that the regression over the timepoints up to 
saturation identifies spectral features associated with the initial drug mechanism of action, 
before saturation, after which the cellular responses become evident.  
In the T:0-6 hrs regression co-efficients for the nucleolar region (Figure 6.5 B), notable 
positive DOX features are observed at 440-465 cm-1 and 1215-1245 cm-1, indicating the 
progressive accumulation of DOX, as shown in Figure 6.4. A concomitant decrease in 
cellular features corresponding to nucleic acids is observed, at 785 cm-1 (cytosine and 
thymine, DNA backbone O–P–O stretching), 813 cm-1 (RNA O–P–O strecthing), 853 cm-
1 (tyrosine ring breathing), 1095 cm-1 (DNA backbone O–P–O stretching), 1270 cm-1 
(RNA uracil and cytosine ring stretching), 1300 cm-1 (RNA cytosine and adenine ring 
stretching), 1376 cm-1 (thymine), and 1577 cm-1 (adenine and guanine), representing a 
modification of their cellular content due to blockage of DNA replication and 
transcription as a result of DOX treatment, as well as a change in the profile of peaks at 
1410, 1445 and 1491 cm-1, indicating lipid denaturation, probably of the surronding 
cytoplasmic membrane and features at 1005 cm-1 (phenylalanine), 1607 cm-1 (tyrosine 
and phenylalanine ring vibration C=C) and 1673 cm-1 (Amide I), indicating a change in 
nucleolar proteins (Farhane, Bonnier, Casey, and Byrne, 2015; Huser and Chan, 2015; 
Kann et al., 2015; Matthews et al., 2010; Notingher, 2007; Notingher et al., 2003; Verrier 
et al., 2004). 
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A. 
 
B. 
 
Figure 6.5: Regression coefficients obtained by PLSR analysis as a function of time over 
progressive exposure time intervals (T) for A. nucleolus and B. nucleus. The dashed 
horizontal line indicates the zero-point for T: 0-6 hrs and the other co-efficients are off 
set for clarity.  
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Over the regression period T:0-12 hrs, although the overall profile of the co-efficients is 
distinct compared to that of the nucleolar region, similar spectral changes are observed 
for the nuclear region, in addition to those at 830 cm-1 (O–P–O asymmetric stretching, 
DNA B form),  881 cm-1 (Deoxyribose ring breathing) and 1340 cm-1 (adenine and 
guanine). 
The nucleolar and nuclear region are composed of similar biochemical constituents, and 
similar changes to these are prominent in the regression co-efficients of both regions. 
However, the distinctly different profiles in Figure 6.5 A (Nucleolus T:0-6 hrs) and Figure 
6.5 B (Nucleus 0-12 hrs) indicate different rates and degrees of interactions with the 
constituent conponents in the different subcellular regions. 
Notably, as shown in Figure S.6.2, for each cellular region, the co-efficients for regression 
against the internalised dose, as determined by the peak intensity in the loading 1 of PCA 
control versus exposed cells (Figure 6.4), are largely invariable, and almost identical to 
the time dependent regression co-efficient profile (T:0-6 hrs for nucleolus and T:0-12 hrs 
for nucleus) (Figure 6.5) up to the saturation point (Figure 6.4) 
So, for both nucleus and nucleolus and for both regression against short time exposure 
and DOX cellular concentration, a notable decrease in DNA and RNA features for 
example at 728, 785-795, 813, 1376 and 1486 cm-1 is evident. However, the changes to 
the nucleic acid features over this initial period are much more pronounced and more 
rapid in the nucleolar region than in the nucleus itself. 
Following the initial DOX binding interactions in the nucleoli and then nuclear regions 
of the cell, and although the DOX concentrations saturate in the nuclear regions after ~12 
hrs, (Figure 6.5), the cellular features continue to evolve as a function of time, in response 
to the action of the drug. This can be clearly seen in Figure 6.5, but, in order to 
differentiate the spectral characteristics of the initial chemical interactions of the drug 
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from the subsequent cellular responses, the spectral evolution over the time period 24-72 
hrs was regressed against time and internalised cellular DOX concentration. Notably, in 
the PLSR analysis of nucleolus and nucleus regressed against time over the later stages, 
shown in Figure 6.6 (I A and II A), only cellular features appear and no DOX features are 
apparent, which confirms the fact that after certain time, DOX reaches a constant 
concentration inside the nuclear regions of the cells, as evidenced by the plateau in Figure 
6.4.  
As seen in Figure 6.6 I, for the nucleolar regions at late stages (24, 48 and 72 hrs), there 
is an increase in protein features at 447, 454, 1005 cm-1 (phenylalanine), 853 cm-1 
(tyrosine ring breathing), 1207 cm-1 (phenylalanine, tryptophan and tyrosine), 1230 cm-1 
(Amide III), and 1660 cm-1 (Amide I), consistent with an afflux of anti-apoptotic protein 
trying to repair DNA and avoid apoptosis (Farhane et al., 2016). There is also a significant 
decrease in DNA features at 785 cm-1 (cytosine and thymine), 830 cm-1 (DNA B form), 
1220 cm-1 (adenine and thymine) and 1577 cm-1 (adenine and guanine), representative of 
DNA depletion and denaturation due to a long term effects of DOX.  
Similar increases in protein features as a function of time in the later stages of exposure 
is apparent in the nuclear area, as shown in Figure 6.6 II, in addition to a progressive 
decrease in DNA features at 785, 795 cm-1 (cytosine and thymine), 1095 cm-1 (DNA 
backbone O–P–O symmetric stretching), 1220 cm-1 (adenine and thymine), 1376 cm-1 
(thymine), 1577 cm-1 (adenine and guanine), and a lipid denaturation indicated by peaks 
at 700-715-720, 1127,  1450 and 1491 cm-1. 
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I. 
 
II. 
 
Figure 6.6: Regression coefficients obtained by PLSR analysis of long term DOX 
exposure over the time period (24-72 hrs) of I. nucleolus and II. nucleus (A) regressed 
against time and (B) against DOX concentration inside cells determined by the peaks 
intensities of the band at 465 cm-1 in loading 1 of PCA exposed cells versus control. 
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In both nucleolar and nuclear regions at prolonged exposures, a notable increase is 
observed in features at 1047 cm-1 (RNA P–O stretching, sugar phosphate –C–O–
stretching), and 1270 cm-1 (RNA Uracil and Cytosine ring stretching), while that at 1376 
cm-1 (thymine) is seen to decrease.The continued changes to RNA features in both 
nucleolus and nucleus over the later time period could be explained by a decrease of RNA 
as a consequence of DNA denaturation and blockage of its replication but the concomitant 
increase in some RNA peaks could be due to nucleolar fragmentation, resulting in RNA 
spread into the nucleus (Boulon et al., 2010; Hein et al., 2013). 
In addition to spectral features which may be characteristic of DNA and RNA depletion 
and nucleolar fragmentation, there is an increase in both lipid and protein features, at 645 
cm-1 (C-C tyrosine), 715 cm-1 (choline), 720 cm-1 (C–C–N+ symmetric stretching 
inphosphatidylcholine), 760 cm-1 (tryptophan ring breathing), 853-877 cm-1 (tyrosine ring 
breathing), 1005 cm-1 (phenylalanine), 1127 cm-1 (C-N stretching), 1410-1445 cm-1 (CH2 
vibrations), 1607 cm-1 (tyrosine and phenylalanine ring vibration C=C), and 1656-1673 
cm-1 (Amide I) (Figure 6.5 and 7), as a cellular response to DOX exposure, which may be 
associated with the efflux of anti-apoptotic protein and a synthesis of lipidic vesicules as 
a way to remove DOX to the extracellular environment (Dellaire and Bazett-Jones, 2007; 
Farhane, Bonnier, Casey, and Byrne, 2015; Matthews et al., 2010; Movasaghi, Rehman, 
and Rehman, 2007). 
The increase in phenylalanine in both nucleolar and nuclear regions seems to be a marker 
of the late apoptosis stage, at which point nucleolar fragmentation is complete, leaving an 
empty space with only cellular membrane (Figure 6.6) (Kann et al., 2015; Moritz et al., 
2010). 
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Thus, it appears that regression against DOX cellular concentration shows the initial DOX 
accumulation inside the cells, its nuclear binding and its subsequent effects, including 
DNA damage, while regression against varying time intervals can elucidate and 
differentiate both the initial DOX mechanism of action and its cellular effects, such as 
depletion in DNA, RNA and proteins leading to apoptosis and the cells reactions to those 
DOX effects which could be a marker of any cellular-drug resistance. 
 
Figure 6.7: Regression coefficients obtained by PLSR analysis of cytoplasm (A) 
regressed against time full range and (B) against DOX concentration inside cells 
determined by peaks intensities of band at 465 cm-1 in loading 1 of PCA exposed cells 
versus control. 
Figure 6.7 shows the PLSR of the cytoplasmic region of the cell against time and DOX 
cellular concentration. In both regression co-efficient profiles, there are obvious DOX 
features at 440-465 cm-1 and 1215-1245 cm-1, in addition to cellular ones related to 
proteins and lipids, for example at 524 cm-1, corresponding to phosphatidylserine 
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externalization as an indicator of cell signalling in apoptosis (Fadok et al., 1998; Kagan 
et al., 2000), 538 cm-1 related to cholesterol ester, which increases due to alteration of the 
function of integral endoplasmic reticulum membrane proteins and is a marker of 
apoptosis (Maxfield and Tabas, 2005; Tabas, 2004), 576-776 cm-1 
(phosphatidylinositol) related to membrane trafficking, 645-830-853 cm-1 (tyrosine), 
749-760 cm-1 (tryptophan), 940 cm-1 (C-C stretching of protein), 1085 and 1128 cm-1 (C-
N stretch), 1268 cm-1 (Amide III), 1410-1450 cm-1 (CH2 deformation), 1607 cm
-1 (C=C 
phenylalanine and tyrosine), 1640-1694 cm-1 (Amide I of different conformational forms 
indicating a protein denaturation) (Matthews et al., 2010; Movasaghi, Rehman, and 
Rehman, 2007). Features at 645-1005 cm-1 (C-C phenylalanine) and 1030 cm-1 (C-H 
phenylalanine) indicate a change in the protein environment due to DOX exposure (Guo 
et al., 2009), while changes in the profile of the band at 1450 cm-1 (C-H deformation) and 
around 1303 cm-1 (lipid C-H vibration) (Movasaghi, Rehman, and Rehman, 2007) are 
consistent with a lipid structure denaturation by peroxidation due to ROS production 
under DOX treatment (Yadav et al., 2014). 
6.4. Discussion: 
Raman spectroscopic microscopy can clearly track the kinetics of the uptake and 
accumulation of the chemotherapeutic drug DOX at a subcellular level in vitro, and can 
differentiate the biochemical responses associated with the subcellular regions of 
nucleolus, nucleus and cytoplasm, both in terms of the mechanisms of action, and the 
subsequent cellular metabolic responses. In both cases, the spectroscopic signatures are a 
complex combination of the contibutions of the many biomolecular responses and their 
evolution requires the use of multivariate regression analysis. Independent Components 
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Analysis can be used to extract the primary contributions of this combinatorial response, 
at each timepoint, as shown in Figure S.6.3, for each exposure timepoint for (A) nucleolar 
and (B) nuclear regions of the cell, again highlighting the multivariate nature of the 
spectral responses. 
The evolution of selected features can be plotted against time, and correlated with that of 
the uptake and accumulation of the DOX in the different subcellular regions, as well as 
each others, as shown in Figure 6.8. The intensities of DNA, RNA, proteins and lipids 
bands was determined by ICA after DOX subtraction, as ICA can identify spectral cellular 
components contributions independently while DOX band was determined by PCA 
control vs exposed cells (Figure 6.4). 
The interaction with DNA and RNA in both the nucleolar and nuclear regions of the cell 
as a function of time is apparent in Figure 6.8 A, showing the evolution of DNA features 
at 830 cm-1 (O–P–O asymmetric stretching, DNA B form) and 881 cm-1 (Deoxyribose 
ring breathing) and RNA features at 1270 cm-1 (RNA Uracil and Cytosine ring stretching) 
and 1300 cm-1 (RNA Cytosine and Adenine ring stretching). Notably, the feature at 785 
cm-1 (Cytosine and Thymine, DNA backbone O–P–O stretching), can be ascribed to either 
DNA or RNA. 
The changes in the nucleic acid bands in the nucleolar region are concomitant with the 
accumulation of DOX, and the changes cease when the accumulation of DOX saturates, 
associating these with an instantaneous interaction with the biochemical components, and 
therefore the initial DOX-DNA binding (Cummings, Bartoszek, and Smyth, 1991; Yang 
et al., 2014). 
In the nucleus, the equivalent changes occur more slowly, but also appear to saturate once 
the accumulation of DOX in the nucleus has saturated. A further observation is that the 
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relative changes in the nucleic acid spectral features are much stronger in the nucleolus 
than in the nuclear region.  
(i)      (ii) 
 
A. (i)       (ii) 
 
Figure 6.8: A. Evolution of DOX (465 cm-1) and selected RNA (785, 1270, 1300 cm-1) 
and DNA (785, 830, 881 cm-1) Raman bands as a function of time for the A549 cell line 
for each nuclear cellular compartment, (i) nucleolus and (ii) nucleus. B. Evolution of 
DOX (465 cm-1) and selected protein (1005, 1230, 1660 cm-1), lipid (1450 cm-1) Raman 
bands as a function of time for the A549 cell line for each nuclear cellular compartment, 
(i) nucleolus and (ii) nucleus. Intensities are expressed in percentage according to the 
maximum value for each nuclear area and standard deviation corresponds to the spectra 
variations for each band. 
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Moreover, the same kinetics of evolution were found using PLSR, highlighting that the 
same cellular features, mainly DNA and RNA are affected by DOX in both nucleolus and 
nucleus, due to interuption of DNA replication and RNA transcription, but at different 
rates and intervals. DOX affects the nucleolus instantaneously, and once saturation of 
DOX is reached at 6 hrs, an almost total reduction of DNA and RNA features to ~20 % 
has occured. In the case of the nucleus, this decrease is slower even after saturation at 12 
hrs and reaches only ~40 % of the initial levels. 
It is also obvious that, after DOX exposure, proteins and lipids (Figure 6.8 B) start 
decreasing as a consequence of RNA/DNA alteration, and then increase at later stages of 
the cellular responses, which corresponds to an increase of anti-apoptotic proteins and a 
synthesis of lipids vesicules as a cellular reaction to the chemotherapeutic treatment, after 
which, cells initiate late apoptosis corresponding to a point of no return.  
Previous studies have investigated the DOX nuclear accumulation by using either DOX 
fluorescence or indirect labeling techniques, showing an intimate relationship between 
DOX nuclear accumulation and its cellular concentration (Gigli et al., 1988). However, 
those approaches present some limitations, as DOX fluorescence can be influenced when 
it intercalates with DNA and the mechanism of action of dyes used to probe, for example 
DNA content (Zenebergh, Baurain, and Trouet, 1984), are unclear and can interfere with 
the process itself (Hovorka et al., 2010; Karukstis et al., 1998). No relationship between 
nuclear DOX accumulation and its cellular effects has been clearly defined. In contrast, 
using Raman micro-spectroscopy as an in vitro label free tool to investigate drug kinetics 
and pharmacodynamics, coupled with multivariate data analysis, shows the DOX cellular 
distribution, interactions and effects. It appears that the early stage responses are 
dominated by the kinetics of the chemotherapeutic drug accumulation, principally in the 
nucleolar region, and by the DOX-DNA interaction. Notably, the observed changes in 
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these early stages are predominantly associated with RNA, rather than DNA, changes to 
which become more prominent in the interactions in the nuclear region. At later stages, 
when the localised DOX concentration has reached the saturation point, the cellular 
response to DOX treatment becomes prominent. Saturation of the nucleolar region prior 
to the nuclear highlights again the importance of this subcellular region, not only in the 
cancer process but also in chemotherapy and cellular resistance, since it is the first to be 
targetted by DOX and as a consequence the first to react to drug exposure, followed by 
the nucleus and finally by the cytoplasm after 48 hrs exposure. The observation that 
appreciable accumulation of DOX in the cytoplasm is only apparent after such prolonged 
exposure times may have implications on the relative contributions of alternatives routes 
towards cell death based on oxidative stress in the cytoplasm (Gewirtz, 1999). 
6.5. Conclusion:  
The Food and Drug Administration classifies DOX as one of the most effective 
chemotherapeutic drug worldwide used for the treatment of various cancers (Carvalho et 
al., 2009; Tacar, Sriamornsak, and Dass, 2013). Nevertheless, it presents serious clinical 
side effects and its full mechanism of action is still not completely understood. For this a 
development of an in vitro screening method to detect drugs inside cells and map their 
mechanism of action and the cellular response is of critical importance. 
In the present work, Raman micro-spectroscopy associated with multivariate data 
analysis (PCA, PLSR and ICA) has been demonstrated to be capable of not only 
monitoring the subcellular accumulation and distribution of the drug inside cells and 
elucidating the mechanism of action, but also differentiating, as a function of time, the 
subsequent cellular response. It is notable that the nucleolus is the first to be saturated by 
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DOX and it is the first cellular compartment to be affected and to react to this treatment, 
highlighting the importance of this organelle in cancer development and in cancer 
therapy. 
The profile of spectroscopic responses is complex, being a label free combinatorial 
response of the affected biochemcial constituents in each region. Nevertheless, that 
profile is well defined in terms of subcellular region and temporal evolution, indicating 
the potential of the technique as an in vitro, pre-clinical screening technique for drug 
efficacy and mode of action. Exploring differences in responses could ultimately 
elucidate meachnisms of cellular resistance, towards applications in companion 
diagnostics. 
6.6. Compliance with Ethical Standards: 
"The authors certify that there is no conflict of interest and they have no affiliations with 
or involvement in any organization or entity with any financial or non-financial interest" 
6.7. Acknowledgement: 
This work was supported by Science Foundation Ireland Principle Investigator Award 
11/PI/1108. 
 
 
 
 
 
 
222 
 
6.8. References: 
Akbari, R and Javar, H J (2013) Efficacy of Capecitabine and 5- Fluorouracil (5-Fu)on 
the Human Breast Cancer Cell Line (Mcf7) – Effect of Concentration. Am J Res 
commun, 1, 6. 
Akhter, M Z and Rajeswari, M R (2014) Interaction of Doxorubicin with a Regulatory 
Element of Hmga1 and Its in Vitro Anti-Cancer Activity Associated with 
Decreased Hmga1 Expression. J. Photochem. Photobiol. B, Biol., 141, 36-46. 
Berthiaume, J M and Wallace, K B (2007) Adriamycin-Induced Oxidative Mitochondrial 
Cardiotoxicity. Cell Biol Toxicol., 23(1), 15-25. 
Bhumika, D P and Priti, J M (2010) An Overview: Application of Raman Spectroscopy 
in Pharmaceutical Field. Curr Pharm Anal., 6(2), 131-41. 
Black, J W and Leff, P (1983) Operational Models of Pharmacological Agonism. Proc. 
R. Soc. Lond., B, Biol. Sci., 220(1219), 141-62. 
Boiret, M, Rutledge, D N, Gorretta, N, Ginot, Y M and Roger, J M (2014) Application of 
Independent Component Analysis on Raman Images of a Pharmaceutical Drug 
Product: Pure Spectra Determination and Spatial Distribution of Constituents. J 
Pharm Biomed Anal., 90, 78-84. 
Bolukbas, D A and Meiners, S (2015) Lung Cancer Nanomedicine: Potentials and 
Pitfalls. Nanomedicine (Lond). 10(21), 3203-12. 
Bonnier, F and Byrne, H J (2012) Understanding the Molecular Information Contained 
in Principal Component Analysis of Vibrational Spectra of Biological Systems. 
Analyst., 137(2), 322-32. 
Boulon, S, Westman, B J, Hutten, S, Boisvert, F M and Lamond, A I (2010) The 
Nucleolus under Stress. Mol Cell., 40(2), 216-27. 
223 
 
Burger, K, Muhl, B, Harasim, T, Rohrmoser, M, Malamoussi, A, Orban, M, Kellner, M, 
Gruber-Eber, A, Kremmer, E, Holzel, M and Eick, D (2010) Chemotherapeutic 
Drugs Inhibit Ribosome Biogenesis at Various Levels. J Biol Chem., 285(16), 
12416-25. 
Byrne, H J, Ostrowska, K M, Nawaz, H, Dorney, J, Meade, A D, Bonnier, F and Lyng, F 
M (2014). Vibrational Spectroscopy: Disease Diagnostics and Beyond In 
Baranska, M (Ed) Optical Spectroscopy and Computational Methods in Biology 
and Medicine Vol. 14, Springer Netherlands, Dordrecht. 
Carvalho, C, Santos, R X, Cardoso, S, Correia, S, Oliveira, P J, Santos, M S and Moreira, 
P I (2009) Doxorubicin: The Good, the Bad and the Ugly Effect. Curr. Med. 
Chem., 16(25), 3267-85. 
Carvalho, F S, Burgeiro, A, Garcia, R, Moreno, A J, Carvalho, R A and Oliveira, P J 
(2014) Doxorubicin-Induced Cardiotoxicity: From Bioenergetic Failure and Cell 
Death to Cardiomyopathy. Med Res Rev., 34(1), 106-35. 
Cummings, J, Bartoszek, A and Smyth, J F (1991) Determination of Covalent Binding to 
Intact Dna, Rna, and Oligonucleotides by Intercalating Anticancer Drugs Using 
High-Performance Liquid Chromatography. Studies with Doxorubicin and Nadph 
Cytochrome P-450 Reductase. Anal Biochem, 194(1), 146-55. 
Dellaire, G and Bazett-Jones, D P (2007) Beyond Repair Foci: Subnuclear Domains and 
the Cellular Response to Dna Damage. Cell Cycle., 6(15), 1864-72. 
El-Awady, R A, Semreen, M H, Saber-Ayad, M M, Cyprian, F, Menon, V and Al-Tel, T 
H (2016) Modulation of Dna Damage Response and Induction of Apoptosis 
Mediates Synergism between Doxorubicin and a New Imidazopyridine 
Derivative in Breast and Lung Cancer Cells. DNA Repair (Amst), 37, 1-11. 
224 
 
El-Kareh, A W and Secomb, T W (2005) Two-Mechanism Peak Concentration Model 
for Cellular Pharmacodynamics of Doxorubicin. Neoplasia., 7(7), 705-13. 
Eom, Y W, Kim, M A, Park, S S, Goo, M J, Kwon, H J, Sohn, S, Kim, W H, Yoon, G 
and Choi, K S (2005) Two Distinct Modes of Cell Death Induced by Doxorubicin: 
Apoptosis and Cell Death through Mitotic Catastrophe Accompanied by 
Senescence-Like Phenotype. Oncogene, 24(30), 4765-77. 
Fadok, V A, Bratton, D L, Frasch, S C, Warner, M L and Henson, P M (1998) The Role 
of Phosphatidylserine in Recognition of Apoptotic Cells by Phagocytes. Cell 
Death Differ., 5(7), 551-62. 
Farhane, Z, Bonnier, F, Casey, A and Byrne, H J (2015) Raman Micro Spectroscopy for 
in Vitro Drug Screening: Subcellular Localisation and Interactions of 
Doxorubicin. Analyst, 140(12), 4212-23. 
Farhane, Z, Bonnier, F, Casey, A, Maguire, A, O'Neill, L and Byrne, H J (2015) Cellular 
Discrimination Using in Vitro Raman Micro Spectroscopy: The Role of the 
Nucleolus. Analyst, 140(17), 5908-19. 
Farhane, Z, Bonnier, F, Maher, M A, Bryant, J, Casey, A and Byrne, H J (2016) 
Differentiating Responses of Lung Cancer Cell Lines to Doxorubicin Exposure: 
In Vitro Raman Micro Spectroscopy, Oxidative Stress and Bcl-2 Protein 
Expression. J Biophotonics. 
Gala, U and Chauhan, H (2015) Principles and Applications of Raman Spectroscopy in 
Pharmaceutical Drug Discovery and Development. Expert Opin Drug Discov., 
10(2), 187-206. 
Gewirtz, D A (1999) A Critical Evaluation of the Mechanisms of Action Proposed for the 
Antitumor Effects of the Anthracycline Antibiotics Adriamycin and 
Daunorubicin. Biochem. Pharmacol., 57(7), 727-41. 
225 
 
Gigli, M, Doglia, S M, Millot, J M, Valentini, L and Manfait, M (1988) Quantitative 
Study of Doxorubicin in Living Cell Nuclei by Microspectrofluorometry. Biochim 
Biophys Acta., 950(1), 13-20. 
Glitsch, M (2016) Essentials of Cell Physiology. Surgery (Oxford). 
Golunski, G, Borowik, A, Derewonko, N, Kawiak, A, Rychlowski, M, Woziwodzka, A 
and Piosik, J (2016) Pentoxifylline as a Modulator of Anticancer Drug 
Doxorubicin. Part Ii: Reduction of Doxorubicin Dna Binding and Alleviation of 
Its Biological Effects. Biochimie, 123, 95-102. 
Green, P S and Leeuwenburgh, C (2002) Mitochondrial Dysfunction Is an Early Indicator 
of Doxorubicin-Induced Apoptosis. Biochim Biophys Acta., 1588(1), 94-101. 
Guo, J, Cai, W, Du, B, Qian, M and Sun, Z (2009) Raman Spectroscopic Investigation on 
the Interaction of Malignanthepatocytes with Doxorubicin. Biophys Chem., 
140(1–3), 57-61. 
Hein, N, Hannan, K M, George, A J, Sanij, E and Hannan, R D (2013) The Nucleolus: 
An Emerging Target for Cancer Therapy. Trends Mol Med., 19(11), 643-54. 
Hofman, J, Skarka, A, Havrankova, J and Wsol, V (2015) Pharmacokinetic Interactions 
of Breast Cancer Chemotherapeutics with Human Doxorubicin Reductases. 
Biochem Pharmacol., 96(3), 168-78. 
Hovorka, D, Subr, V, Vetvicka, D, Kovar, L, Strohalm, J, Strohalm, M, Benda, A, Hof, 
M, Ulbrich, K and Rihova, B (2010) Spectral Analysis of Doxorubicin 
Accumulation and the Indirect Quantification of Its Dna Intercalation. Eur J 
Pharm Biopharm., 76(3), 514-24. 
Huser, T and Chan, J (2015) Raman Spectroscopy for Physiological Investigations of 
Tissues and Cells. Adv. Drug Deliv. Rev., 89, 57-70. 
226 
 
Kagan, V E, Fabisiak, J P, Shvedova, A A, Tyurina, Y Y, Tyurin, V A, Schor, N F and 
Kawai, K (2000) Oxidative Signaling Pathway for Externalization of Plasma 
Membrane Phosphatidylserine During Apoptosis. FEBS Lett., 477(1-2), 1-7. 
Kallaway, C, Almond, L M, Barr, H, Wood, J, Hutchings, J, Kendall, C and Stone, N 
(2013) Advances in the Clinical Application of Raman Spectroscopy for Cancer 
Diagnostics. Photodiagnosis Photodyn Ther., 10(3), 207-19. 
Kann, B, Offerhaus, H L, Herman, L, Windbergs, M and Otto, C (2015) Raman 
Microscopy for Cellular Investigations — from Single Cell Imaging to Drug 
Carrier Uptake Visualization. Adv. Drug Deliv. Rev., 89, 71-90. 
Karukstis, K K, Thompson, E H, Whiles, J A and Rosenfeld, R J (1998) Deciphering the 
Fluorescence Signature of Daunomycin and Doxorubicin. Biophys Chem., 73(3), 
249-63. 
Keating, M E, Nawaz, H, Bonnier, F and Byrne, H J (2015) Multivariate Statistical 
Methodologies Applied in Biomedical Raman Spectroscopy: Assessing the 
Validity of Partial Least Squares Regression Using Simulated Model Datasets. 
Analyst., 140(7), 2482-92. 
Lo, S J, Lee, C C and Lai, H J (2006) The Nucleolus: Reviewing Oldies to Have New 
Understandings. Cell Res., 16(6), 530-8. 
Matthews, Q, Jirasek, A, Lum, J, Duan, X and Brolo, A G (2010) Variability in Raman 
Spectra of Single Human Tumor Cells Cultured in Vitro: Correlation with Cell 
Cycle and Culture Confluency. Appl Spectrosc., 64(8), 871-87. 
Maxfield, F R and Tabas, I (2005) Role of Cholesterol and Lipid Organization in Disease. 
Nature, 438(7068), 612-21. 
Mitry, M A and Edwards, J G (2016) Doxorubicin Induced Heart Failure: Phenotype and 
Molecular Mechanisms. IJC Heart & Vasculature., 10, 17-24. 
227 
 
Moritz, T J, Taylor, D S, Krol, D M, Fritch, J and Chan, J W (2010) Detection of 
Doxorubicin-Induced Apoptosis of Leukemic T-Lymphocytes by Laser Tweezers 
Raman Spectroscopy. Biomed Opt Express., 1(4), 1138-47. 
Movasaghi, Z, Rehman, S and Rehman, I U (2007) Raman Spectroscopy of Biological 
Tissues. Appl. Spectrosc. Rev., 42(5), 493-541. 
Muratore, M (2013) Raman Spectroscopy and Partial Least Squares Analysis in 
Discrimination of Peripheral Cells Affected by Huntington's Disease. Anal Chim 
Acta., 793, 1-10. 
Nawaz, H, Bonnier, F, Meade, A D, Lyng, F M and Byrne, H J (2011) Comparison of 
Subcellular Responses for the Evaluation and Prediction of the Chemotherapeutic 
Response to Cisplatin in Lung Adenocarcinoma Using Raman Spectroscopy. 
Analyst., 136(12), 2450-63. 
Notingher, I (2007) Raman Spectroscopy Cell-Based Biosensors. Sensors (Basel). 7(8), 
1343-58. 
Notingher, I, Verrier, S, Haque, S, Polak, J M and Hench, L L (2003) Spectroscopic Study 
of Human Lung Epithelial Cells (A549) in Culture: Living Cells Versus Dead 
Cells. Biopolymers, 72(4), 230-40. 
Olson, M O, Dundr, M and Szebeni, A (2000) The Nucleolus: An Old Factory with 
Unexpected Capabilities. Trends Cell Biol., 10(5), 189-96. 
Orsolic, I, Jurada, O, Pullen, N, Oren, M, Eliopoulos, A G and Volarevic, S (2016) The 
Relationship between the Nucleolus and Cancer: Current Evidence and Emerging 
Paradigms. Semin Cancer Biol., 37-38, 36-50. 
Parastar, H, Jalali-Heravi, M and Tauler, R (2012) Is Independent Component Analysis 
Appropriate for Multivariate Resolution in Analytical Chemistry? Trends Analyt 
Chem., 31, 134-43. 
228 
 
Pence, I and Mahadevan-Jansen, A (2016) Clinical Instrumentation and Applications of 
Raman Spectroscopy. Chem Soc Rev., 45(7), 1958-79. 
Quin, J E, JDevlin, J R, Cameron, D, Hannan, K M, Pearson, R B and Hannan, R D (2014) 
Targeting the Nucleolus for Cancer Intervention. Biochim. Biophys. Acta., 
1842(6), 802-16. 
Sardao, V A, Oliveira, P J, Holy, J, Oliveira, C R and Wallace, K B (2009) Morphological 
Alterations Induced by Doxorubicin on H9c2 Myoblasts: Nuclear, Mitochondrial, 
and Cytoskeletal Targets. Cell Biol Toxicol., 25(3), 227-43. 
Schiller, J H, Gandara, D R, Goss, G D and Vokes, E E (2013) Non-Small-Cell Lung 
Cancer: Then and Now. J. Clin. Oncol., 31(8), 981-3. 
Sieuwerts, A M, Klijn, J G, Peters, H A and Foekens, J A (1995) The Mtt Tetrazolium 
Salt Assay Scrutinized: How to Use This Assay Reliably to Measure Metabolic 
Activity of Cell Cultures in Vitro for the Assessment of Growth Characteristics, 
Ic50-Values and Cell Survival. Eur J Clin Chem Clin Biochem., 33(11), 813-23. 
Suggitt, M and Bibby, M C (2005) 50 Years of Preclinical Anticancer Drug Screening: 
Empirical to Target-Driven Approaches. Clin Cancer Res., 11(3), 971-81. 
Tabas, I (2004) Apoptosis and Plaque Destabilization in Atherosclerosis: The Role of 
Macrophage Apoptosis Induced by Cholesterol. Cell Death Differ., 11 Suppl 1, 
S12-6. 
Tacar, O, Sriamornsak, P and Dass, C R (2013) Doxorubicin: An Update on Anticancer 
Molecular Action, Toxicity and Novel Drug Delivery Systems. J Pharm 
Pharmacol., 65(2), 157-70. 
Trusheim, M R and Berndt, E R (2015) The Clinical Benefits, Ethics, and Economics of 
Stratified Medicine and Companion Diagnostics. Drug Discov Today, 20(12), 
1439-50. 
229 
 
Twentyman, P R and Luscombe, M (1987) A Study of Some Variables in a Tetrazolium 
Dye (Mtt) Based Assay for Cell Growth and Chemosensitivity. Br J Cancer., 
56(3), 279-85. 
Umsumarng, S, Pitchakarn, P, Sastraruji, K, Yodkeeree, S, Ung, A T, Pyne, S G and 
Limtrakul, P (2015) Reversal of Human Multi-Drug Resistance Leukaemic Cells 
by Stemofoline Derivatives Via Inhibition of P-Glycoprotein Function. Basic 
Clin. Pharmacol. Toxicol., 116(5), 390-7. 
Vankeirsbilck, T, Vercauteren, A, Baeyens, W, Van der Weken, G, Verpoort, F, Vergote, 
G and Remon, J P (2002) Applications of Raman Spectroscopy in Pharmaceutical 
Analysis. Trends Analyt Chem., 21(12), 869-77. 
Verrier, S, Notingher, I, Polak, J M and Hench, L L (2004) In Situ Monitoring of Cell 
Death Using Raman Microspectroscopy. Biopolymers, 74(1-2), 157-62. 
Wallace, K B (2003) Doxorubicin-Induced Cardiac Mitochondrionopathy. Pharmacol 
Toxicol., 93(3), 105-15. 
Wang, G, Ding, Q and Hou, Z (2008) Independent Component Analysis and Its 
Applications in Signal Processing for Analytical Chemistry. Trends Analyt 
Chem., 27(4), 368-76. 
Woods, S J, Hannan, K M, Pearson, R B and Hannan, R D (2015) The Nucleolus as a 
Fundamental Regulator of the P53 Response and a New Target for Cancer 
Therapy. Biochim Biophys Acta., 1849(7), 821-9. 
Yadav, N, Pliss, A, Kuzmin, A, Rapali, P, Sun, L, Prasad, P and Chandra, D (2014) 
Transformations of the Macromolecular Landscape at Mitochondria During Dna-
Damage-Induced Apoptotic Cell Death. Cell Death Dis., 5, e1453. 
Yang, F, Teves, S S, Kemp, C J and Henikoff, S (2014) Doxorubicin, Dna Torsion, and 
Chromatin Dynamics. Biochim Biophys Acta, 1845(1), 84-9. 
230 
 
Zenebergh, A, Baurain, R and Trouet, A (1984) Cellular Pharmacology of Detorubicin 
and Doxorubicin in L1210 Cells. Eur J Cancer Clin Oncol., 20(1), 115-21. 
Zhang, D, Luo, G, Ding, X and Lu, C (2012) Preclinical Experimental Models of Drug 
Metabolism and Disposition in Drug Discovery and Development. Acta Pharm 
Sin B., 2(6), 549-61. 
 
 
 
 
 
 
 
 
 
 
 
 
231 
 
6.9. Supplementary Material: 
A.      B. 
 
Figure S.6.1: AB and MTT in vitro dose dependent cytotoxicity assays of DOX of A549 
cell line A. 48 hrs exposure and B. 72 hrs exposure. Viability is expressed as % compared 
to control, and the error bars indicate the standard deviation of six independent replicate 
measurements. 
All viability cures were fitted with Equation 1(Black & Leff, 1983) 
V = Vmin + (Vmax - Vmin)/ (1 + (C/IC50)
 n)   Equation 1 
where V is the % viability, Vmin is the minimum viability, Vmax is the maximum viability, 
C is the DOX concentration, n is the Hill slope, and IC50 is the concentration which elicits 
50% of the maximum response. 
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A. 
 
B. 
 
Figure S.6.2: Regression coefficients obtained by PLSR analysis of A. nucleolus and B. 
nucleus regressed against DOX concentration inside cells (D) determined by the peaks 
intensities of the band at 465 cm-1 in loading 1 of PCA exposed cells versus control, with 
time incrementation. The dashed horizontal line indicates the zero-point for D: 0-6hrs and 
the other co-efficients are off set for clarity.  
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A. 
 
B. 
 
Figure S.6.3: First ICA component of A549 cells, explaining the majority of variance, 
for control cells (0 hrs) and for each time exposure (2, 6, 12, 24, 48 and 72 hrs) after DOX 
spectrum subtraction of A. nucleolus and B. nucleus with highlighted cellular features 
changing according to DOX exposure duration. 
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Chapter 7: Doxorubicin kinetics and effects on lung cancer cell 
lines using in vitro Raman micro-spectroscopy: Binding 
signatures, Drug resistance and DNA repair  
 
The following chapter reproduces the journal article, Z.Farhane, F.Bonnier, O.Howe, 
A.Casey and H.J.Byrne, J. Biophotonics 1–14 (2017) / DOI 10.1002/jbio.201700060, in 
which the section and figure numbers have been adapted to the prescribed thesis format. 
All experiments, data analysis and paper writing were performed by Z.F.  
F.B., O.H. and A.C. assisted in the experimental design.  
H.J.B. assisted in the project design and proofing of the manuscript.    
Graphical Abstract: 
 
 
DNA damage and repair measured by Raman micro-spectroscopy and Mean 
Fluorescence of γH2AX after DOX exposure. Intensities expressed on percentage 
according to the maximum value for both cell lines. 
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Abstract:  
Raman micro-spectroscopy is a non-invasive analytical tool, whose potential in cellular 
analysis and monitoring drug mechanisms of action has already been demonstrated, and 
which can potentially be used in pre-clinical and clinical applications for the prediction 
of chemotherapeutic efficacy. To further investigate such potential clinical application, it 
is important to demonstrate its capability to differentiate drug mechanisms of action and 
cellular resistances. Using the example of Doxorubicin (DOX), in this study, it was used 
to probe the cellular uptake, signatures of chemical binding and subsequent cellular 
responses, of the chemotherapeutic drug in two lung cancer cell lines, A549 and Calu-1. 
Multivariate statistical analysis was used to elucidate the spectroscopic signatures 
associated with DOX uptake and subcellular interaction. Biomarkers related to DNA 
damage and repair, and mechanisms leading to apoptosis were also measured and 
correlated to Raman spectral profiles. Results confirm the potential of Raman 
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spectroscopic profiling to elucidate both drug kinetics and pharmacodynamics and 
differentiate cellular drug resistance associated with different subcellular accumulation 
rates and subsequent cellular response to DNA damage, pointing towards a better 
understanding of drug resistance for personalised targeted treatment. 
 
Keywords: Raman micro-spectroscopy, Doxorubicin, Cytotoxicity, lung cancer cell 
lines, bind signature, DNA repair. 
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7.1. Introduction: 
In the continued search for more effective chemotherapeutic treatments, there is a 
concomitant need for the development of improved screening techniques, particularly at 
the pre-clinical stage. Development of a new drug product from start to end is a very long 
process, taking on average 12 years, and costing, on average, $1.2 billion per product 
(DiMasi, Grabowski, and Hansen, 2003, 2016; Petrova, 2013). 
EU Directive-2010/63/EU on the replacement, reduction and refinement of animal 
experimentation has prioritised the development of rapid, cost effective in vitro 
techniques for toxicological and pharmaceutical screening applications, amongst others. 
High Throughput Screening techniques allow for the evaluation of multiple biochemical 
and morphological parameters in cells based on image analysis of morphological changes 
or monitoring multiple fluorescently labelled species/processes in a cellular population 
(Flow Cytometry) or at a subcellular level (Confocal Microscopy) (Szymański, 
Markowicz, and Mikiciuk-Olasik, 2012). Notably, however, such screening and 
analytical techniques are phenomenological rather than molecularly specific and thus are 
limited in their ability to elucidate the underlying mechanisms. Alternative, high content 
assaying techniques for in vitro cytological screening and analysis are therefore desirable. 
Furthermore, despite the increased understanding of cancer biology and cellular drug 
mechanisms, all patients have a varied response to chemotherapeutic treatment and can 
develop adverse reactions and resistance to many approved drugs on the market. As an 
example, lung cancer remains the most common cause of cancer death worldwide (Ferlay 
et al., 2015; Jemal et al., 2010), despite the recent significant process in treatment and 
prevention (Cabeza et al., 2017; Tsao et al., 2016) and chemotherapeutic resistance is a 
major cause of treatment failure (Chen, Chang, and Cheng, 2017). This highlights the 
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need for personalised predictive testing to identify and characterise clinical biomarkers 
related either to the drug effects or to patient resistance. The development of an analytical 
tool for prediction of chemosensitivity, either in pre-clinical or diagnostic stages, is of 
great importance in order to adapt cancer treatment for each individual patient (Cho, Jeon, 
and Kim, 2012; Overby and Tarczy-Hornoch, 2013). 
Raman micro-spectroscopy is an analytical technique whose potential for biological 
analysis has already been demonstrated (Butler et al., 2016; Byrne et al., 2015; Efeoglu, 
Casey, and Byrne, 2016). Therefore, it can be considered as a potential candidate for 
exploring pre-clinical drug development and clinical applications, by identifying 
signatures of drug mechanisms of interaction and even of cell dependent drug at a 
subcellular level. 
As a proof of concept, a commercialy available drug Doxorubicin (DOX) is used in this 
study to demonstrate the potential of  Raman micro-spectroscopy to monitor the uptake, 
interaction mechanisms and subsequent cellular responses, for pre-clinicial screening, as 
well as to differentiate the responses of two different cell lines, identifying markers of 
drug resistance, and therefore its potential as a companion diagnostic tool for personalized 
medicine. DOX is an anthracycline widely used in chemotherapy for the treatment of 
various human cancers and aggressive tumours (Agudelo et al., 2014; Rabbani, Finn, and 
Ausio, 2005), despite its serious side effects, principally cardiotoxicity, and a not fully 
understood mechanism of action (Farhane et al., 2015; Gautier et al., 2015; Gu et al., 
2016). In previous in vitro reports, different relative contributions of subcellular processes 
have been observed, depending on cell line, (Farhane et al., 2017) including ROS 
production, intercalation between nucleic base pairs and Topoisomerase II inhibition, 
blocking of DNA replication (Farhane et al., 2015; Hasanzadeh and Shadjou, 2016) and 
induction of DNA double stand breaks (DSB) by nucleosome turnover increase, leading 
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to cellular apoptosis (Ohnishi, Mori, and Takahashi, 2009; Ross and Bradley, 1981; Yang, 
Kemp, and Henikoff, 2015). DSB induce a DNA damage response (DDR) which can be 
visualised locally as an accumulation of repair proteins, known as nuclear foci (Brandsma 
and Gent, 2012) and chromatin modification acting as an adaptor attracting and localizing 
retention of DNA repair proteins. The cellular DNA damage and repair capacity 
influences the effects of an anticancer drug (Helleday et al., 2008) and can be used as a 
biomarker of chemotherapeutic efficacy and resistance (Ivashkevich et al., 2012). 
Moreover, resistance to apoptosis, programmed cell death, by either increase of apoptosis 
inhibitor protein or, higher tolerance to DNA damage or DNA repair, is associated with 
chemoresistance (Gu et al., 2016) and a poor clinical prognosis in cancer therapy and can 
be used as a marker for individualised treatment (de Bruin and Medema, 2008). 
The present study expands the provious work exploring the use of Raman micro-
spectroscopy to monitor DOX effects and cellular responses in vitro (Farhane et al., 2015; 
Farhane et al., 2017) to a comparison of the uptake kinetics and responses of two different 
histological subtype cell lines, A549 and Calu-1. In order to extract biological information 
contained in Raman spectra, multivariate data analysis consising of Principal Component 
Analysis (PCA), Partial Last Square Regression (PLSR) and Independent Component 
Analysis (ICA) is used. Raman investigations are supported by cytotoxicity assays;  
apoptotic marker of nuclear condensation, specific anti-apoptotic protein (bcl-2) and 
DNA damage and repair by measurement of γH2AX, to identify different DOX 
sensitivities, monitor cellular uptake and response mechanisms. 
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7.2. Materials and methods:  
7.2.1. Materials: 
A549 human lung adenocarcinoma cells with the alveolar type II phenotype were 
obtained from ATCC (Manassas, VA, USA) and Calu-1 human lung epidermoid 
carcinoma cell line, was kindly provided by Dr. Josep Sulé-Suso, Institute for Science & 
Technology in Medicine, Keele University, Guy Hilton Research Centre UK and Cancer 
Centre, Royal Stoke University Hospital, University Hospitals of North Midlands, UK.  
A Doxorubicin stock solution of concentration 17.25 mM was prepared by dilution of 
Doxorubicin hydrochloride® powder (Sigma Life Sciences, Ireland) in 1 mL sterile water. 
Alamar blue (AB) (10X ready to use solution) and 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl tetrazolium bromide (MTT) were obtained from Sigma Aldrich, Ireland.  
For cytotoxicity assays, an AB/MTT solution, 1.5 mL of AB and 3 mL of MTT stock 
solution (2.5 mg/mL, 25 mg MTT/10 mL PBS) in 30 mL of fresh medium was prepared 
prior to performing the assays. 
Nucred® live 647 Ready Probes® Reagent, used to image the cellular nuclear 
condensation, the fixation/permeabilization kit, BD Cytofix/Cytoperm (BD 554714), and 
FITC Mouse Anti-Human bcl-2 set with an IgG1 isotype control (BD 556357) was 
purchased from BioSciences, Ireland. 
γH2AX reagents, Alexa Fluor® 647 anti H2AX phospho (Ser 139) and Alexa Fluor® 647 
mouse IgG1 isotype control (ICFC), Biolegends, were supplied through Medical Supply 
Company Ltd., Ireland.  
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7.2.2. Cell culture: 
A549 cells were cultured in DMEM-F12 with 10 % foetal bovine serum (FBS) and Calu-
1 cells in RPMI with 10 % FBS, both at 37 °C in a humidified atmosphere containing 5 
% CO2 and cells were split every two days to maintain ~60 % confluency. 
For Cytotoxicity assays, Confocal Laser Scanning Fluorescence Microscopy (CLSM) and 
Raman micro spectroscopic analysis, the cell number was determined using a Beckman 
Coulter Particle Count and Size Analysis® Z2 Cell Counter. 
7.2.3. Cytotoxicity assays: 
AB and MTT assays were performed in 96 well plates and a total number of 1x105 cells 
(4x103  cells/mL), 1 x 104 (4x102 cells/mL) and 5x103 cells (2x102 cells/mL), respectively 
for 0-24 hrs, 48 hrs and 72 hrs, with three replicate plates of each. After 24 hrs incubation, 
plates were washed with phosphate buffered saline solution (PBS) and DOX was added 
in a concentration range from 0 µM (as a control) to 50 µM. 
AB and MTT assays were both measured with a Cytotox SpectraMax®M3 plate reader 
using Soft Max® Pro 6.2.2 software. After 6, 24, 48 and 72 hrs incubation in DOX, plates 
were washed with PBS and 100µL of AB/MTT solution were added to each well. Plates 
were then incubated for 3 hrs and AB fluorescence was measured first in the plate reader 
using 540 nm excitation and 595 nm emission, then the medium was removed, the plates 
were washed with PBS and 100 µL of DMSO (Dimethyl sulfoxide) were added in each 
well. MTT absorbance was read at 570 nm.  
All cytotoxicity assays were made in triplicate and repeated three times and viability data 
was fitted by a four parameter Hill equation analysis using SigmaPlot 10.0, to yield values 
of the mean inhibitory concentration, IC50. 
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7.2.4. Raman micro-spectroscopy: 
Cells (~ 1x 104/window) were seeded and incubated on CaF2 windows (Crystan Ltd, UK) 
for 24 hrs for both control and exposure to DOX. The medium was then removed and 
samples were rinsed twice with sterile PBS and covered with DOX at each corresponding 
IC50 inhibitory concentration, adjusted to the cell number (Farhane, Bonnier, and Byrne, 
2017). After each incubation period, 2, 6, 12, 24, 48 and 72 hrs, cells were washed twice 
with sterile PBS and fixed in formalin (4 %, 15 min). 
A Horiba Jobin-Yvon LabRAM HR800 spectrometer with a 785 nm, 300 mW diode laser 
as source, Peltier cooled 16-bit CCD, 300 lines/mm grating and 100 μm confocal hole, 
was used for this work. Spectra were acquired in the range from 400 cm-1 to 1800 cm-1 
using a x100 objective (LCPlanN, Olympus), in dry conditions, for 30 s two times, from 
three cell locations: cytoplasm, nucleus and nucleolus, visible under white light 
illumination. A final data set of 30 points per cell location for each time point, 2, 6, 12, 
24, 48 and 72 hrs was produced after DOX exposure and for control cells, for each cell 
line, amounting to a total of over 210 cells per cell line, corresponding to a total data set 
of 1260 spectra. 
7.2.5. Data analysis:  
Raman spectral pre-processing and analysis were performed in Matlab 2013 using 
algorithms developed in house. Prior to analysis, background was subtracted using a 
NCLS (non-negatively constrained least squares) algorithm and spectra were smoothed 
(Savitsky-Golay filter 3th order, 11 points), baseline corrected (fifth order polynomial) 
and vector normalised.  
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PCA was employed as an unsupervised multivariate approach to analyse data and the 
effects of doxorubicin in each cell localisation. The order of the PCs denotes their 
importance to the dataset and PC1 describes the highest amount of variation (Efeoglu, 
Casey, and Byrne, 2016; Farhane et al., 2015). 
PLSR, a statistical regression technique which reduces the dimensionality of the data and 
correlates information, here represented by the Raman spectra, to time evolution, was 
employed to track the temporal dependent evolution of the spectral signatures in the 
subcellular regions (Efeoglu, Casey, and Byrne, 2016; Keating et al., 2015). The 
percentage of variance explained as a function of the number of components was 
calculated using 10-fold cross validation and from a plot of the percent of variance 
explained function of number of components, the majority percentage of variance (above 
90 %) was found to be explained by the first 3 components. The regression coefficients 
obtained by PLSR of Raman data regressed against time were plotted and analysed. As a 
function of frequency, the co-efficients illustrate the spectral features which are 
influenced by the intracellular interaction of the DOX and the resulting metabolic 
changes. 
ICA was also employed as an extension to PCA. ICA is an unsupervised statistical 
technique able to identify latent variables called independent components. In the case of 
Raman micro-spectroscopy, ICA can be used to identify spectral contributions such as 
those from substrate, using the same number of ICs as PCs, which can then be removed 
or studied in their own right (Boiret et al., 2014; Vrabie et al., 2007). 
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7.2.6. Nuclear condensation:  
Approximately 1 x 104 cells were allowed to attach on uncoated glass bottom Petri dishes 
(MatTek Corporation, USA) for two hours, after which they were covered with cell 
culture medium. After 24 hrs incubation, the medium was removed and samples were 
rinsed twice with sterile PBS, after which new fresh medium containing DOX 
corresponding to the inhibitory concentration, IC50, determined by the cytotoxicity assays 
for each cell line, and adjusted to the cell number (Farhane, Bonnier, and Byrne, 2017), 
was added  and cells were incubated for each corresponding time point.  
After incubation, old medium was removed and 2 mL of Nucred® solution in medium 
was added and, after 15 to 30 min incubation, samples were rinsed twice with sterile PBS 
and kept in PBS for live cell imaging using CLSM. Control samples without exposure to 
DOX were also prepared in parallel, and incubated for 2, 6, 12, 24, 48 and 72 hrs. 
CLSM images were recorded using an inverted Zeiss LSM 510 Confocal Laser Scanning 
Microscope equipped with a x60 oil immersion objective. DOX fluorescence was excited 
with an argon ion laser at 488 nm, and the emission was collected at 530 nm, while 
Nucred® was measured using 633 and 690 nm, excitation and emission, respectively.  
Using ImageJ software, after fluorescence background subtraction, the mean fluorescence 
intensity of Nucred® was measured for 10 cells for each cell line and each time point.  
7.2.7. Bcl-2 protein expression: 
Cells (3x 104/flasks) were cultured in T25 flasks over 24 hrs, and then exposed  to a DOX 
dose corresponding to the inhibitory concentration, IC50, adjusted to the cell number 
(Farhane, Bonnier, and Byrne, 2017), determined by cytotoxicity assays for each time 
point (from 2 hrs to 72 hrs) and each cell line. After each incubation period, cells were 
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trypsinised and centrifuged in 5 mL fresh medium at 4 °C and 1100 rpm for 5 min and 
they were then re-suspended in 1 mL Ice Cold Dulbecco's Phosphate-Buffered Saline 
(DPBS) buffer and centrifuged at 4 °C and 2500 rpm for 5 min. Cells were re-suspended 
in 750 µL ice cold DPBS buffer and transferred to Eppendorf tubes to which 250 µL of 
fixation buffer were added. After 30 min incubation at 4 ºC, the fixed cells were washed 
twice in perm/wash buffer, centrifuged (2500 Rpm for 5 min at 4 ºC) and then gently re-
suspended in 50 µL perm/wash buffer, after which 20 µL of the antibody were added and 
the cells were incubated for 60 min in the dark at 4 ºC. The cells were then washed twice 
in perm/wash buffer, centrifuged (2500 Rpm for 5 min at 4 ºC) to remove unbound 
antibody and finally re-suspended in 1mL stain buffer. 10,000 cells were analysed by 
Flow Cytometry using a BD Biosciences Accuri C6 Flow Cytometer (Becton Dickinson, 
Oxford, UK). The Accuri Flow Cytometry software was used for the analysis of Flow 
Cytometry samples and data processing. 
7.2.8. γH2AX expression: 
Cells (106/flask) were cultured in T25 flasks over 24 hrs, and then exposed to a DOX dose 
corresponding to the inhibitory concentration, IC50, adjusted to the cell number (Farhane, 
Bonnier, and Byrne, 2017), determined by cytotoxicity assays for each time point (from 
2 hrs to 72 hrs) and each cell line. 
After each incubation period, cells were trypsinised and centrifuged in 5 mL fresh 
medium at 4°C and 1100 rpm for 5 min, then were re-suspended with 1mL PBS, 
transferred to an Eppendorf tube and centrifuged at 400 g for 5 min at 4 ºC. Cells were 
re-suspended in 200 µL of formalin 2 % v/v in PBS and incubated for 10 min. If not used 
immediately, cells can be kept in 1mL ice-cold ethanol 70 % and samples and stored at -
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20 ºC for up to two weeks or overnight at 4 ºC. Cells were then re-suspended in 500 µL 
Triton X-100 0.25 % v/v in PBS and incubated at Room Temperature (RT) for 5 min or 
30 min at 4 ºC, after which cells were centrifuged at 400 g for 5 min at RT and re-
suspended in 200 µL Bovine serum albumin (BSA) solution (2 mg/100 mL) and 
incubated at RT for 30 min. After centrifugation at 400 g for 5 min at RT, cells were re-
suspended in 150 µL antibody solution diluted 1:500 in BSA solution and incubated at 
RT for 2 hrs or overnight at 4ºC. The cells were then washed thrice in PBS and finally re-
suspended in 1mL BSA solution. 30,000 cells were analysed by Flow Cytometry using a 
BD Biosciences Accuri C6 Flow Cytometer (Becton Dickinson, Oxford, UK). The Accuri 
Flow Cytometry software was used for the analysis of Flow Cytometry samples and data 
processing. 
7.3. Results and discussion: 
7.3.1. Cytotoxicity assays: 
Figure 7.1 shows the dose dependent responses of the cytotoxicity assays, AB and MTT, 
for early (6-24 hrs) and late (48 hrs-72 hrs) stage to DOX exposure, for both cell lines, 
A549 and Calu-1. Viability is expressed as % compared to control and the error bars 
indicate the standard deviation of six independent replicate measurements in triplicate 
and repeated three times.  
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A1.          A2.
 
B1.          B2. 
 
Figure 7.1: AB in vitro dose dependent cytotoxicity assays of DOX A1. A549 cell line 
and A2. Calu-1 cell line and MTT in vitro dose dependent cytotoxicity assays of DOX 
B1. A549 cell line and B2. Calu-1cell line. Viability is expressed as % compared to 
control, and the error bars indicate the standard deviation of six independent replicate 
measurements. 
For both in vitro assays and for all exposure times, a partial loss of cell population 
viability is observed for the two cell lines. All viability curves were fitted with Eq. (1) 
(Black and Leff, 1983) 
V = Vmin + (Vmax - Vmin)/ (1 + (C/IC50)
 n)   Equation 1 
where V is the % viability, Vmin is the minimum viability, Vmax is the maximum viability, 
C is the DOX concentration, n is the Hill slope, and IC50 is the concentration which elicits 
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50 % of the maximum response. IC50 values are quoted with the error generated from the 
fit to all mean data points. 
The AB and MTT assays for the A549 cell line show similar responses for each time 
exposure (Figure 7.1 A1 and B1) except for the early stage of 6 hrs, at which time point 
AB appears to be less sensitive than MTT. A slightly different profile is observed for the 
Calu-1 cell population (Figure 7.1 A2 and B2), whereby the AB assay is seen to be less 
sensitive for both 6 and 24 hrs exposure times (Table 7.1). 
Table 7.1: DOX IC50 concentration determined by the AB and MTT assays for the two 
cell lines A549 and Calu-1.  
 Time (hrs) 6 24 48 72 
IC
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A
5
4
9
 AB 
MTT 
1.52±0.20 
1.61±1.43 
0.42 ± 0.06 
0.55 ± 0.16 
0.30± 0.04 
0.31± 0.05 
0.29± 0.02 
0.27± 0.02 
C
al
u
-1
 AB 
MTT 
1.67±0.29 
1.90±0.76 
0.69 ± 0.13 
0.90 ±0.24 
0.62±0.12 
0.72±0.15 
0.37±0.01 
0.41±0.08 
The AB assay is an expression of general cellular metabolism, while the MTT assay is a 
reflection of mitochondrial activity (Farhane et al., 2015). Mitochondrial dysfunction is 
an early effect of DOX which explains the difference in the two assays for early exposure 
time points (Green and Leeuwenburgh, 2002). The notably different cytotoxic profiles 
for the two cell lines, up to 48 hrs exposure to DOX, are consistent with a higher intrinsic 
resistance of the Calu-1 cell line to the chemotherapeutic drug, whereby Calu-1 cells 
remain more viable than A549 cells at comparable doses and equivalent exposure times.  
The difference in cytotoxicity response between MTT and AB and between the two cell 
lines suggests different contributions of drug mechanisms of action and relatively 
different cellular behaviours to the drug treatment, resulting in a delayed response of 
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Calu-1 cell line compared to A549, as indicated by the lower sensitivity of the AB assay 
up to 24 hrs exposure. The MTT assay has been widely used as an indicator of 
chemosensitivity of cancer cell lines to a chemotherapeutic drug and shows a good 
correlation of the in vitro results with clinical observations (Burton, 2005; Campling et 
al., 1991; Carmichael et al., 1988) and the difference in MTT responses between the two 
cell lines is indicative of a higher chemosensitivity of A549 cells compared to Calu-1. 
Therefore, the IC50 concentration determined by MTT assay was used for the rest of 
experiments. 
7.3.2. Raman micro-spectroscopy: 
Raman micro-spectroscopy has previously demonstrated that A549 and Calu-1 present 
different sensitivities to DOX treatment after 24 hrs exposure as a result of different 
relative contributions of the different mechanisms of action involved (Farhane et al., 
2017). In order to further investigate the subcellular differences at early and late stages of 
exposure, Raman profiles for both cell lines were compared after 2, 6, 12, 24, 48 and 72 
hrs exposure to DOX and spectra were taken from the three subcellular compartments, 
nucleolus, nucleus and cytoplasm (the example of original and pre-processed data of 
Calu-1 24 hrs exposure is shown in Figure S.7.1). 
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Figure 7.2: A. Pre-processed Raman spectrum of Doxorubicin dissolved in sterile water, 
and loading 1 corresponding to PC1 of PCA of Calu-1 control cells versus Calu-1 2 hrs 
exposure of B. nucleolus and C. nucleus.   
As previously and for comparibility purposes, the IC50 concentration, as determined by 
the MTT assay, for 24 hrs was used for early exposure from 2 to 24 hrs and for 48 and 72 
hrs, each corresponding IC50 concentration was used (Farhane, Bonnier, and Byrne, 
2017). 
Multivariate data anlysis, consisting of PCA, PLSR and ICA, was employed in order to 
analyse in more detail the spectral features due to DOX exposure and compare the cellular 
effects and responses between the two cell lines and between the different exposure times.  
A pairwise PCA of exposed cells for each time point versus control for each cellular 
compartment was analysed and separation was observed according to PC1 for all time 
points. As an example PCA of control versus 24 hrs exposed for Calu-1 cells is shown in 
Figure S.7.2. Figure 7.2 shows the loading of PC1 for the nucleus and nucleolus of Calu-
1 cells after 2 hrs exposure, compared to the spectrum of the DOX stock solution. 
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As seen in Figure 7.2, obvious DOX features at 440 and 465 cm−1, respectively derived 
from C–C–O and C–O vibrations, and 1085, 1215 and 1245 cm−1, related to C–O–H, C–
O and C–H, are observed in the spectra of the nucleolar, and nuclear regions, highlighting 
the DOX uptake into Calu-1 cells after only 2 hrs exposure. 
In both nucleolus and nucleus of Calu-1 cells, features at 1430-1450 cm-1 are also 
observed, corresponding to guanine and cytosine (absent in control cells) and are related 
to DOX-DNA intercalation inducing damage and/or conformational changes (Rabbani, 
Finn, and Ausio, 2005). The same features have been observed after 24 hrs of DOX 
interaction in A549 cells (Farhane et al., 2017) confirming the early stage DOX-DNA and 
RNA binding for both cell lines (Agudelo et al., 2013). The decrease in the bands at 785 
and 813 cm−1, corresponding respectively to DNA backbone O–P–O and RNA O–P–O 
phosphodiester bond stretching, confirm an early DOX effect in Calu-1 cells consistent 
with its main mechanism of action, DNA intercalation, interfering with both DNA and 
RNA polymerase, inducing DNA replication and RNA transcription blockage (Farhane 
et al., 2015; Thorn et al., 2011). 
In order to further analyse the DOX cellular kinetics, the DOX peak intensity at 465 cm-
1, the loading of PC1 of each time point and cellular compartment for both cancer cells 
was analysed. This DOX band was chosen due to the minimal influence by the proximity 
of cellular compounds features. 
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Figure 7.3: Evolution of DOX, represented by the Raman band at 465 cm-1, as a function 
of time for the A549 and Calu-1 cell line for each cellular compartment, nucleolus, 
nucleus and cytoplasm. Intensities are expressed as percentage according to the maximum 
value over the three cellular compartments and the two cell lines and standard deviation 
corresponds to the spectral variations of the Raman band over the 30 measurements per 
location. 
Figure 7.3 shows the time evolution of this band in each subcellular region for each cell 
line. Intensity is expressed in percentage function of the highest value observed over all 
the measurements, that of the A549 nucleolar region after 6 hrs exposure. For both cell 
lines, in each subcellular region, (Figure 7.3) there is a progressive increase of 
intracellular DOX concentration until a plateau is reached. As previously described for 
A549 cells, DOX accumulation is initially observed in the nucleoli, reaching saturation 
at ~6 hrs, then in the nucleus, reaching saturation at ~12 hrs, before it finally begins to 
accumulate in the cytoplasm, at ~48 hrs, after saturation of nuclear binding sites (El-
Kareh and Secomb, 2005; Zenebergh, Baurain, and Trouet, 1984).  
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A. 
 
B. 
 
Figure 7.4: A. Loading 1 of PC1 of control versus exposed cells. A. Nucleolus A549 
control versus 6 hrs exposure compared to that of nucleolus Calu-1 control versus 2 hrs 
exposure B. Nucleus A549 control versus 12 hrs exposure and nucleus Calu-1 control 
versus 6 hrs exposure.  
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Notably, the subcellular accumulation in Calu-1 is much more rapid, saturating at ~2 hrs 
in the nucleoli, ~6 hrs in the nucleus and is detectable in the cytoplasm after only ~24 hrs.  
Despite the fact that DOX-DNA intercalation starts at early stages for both cell lines, 
according to the DOX Raman band, DOX saturation for both nuclear areas happens more 
rapidly in Calu-1 cells than A549, after which DOX concentration inside the combined 
nuclear regions becomes approximately constant and accumulation in the cytoplasm due 
to additional drug taken up by cells is only evident after ~48 hrs for A549 and earlier at 
~24 hrs for Calu-1, due, in both cell lines, to nuclear membrane disruption (Farhane, 
Bonnier, and Byrne, 2017). The saturation levels in each subcellular region are 
comparable for each cell line, although significantly lower levels of DOX are recorded in 
the cytoplasmic region of A549. 
In order to compare the DOX mechanism of action and cellular responses, cellular 
features were analysed in more detail over the time periods before and after DOX 
saturation for the nuclear and cytoplasmic compartments. 
As seen in Figure 7.4, which shows the loading of PC1 of control cells versus exposed in 
the nuclear regions below the saturation point, almost identical loadings are obtained for 
both cell lines, including dominant DOX peaks at 440, 465, 1215 and 1245 cm−1. Guanine 
and cytosine features are prominent, respectively at 1430 and 1450 cm−1, confirming 
DOX intercalation and RNA interaction in the nucleolus and DNA in the nuclear region, 
related to DOX binding inducing changes in DNA conformation with a partial transition 
of DNA from B to A form (change in the ratio between 813 cm−1 and 830 cm−1 bands) 
and blockage of DNA synthesis and as a consequence a decrease in RNA (Agudelo et al., 
2014; Farhane et al., 2015). 
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Up to the saturation point, the same spectral features assigned to DOX mechanism of 
action by nuclear intercalation were thus found for A549 and Calu-1, giving a 
reproducible signature of the binding interaction, which appears to be same for the two 
cell lines. 
In order to track the cellular changes after saturation, PLSR was employed and spectra 
were regressed against time starting from each saturation point 2 hrs and 6 hrs for Calu-
1 cells and 6 hrs and 12 hrs for A549 cells, respectively for nucleolus and nucleus. The 
regression coefficients obtained are shown in Figure 7.5. 
In both cell lines, for the nucleolar regions (Figure 7.5 A), a notable decrease in features 
at 728 cm-1 (adenine) 785 cm-1 (cytosine, thymine and DNA backbone O–P–O), 813 cm-
1 (RNA O–P–O stretching), 1095 cm-1 (DNA PO2− symmetric stretching) and 1376 cm-1 
(thymine), are consistent with a decrease in nucleic acid contributions due to the DOX 
mechanism of action by nucleolar interaction, inducing DNA replication blockage, and 
decrease of RNA features by inhibiting RNA synthesis at the level of rRNA transcription, 
inhibiting ribosome biogenesis, and, as a consequence, alteration of nucleolar structure 
(Orsolic et al., 2016), size, shape and fragmentation (Farhane, Bonnier, and Byrne, 2017; 
Farhane et al., 2015; Farhane et al., 2017), inducing nucleolar stress dependent apoptosis 
(Avitabile et al., 2011; Woods et al., 2015). 
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A. 
 
B. 
 
Figure 7.5: Regression coefficients obtained by PLSR analysis as a function of time after 
DOX saturation for A549 and Calu-1 cells for A. nucleolus and B. nucleus. 
The increase in proteins and lipids features at respectively 447-454 cm-1 (phenylalanine), 
(those two bands can be detected clearly due to the fact that, after saturation, the DOX 
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cellular concentration becomes constant and therefore the peaks of the drug itself are no 
longer evident in the regression), 645-877 cm-1 (C-C tyrosine), 940 cm-1 (C-C stretching 
of protein), 1207 cm-1 (phenylalanine, tryptophan and tyrosine), 1230  cm-1 (Amide III), 
1520-1545 cm-1 (Amide II) , 1605 cm-1 (C=C phenylalanine and tyrosine), 1670 cm-1 
(Amide I) 1410-1450 cm-1 (CH2 deformation) are consistent with an efflux of anti-
apoptotic and repair proteins, as a cellular defense against DOX exposure, and a lipid 
denaturation of the surronding cytoplasmic membrane (Farhane et al., 2015; Verrier et 
al., 2004). 
In addition to depletion of spectral features related to DNA in the nuclear area for both 
cell lines, such as those at 795 cm-1, 1095 cm-1 and 1376 cm-1  (Figure 7.5 B), there is an 
increase in both lipid and protein features, at 645 cm-1 (C-C tyrosine), 715 cm-1(choline), 
760 cm-1 (tryptophan ring breathing), 853-877 cm-1 (tyrosine ring breathing), 1127 cm-1 
(C-N stretching), 1445 cm-1 (CH2 vibrations), 1491 cm
-1 (C-H deformation), 1607 cm-1 
(tyrosine and phenylalanine ring vibration C=C), and 1650 cm-1 (Amide I), again 
consistent with a cellular response to DOX associated with anti-apoptotic protein and a 
synthesis of lipidic vesicules as a way to remove DOX to the extracellular environment.  
For both the nucleolus and nucleus in A549 cells, a notable increase in features at 1047 
cm-1 (RNA P–O stretching, sugar phosphate –C–O–stretching), and 1270 cm-1 (RNA 
Uracil and cytosine ring stretching) is due to nucleolar fragmentation, resulting in RNA 
spread (Chen et al., 2012).  
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B. (i)      (ii) 
 
C. (i)       (ii) 
 
Figure 7.6: A. Evolution of DOX (465 cm-1) and selected RNA (785, 813 and 1270 cm-
1) and DNA (728, 785, 813 and 830 cm-1) Raman bands as a function of time B. Evolution 
of DOX (465 cm-1) and selected protein (645, 1005 and 1250 cm-1) and lipid (1450 cm-1) 
Raman bands as a function of time for the Calu-1 cell line for each nuclear cellular 
compartment, (i) nucleolus and (ii) nucleus. Intensities are expressed in percentage 
according to the maximum value for each nuclear area and standard deviation corresponds 
to the spectra variations for each band. 
The increase in phenylalanine at 1005 cm-1 seems to be a marker of the late apoptosis 
stage, at which point nucleolar fragmentation is complete, leaving an empty space with 
only cellular membrane, while in Calu-1 cells and for both nuclear regions, there is an 
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increase in the 1270 cm-1 band and a decrease in the 1047 and 1005 cm-1 bands, which 
could be explained by the fact that the nucleolar fragmentation is less advanced in Calu-
1 than A549 cells, due to a delay in apoptosis by a higher production of anti-apoptotic 
proteins. In the nucleus of the Calu-1 cell line, there is also an increase in some DNA 
bands at 785 cm-1 and 1577 cm-1, which may be due to an increase DNA repair. 
In order to highlight the increase of cellular compounds, namely DNA, RNA, proteins 
and lipids in Calu-1 cells, the evolution of related spectral features in both nucleolus and 
nucleus, 785 cm-1 and 813 cm-1 (DNA⁄RNA), 728 cm-1 and 830 cm-1 (DNA), 645 cm-1, 
1005 cm-1 and 1250 cm-1 (proteins) and 1450 cm-1 (lipids), as a function of time can be 
plotted (Figure 7.6). The band intensities were determined by ICA after DOX 
substraction. The DOX band was determined, as Figure 7.3, by PCA control vs exposed 
cells. The evolution of similar bands in A549 cells has been demonstrated previously 
(Farhane, Bonnier, and Byrne, 2017). 
A notable decrease in DNA and RNA features is observed (Figure 7.6 A (i) and A (ii)) at 
the early stage, concomitant with DOX nuclear accumulation and binding, due to 
DNA⁄RNA alteration, followed by an increase in the same features starting from ~24 hrs, 
as a cellular response by increasing DNA repair. However, the changes appear to be 
slower in the nucleus and much stronger in the nucleolus, in which a decrease of nucleic 
acids to less than 10 % is observed, after which they increase to almost the same 
proportion ~40 %. The decrease in nucleic acid features appears also to be stronger in 
Calu-1 compared to A549 (Farhane, Bonnier, and Byrne, 2017). After DOX saturation, 
~2 hrs for the nucleolus and ~6 hrs for the nucleus, proteins and lipids start increasing 
(Figure 7.6 B (i) and B (ii)), consistent with the production of anti-apoptitic proteins and 
a synthesis of lipidic vesicules inducing resistance to apoptosis and as a consequence 
resistance to the chemotherapeutic drug.  
260 
 
In both nucleolar and nuclear regions, similar kinetics of cellular compounds were found 
for the two cell lines (Farhane, Bonnier, and Byrne, 2017) at the early stages, resulting in 
a decrease of all cellular features, and after DOX nuclear saturation an increase of protein 
and lipids is observed, while nucleic features keep decreasing for A549, in contrast to 
Calu-1 cells which, at prolonged exposures, show signs of recovery by DNA repair, 
resulting in an increase of nucleic acids features. 
In both PLSR regression co-efficient profiles for the cytoplasmic region, for the two cell 
lines, as shown in Figure 7.7, there are obvious DOX features at 440-465 cm-1 and 1215-
1245 cm-1. An increase in protein and lipid features is also evident, for example at 524-
733 cm-1, corresponding to phosphatidylserine externalization (in healthy cells, 
aminophospholipids are localised in the inner cytoplasmic membrane) due to membrane 
alteration (Kagan et al., 2000; Wlodkowic et al., 2011) as an indicator of apoptosis (Lee 
et al., 2013; Ziegler and Groscurth, 2004), 538 cm-1 (cholesterol ester), related to 
alteration of endoplasmic reticulum membrane as a marker of apoptosis (Farhane, 
Bonnier, and Byrne, 2017), 576-720 cm-1 (phosphatidylinositol and 
phosphatidylcholine) related to membrane trafficking, 645-830-853 cm-1 (tyrosine), 1268 
cm-1 (Amide III), 1364 cm-1 (tryptophan), 1410-1450 cm-1 (CH2 deformation) and 1635-
1660 cm-1 (Amide I of different conformational forms) indicating a protein and lipid 
denaturation due to DOX treatment. 
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Figure 7.7: Regression coefficients obtained by PLSR analysis as a function of time over 
full range of cytoplasmic region  for A549 and Calu-1 cells. 
In addition to the common protein and lipid denaturation indicators between the two cell 
lines, there is a more notable increase in Calu-1 cells of the bands at 917 cm-1 (Ribose 
vibration) (Movasaghi, Rehman, and Rehman, 2007), 940 cm-1 (C-C stretching of 
protein), 1030 cm-1 (C-H phenylalanine), 1047 cm-1 (RNA P–O stretching, sugar 
phosphate –C–O–stretching) and 1085 and 1128 cm-1 (C-N stretching) corresponding to 
higher RNA, protein and lipids structure denaturation by oxidative stress due to ROS 
production, one of the DOX mechanisms of action which has previously been shown to 
be more prominent in Calu-1 than A549 cells (Efeoglu, Casey, and Byrne, 2016; Farhane 
et al., 2017). 
Therefore, according to the Raman profile, for the two cell lines, DOX appears to have 
the same binding signatures as seen in loading 1 of PC1 of PCA of control versus exposed 
cells up to saturation point (Figure 7.4), but Calu-1cells, despite an earlier DOX cellular 
accumulation (Figure 7.3), seem to be more resistant, as indicated by the lower cytotoxic 
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response, due to an efflux of anti-apoptotic protein and an increased DNA repair at the 
later stages. In order to confirm those observations, bcl-2, an anti-apoptotic protein, and 
γH2AX, a marker of DNA damage and repair, were measured in both cell lines and the 
results were correlated to the Raman analysis. 
7.3.3. Apoptosis, Bcl-2 protein and DNA repair: 
Apoptosis is a programmed caspase-mediated cell death characterised by morphological 
cellular changes, including nuclear and cytoplasmic condensation with externalisation of 
phosphatidylserine and formation of apoptotic bodies, with maintenance of intact cellular 
membrane. During the later stages, the nucleus further condenses (pyknosis), which is the 
most characteristic morphological marker of apoptosis (Elmore, 2007; Plesca, Mazumder, 
and Almasan, 2008), and this is followed by nuclear shrinkage (karyorrhexis) and loss of 
cellular shape by cytoskeleton cleavage and membrane blebbing (Fink and Cookson, 
2005; Saraste and Pulkki, 2000). 
Figure 7.8 shows the evolution of Nucred® fluorescence, as an indicator of nuclear 
condensation, as a function of time for the two cell lines. In both cases, there is a slight 
increase in fluorescence in the early stages of drug exposure, and the maximum 
fluorescence is observed at 24 hrs. The maximum is significantly higher for Calu-1 than 
A549, due to a higher level of chromatin condensation induced by DNA damage due to 
DOX-DNA interaction (Rabbani, Finn, and Ausio, 2005), confirming the Raman 
observations (Figure 7.6). 
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Figure 7.8: Mean Fluorescence of Nucred® after DOX exposure measured by Confocal 
Laser Scanning Microscopy and ImageJ for A549 and Calu-1 cells, expressed on 
percentage according to the maximum value for both cell lines. 
Subsequently, the fluorescence decreases more rapidly in A549 than Calu-1, as a 
consequence of a higher apoptotic response in Calu-1, via chromatin condensation, 
(Burgess et al., 2014) confirming the Raman results showing that the two cell lines have 
the same behaviour at early stages but are different in the later stages. Despite the fact 
that DOX saturates the nuclear area earlier in Calu-1 than A549, and exhibits higher DNA 
damage levels, Calu-1 cells appear to be more viable at later stages, which suggest a more 
effective defence mechanism in Calu-1, increasing cell survival (Roos and Kaina, 2006; 
Roos, Thomas, and Kaina, 2016), and as a consequence a higher resistance to DOX. 
This drug resistance could be explained by either a higher expression of anti-apoptotic 
protein or an increase in DNA repair, or both. 
The expression profile of bcl-2 (B cell lymphoma) an anti-apoptotic protein synthesized 
as a direct response to DNA damage (Farhane et al., 2017), as a function of time for the 
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two cell lines is shown in Figure 7.9. A similar profile is observed, with up regulation 
followed by a diminution of the bcl-2 protein level as a function of time. Nevertheless, 
the maximum level of bcl-2 is reached at 12 hrs in the A549 cell line and 48 hrs in Calu-
1, with an obviously consistently higher expression for the later stage over the time range. 
This higher level of bcl-2 protein contributes to cellular resistance to apoptosis inducing 
a chemotherapeutic drug resistance.  
 
Figure 7.9: Bcl-2 anti-apoptotic protein level determined by Flow Cytometry after DOX 
exposure from time point 2 to 72 hrs for A549 and Calu-1 cells, expressed on percentage 
according to the maximum value for both cell lines. 
A specific change in response to DSB is the phosphorylation of H2AX histone, 
representing 2 to 25 % of the total H2A protein, by members of phosphoinositide 3-kinase 
related proteins of DDR, into γH2AX a sensitive indicator of DSB and efficiency of 
subsequent DNA repair (Ohnishi, Mori, and Takahashi, 2009; Podhorecka, 
Skladanowski, and Bozko, 2010; Srivastava et al., 2009), which is facilated by γH2AX 
dephosphorylation by protein phosphatase 2A (Kuo and Yang, 2008; Sharma, Singh, and 
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Almasan, 2012). The phosphorylation of γH2AX is thus an early indicator of DSB 
(Fernandez-Capetillo et al., 2004; Plesca, Mazumder, and Almasan, 2008) and the 
number of γH2AX nuclear foci is directly correlated with the number of DSBs, 
(Takahashi and Ohnishi, 2005) which means the more damage there is, the more nuclear 
foci will be found. Flow Cytometry is a sensitive and rapid technique for the measurement 
of γH2AX phosphorylation at cellular level (Sharma, Singh, and Almasan, 2012). 
As seen in Figure 7.10, showing the γH2AX expression after DOX exposure for each 
time point for the two cell lines, there is a progressive increase of γH2AX until a 
maximum is reached, followed by a later decrease for the two cell lines. However, for 
Calu-1, an obvious higher phosphorylation is observed for early stages explained by a 
higher DNA damage, as observed in the Nucred® (Figure 7.8) and Raman results (Figure 
7.6) and the maximum expression is observed at 12 hrs, while for A549 it is observed at 
24 hrs, consistent with a more rapid uptake of the drug in the nuclear regions of Calu-1. 
After the 12 hrs maximum, the γH2AX levels are seen to decrease more rapidly for the 
Calu-1 cells than observed for the A549. The decrease in γH2AX corresponds to 
dephosphorylation of this histone after DNA repair and this dephosphorylation is 
proportional to DNA repair mechanisms which occur over time to repair the DNA 
damage. In this case, it appears that there is an increased tolerance to DNA damage and 
a higher degree of DNA repair in Calu-1 cells than in A549, confirming the Raman 
observations (Figure 7.5 and 7.6) showing a recovery in DNA features for Calu-1 at the 
later stages inducing a delay and resistance to apoptosis. 
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Figure 7.10: Mean Fluorescence of γH2AX after DOX exposure measured by Flow 
Cytometry for A549 and Calu-1 cells, expressed on percentage according to the 
maximum value for both cell lines. 
Raman micro spectroscopic results elucidate both drug kinetics and mechanism of action, 
giving a fingerprint of chemical binding, nucleic acid intercalation, and signatures of 
cellular resistance associated with tolerance to DNA damage, synthesis of anti-apoptotic 
protein and DNA repair. Multivariate data analysis (PCA, ICA and PLSR) indicates that 
the two cell lines have different rates of uptake, resulting in earlier saturation of both 
nucleolar and nuclear compartments for the Calu-1 cell line, and an earlier appearance of 
DOX in cytoplasm due to nuclear disruption. It has been reported that cellular uptake of 
the weakly-basic drug DOX is dependent on the extracellular pH (Swietach et al., 2012), 
and thus, the lower pH of the DMEM-F12 (pH 7-7.4) compared to that of RPMI (pH 8.2 
± 0.3) may be the cause of a slower uptake of DOX in A549 cells compared to Calu-1. 
However, the degree of accumulation in the nulei and nucleoli is seen to be similar in the 
two cell lines, indicating that there are no intracellular pH dependent differences between 
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the cell lines (Swietach et al., 2012). After passive diffusion through the cellular 
cytoplasmic membrane due to its high lipophilicity, DOX binds directly to proteasomal 
transporters and translocates into the combined nuclear area whereupon it binds to nucleic 
acids and rapidly saturates the nucleolar region (Farhane, Bonnier, and Byrne, 2017). 
Cellular efflux regulators can also impact on the rate of accumulation in the cell nucleus 
(Shen et al., 2007), altought the enhanced DOX cellular uptake observed in Calu-1 
compared to A549 cells should be associated with higher cytotoxicity in Calu-1 cells (Kik 
et al., 2009). The fact that the inverse is observed is a strong indication that the cellular 
resistance has origin in higher tolerance to DNA damage with higher synthesis of anti-
apoptotic proteins. 
Critically, the early signatures of interactin of the drug, associated with the drug 
interaction, are comparable in the two cell lines, indicating that the methodology can be 
developed for label free, prescreening of drug candidates in vitro. 
Regression against time after DOX saturation in the respective nuclear regions shows 
essentially the subsequent cellular responses to DOX exposure, including DNA⁄RNA 
damage leading to apoptosis and the different cellular reactions such as synthesis of 
lipidic vesicules and increase in protein features. Despite the fact that same binding 
signature was found for the two cell lines, Calu-1 cells show higher resistance, correlated 
with notably different dose dependent cytotoxic response profiles, suggesting a higher 
viability, firstly by increased tolerence to DNA damage manifest as a decrease of DNA 
to ~10 % of control compared to 40 % in A549, confirmed by higher nuclear condensation 
according to the Nucred® assay, and larger amount of γH2AX at early exposure points 
and secondly, higher expression of anti-apoptotic proteins, principaly bcl-2 one and 
higher DNA repair, confirmed by H2AX dephosphorylation at later stages.  
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7.4. Conclusion:  
Raman micro-spectroscopy has already demonstrated its potential to track in vitro the 
kinetics and accumulation of the chemotherapeutic drug DOX at a subcellular level and 
to identify its different mechanism of action (Farhane, Bonnier, and Byrne, 2017; Farhane 
et al., 2015; Farhane et al., 2017). The present study not only confirms its ability to 
monitor drug cellular kinetics and mechanism of action but also to differentiate between 
cellular reactions and resistance. In fact, the two lung cell lines exhibit different 
behaviours with higher nuclear condensation, measured by Nucred®, and a higher 
resistance of Calu-1, despite the similar drug chemical binding, with a higher tolerance to 
DNA damage and implications of DNA repair mechanism confirmed by expression of 
γH2AX protein, and resistance to apoptosis by bcl-2 protein expression. 
Thus, Raman micro-spectroscopy is able not only to track the subcellular accumulation 
of the drug as function of time but also to identify its mechanism of action, the subsequent 
cellular response and to differentiate cellular resistance. Therefore, it can be used as an in 
vitro, pre-clinical screening technique for drug mechanism of action and efficacy in order 
to aid preclinical drug development. Furthermore, the ability of Raman micro-
spectroscopy to monitor subcellular processes associated with drug resistances suggests 
its potential as an in vitro companion diagnostics technique to screen for personalised 
therapies. 
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7.7. Supplementary Information: 
A. 
 
B. 
 
Figure S.7.1: Raman spectra of Calu-1 cells exposed for 24 hrs at corresponding DOX 
IC50 concentration of 0.9 µM A. original data and B. pre-processed of nucleolus (black), 
nucleus (red) and cytoplasm (blue). 
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A. 
 
B. 
 
Figure S.7.2: PCA of nucleolar, nuclear and cytoplasmic regions of A. Calu-1 control 
versus 24 hrs exposed with corresponding loadings of PC1 and PC2 B. Pairwise PCA of 
Calu-1 control versus 24 hrs exposed for each subcellular region and the corresponding 
loadings of PC1 and PC2. 
 Nucleolus    Nucleus     Cytoplasm     Calu-1 control 
 Nucleolus    Nucleus     Cytoplasm     Calu-1 24 hrs exposed 
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Chapter 8: An in vitro study of the interaction of the 
chemotherapeutic drug Actinomycin D with lung cancer cell 
lines using Raman micro-spectroscopy 
  
The following chapter reproduces the journal article, Z. Farhane, F. Bonnier and H.J. 
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numbers have been adapted to the prescribed thesis format. 
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Graphical Abstract: 
 
A. Pre-processed Raman spectrum of ACT stock solution dissolved in sterile water and 
mean spectrum with standard deviation of B. Nucleolus, C. Nucleus and D. Cytoplasm 
of A549 cell lines after 48hrs exposure to the corresponding IC50. 
280 
 
An in vitro study of the interaction of the chemotherapeutic drug 
Actinomycin D with lung cancer cell lines using Raman micro-
spectroscopy. 
Z.Farhane1, 2*, F.Bonnier3 and H.J.Byrne1 
1FOCAS Research Institute, Dublin Institute of Technology, Kevin Street, Dublin 8, 
Ireland. 
2School of Physics, Dublin Institute of Technology, Kevin Street, Dublin 8, Ireland 
3Université François-Rabelais de Tours, Faculty of Pharmacy, EA 6295 
Nanomédicaments et Nanosondes, 31 avenue Monge, 37200 Tours, France 
*Corresponding author: zeineb.farhane@mydit.ie 
 
 
Abstract: 
 
The applications of Raman micro-spectroscopy have been extended in recent years into 
the field of clinical medicine, and specifically in cancer research, as a non-invasive 
diagnostic method in vivo and ex vivo, and the field of pharmaceutical development as a 
label free predictive technique for new drug mechanisms of action in vitro. To further 
illustrate its potential for such applications, it is important to establish its capability to 
fingerprint drug mechanisms of action and different cellular reactions. 
In this study, cytotoxicity assays were employed to establish the toxicity profiles for 48 
and 72 hrs exposure of lung cancer cell lines, A549 and Calu-1, after exposure to 
Actinomycin D (ACT) and Raman micro-spectroscopy was used to track its mechanism 
of action at subcellular level and subsequent cellular responses. Multivariate data analysis 
was used to elucidate the spectroscopic signatures associated with ACT chemical binding 
and cellular resistances. Results show that the ACT uptake and mechanism of action are 
similar in the two cell lines, while A549 cells exhibits spectral signatures of resistance to 
281 
 
apoptosis related to its higher chemoresistance to the anticancer drug ACT. The 
observations are discussed in comparison to previous studies of the similar anthracyclic 
chemotherapeutic agent Doxorubicin. 
 
Keywords: Raman micro-spectroscopy, Actinomycin D, A549, Calu-1, binding 
signature 
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8.1. Introduction: 
Raman micro-spectroscopy is a non-invasive analytical tool, whose potential in clinical 
applications to distinguish between normal and cancer cells and monitoring drug 
mechanisms of action has already been demonstrated (Byrne, 2014; Byrne et al., 2013; 
Farhane, Bonnier, Casey, and Byrne, 2015; Farhane, Bonnier, Casey, Maguire, et al., 
2015; Jamieson and Byrne, 2016). Therefore, it can potentially be used in pre-clinical 
development for the prediction of chemotherapeutic efficacy and potentially ultimately 
as a companion diagnostic tool. In order to assure its application as a predictive tool, 
Raman spectroscopy should provide information about drug mechanisms of action and 
cellular reactions or resistance. Previous studies were made using Raman micro 
spectroscopy and chemotherapeutic drugs such as Cisplatin (Nawaz et al., 2011), 
Vincristine (Nawaz et al., 2013), Erlotinib (Yosef et al., 2015), Panitumumab (El-
Mashtoly et al., 2015) and Doxorubicin (DOX) (Farhane, Bonnier, and Byrne, 2017) 
showing the potential of this vibrational technique to track drug mechanisms of action 
and cellular effects.  
The present study further extends the Raman investigations to analyse the interaction of 
Actinomycin D, an anticancer drug used in clinics, and to confirm the commonality of 
the chemical binding signature across the anthracycline chemotherapeutic group. 
Actinomycin D (ACT) is a polypeptide antibiotic chemotherapeutic drug, isolated from 
Streptomyces, developed in the 1950s and clinically approved 10 years later (Cibi and 
Jayakumaran Nair, 2016; Liu et al., 2016). It blocks both DNA and RNA expression, and 
as a consequence protein synthesis, by inhibition of RNA polymerase and transcription 
in nucleoli and therefore induces cellular p53-independant apoptosis (Cassé et al., 1999; 
Hasanzadeh and Shadjou, 2016; Kleeff et al., 2000; Nazari et al., 2012; Schwartz et al., 
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1965; Yung, Bor, and Chan, 1990). It intercalates preferentially between guanine and 
cytosine base pairs in DNA via the phenoxazone ring and forms strong hydrogen bonds 
in the minor groove between the two pentapeptide side chains and the guanine 2 amino 
groups, blocking the subsequent chain elongation (Chinsky and Turpin, 1978; Enache and 
Volanschi, 2008; Hasanzadeh and Shadjou, 2016). ACT is also able to bind externally to 
DNA, to the terminal GC base pairs, and to interact with double and single stranded DNA 
and some DNA sequences containing no GC binding site (Lohani, Singh, and Moganty, 
2016; Lu et al., 2015; Sha and Chen, 2000; Takahashi and Ohnishi, 2005). This antitumor 
drug is used clinically for the treatment of highly aggressive malignancies (Lohani, Singh, 
and Moganty, 2016) such as pancreatic (Kleeff et al., 2000), Wilm’s tumour, testicular 
and trophoblastic cancer (Bensaude, 2011; Lu et al., 2015) and in combination with other 
chemotherapeutic drugs for the treatment of high risk cancers (Sha and Chen, 2000). 
Using ACT and two histological subtype lung cancer cell lines, A549 and Calu-1, Raman 
spectroscopic investigations were supported by cytotoxicity assays, and multivariate data 
analysis, consisting of Principal Component Analysis (PCA) and Independent 
Component Analysis (ICA), was used to extract biological information contained in the 
Raman spectra. Results confirm the potential of Raman micro-spectroscopy as an in vitro 
analytical tool for biological analyses and in the prediction of drug mechanisms of action 
and cellular reactions.  
8.2. Materials and methods:  
8.2.1. Materials: 
A549 human lung adenocarcinoma cells with the alveolar type II phenotype were 
obtained from ATCC (Manassas, VA, USA) and the Calu-1 human lung epidermoid 
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carcinoma cell line was kindly provided by Dr. Josep Sulé-Suso, Institute for Science & 
Technology in Medicine, Keele University, Guy Hilton Research Centre UK and Cancer 
Centre, Royal Stoke University Hospital, University Hospitals of North Midlands, UK.  
An Actinomycin D stock solution of concentration 398 µM was prepared by dilution of 
Actinomycin D® powder (Sigma Life Sciences, Ireland) in 4mL sterile water. 
Alamar blue (AB) (10X ready to use solution) and 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl tetrazolium bromide (MTT) were obtained from Sigma Aldrich, Ireland.  
For cytotoxicity assays, an AB/MTT solution, 1.5 mL of AB and 3 mL of MTT stock 
solution (2.5 mg/mL, 25 mg MTT/10 mL PBS) in 30 mL of fresh medium was prepared 
prior to performing the assays. 
8.2.2. Cell culture: 
A549 cells were cultured in DMEM-F12 (Dulbecco's Modified Eagle's Medium/Nutrient 
Mixture F-12) with 10 % FBS (foetal bovine serum)and Calu-1 cells in RPMI (Roswell 
Park Memorial Institute Medium)with 10 % FBS, both at 37 °C, in a humidified 
atmosphere containing 5 % CO2, and cells were split every two days to maintain ~60% 
confluency. 
For cytotoxicity assays and Raman micro spectroscopic analysis, the cell number was 
determined using a Beckman Coulter Particle Count and Size Analysis® Z2 Cell Counter. 
8.2.3. Cytotoxicity assays: 
AB and MTT assays were performed in 96 well plates and a total number of 1x105 cells 
(4x103 cells/mL), 1 x 104 (4x102 cells/mL) and 5x103 cells (2x102 cells/mL), respectively 
were used for 24, 48 and 72 hrs, with three replicate plates of each. After 24 hrs 
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incubation, plates were washed with phosphate buffered saline solution (PBS) and ACT 
was added in a concentration range from 0 µM (as a control) to 50 µM for 24 hrs and 
from 0 to 0.5 µM for 48 and 72 hrs. 
AB and MTT assays were both measured with a Cytotox SpectraMax®M3 plate reader 
using Soft Max® Pro6.2.2 software. After 24, 48 and 72 hrs incubation in ACT, plates 
were washed with PBS and 100µL of AB/MTT solution were added to each well. Plates 
were then incubated for 3 hours and AB fluorescence was measured first in the plate 
reader, using 540 nm excitation and 595 nm emission, whereupon the medium was 
removed, the plates were washed with PBS and 100 µL of DMSO (Dimethyl sulfoxide) 
were added in each well. MTT absorbance was then read at 570 nm.  
All cytotoxicity assays were made in triplicate and repeated three times and viability data 
was fitted by a four parameter Hill equation analysis using SigmaPlot 10.0, to yield values 
of the mean inhibitory concentration, IC50. 
8.2.4. Raman micro-spectroscopy: 
Cells (~ 1x 104/window) were seeded and incubated on CaF2 windows (Crystan Ltd, UK) 
for 24 hrs for both control and exposure to ACT. The medium was then removed and 
samples were rinsed twice with sterile PBS and covered with ACT at each corresponding 
IC50 for exposed cells and fresh medium for unexposed controls. After each incubation 
period, 48 and 72 hrs, exposed and unexposed control cells were washed twice with sterile 
PBS and fixed in formalin (4 %, 15 min). 
A Horiba Jobin-YvonLabRAM HR800 spectrometer with a 785 nm, 300 mW diode laser 
as source, Peltier cooled 16-bit CCD, 300 lines/mm grating and 100 μm confocal hole, 
was used for this work. Spectra were acquired in the range from 400 cm-1 to 1800 cm-1 
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using a x100 objective (LCPlanN, Olympus), in dry conditions, for 30 s two times, from 
three cell locations: cytoplasm, nucleus and nucleolus, identifiable under white light 
illumination. The final data set of a total of 720 spectra was thus derived from 30 cells, 
each measured in the nucleolus, nucleus and cytoplasm, for each exposure time (2) and 
control (2), for each cell line (2). 
8.2.5. Data analysis:  
Raman spectral pre-processing and analysis were performed in Matlab 2013 using 
algorithms developed in house. Prior to analysis, background was subtracted using a 
NCLS (non-negatively constrained least squares) algorithm and spectra were smoothed 
(Savitsky-Golay filter 3th order, 11 points), baseline corrected (fifth order polynomial) 
and vector normalised. 
PCA allows the reduction of the number of variables in a multidimensional dataset, 
although it retains most of the variation within the dataset. It represents the spectra in data 
groupings of similar variability, allowing the identification and differentiation of different 
spectral groups. The loadings of the PCs represent the variance for each variable 
(wavenumber) for a given PC, and analysis of the loadings can give information about 
the source of the variability inside a dataset, derived from variations in the molecular 
components contributing to the spectra. It has been demonstrated that the PC loadings can 
be most simply understood when analysis of datasets is undertaken in a pairwise fashion. 
Although PCA does not cluster the data, per se, in the same manner as for example 
Hierarchical or K-Means Cluster Analysis, whereby differential distribution of the data 
according to negative or positive loadings associates specific spectral features with that 
dataset. PCA was employed as an unsupervised multivariate approach to analyse data and 
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the effects of ACT in each cell localisation by identification and differentiation of 
different spectral groups using scatter plots and loadings showing a representation of 
spectral features responsible for the variance between data groups according to 
wavenumbers. The order of the PCs denotes their importance to the dataset and PC1 
describes the highest amount of variation (Bonnier and Byrne, 2012; Brauchle and 
Schenke-Layland, 2013; Pavićević et al., 2012). 
ICA was also employed as an extension to PCA. ICA is an unsupervised statistical 
technique able to identify latent variables called independent components in each data set 
separately. In the case of Raman micro-spectroscopy, ICA can be used to identify spectral 
contributions such as those from substrate, which can then be removed or studied in their 
own, using the same number of ICs (three components) as PCs, as estimated by PCA, 
explaining the majority of variance, and only the first component for each cellular 
compartment was plotted (Farhane, Bonnier, and Byrne, 2017; Hyvärinen and Oja, 2000; 
Lee, 1998).  
8.3. Results and discussion: 
8.3.1. Cytotoxicity assay: 
After 24 hrs exposure, more than 60 % of cells remain viable according to both the AB 
and MTT assays at the maximum dose of 50µM for both cell lines (data not shown), 
which is consistent with literature reporting late onset of ACT effects (Kleeff et al., 2000).  
Therefore, for the rest of the experiments, only 48 and 72 hrs exposure times where 
analysed in this study. 
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A1.                                                                     A2. 
     
B1.                                                                       B2. 
      
 
Figure 8.1: AB and MTT in vitro dose dependent cytotoxicity assays of ACT of A549 
cell line A1. 48 hrs exposure and A2. 72 hrs exposure and Calu-1 cell line B1. 48 hrs 
exposure and B2. 72 hrs exposure.  
Figure 8.1 shows the dose dependant responses of the cytotoxicity assays, AB and MTT, 
for 48 and 72 hrs to ACT exposure, for both cell lines, A549 and Calu-1. Viability is 
expressed as % compared to control (non-exposed healthy cells), and the error bars 
indicate the standard deviation of six independent replicate measurements. 
For both in vitro assays and for all exposure times, a partial loss of cell population 
viability is observed for the two cell lines. 
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The IC50 values measured by the AB and MTT assays were found to be almost the same 
for A549 cells, at the respective time points, while for Calu-1, the AB assay is 
significantly less sensitive than MTT (Table 8.1). 
Table 8.1: IC50 concentration determined by the AB and MTT assays for the two cell 
lines A549 and Calu-1 after 48 and 72 hrs exposure to ACT.  
 Cell line A549 Calu-1 
IC
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4
8
 h
rs
 AB 
MTT 
0.0095±0.0023 
0.01±0.001 
0.0189± 0.0005 
0.0065± 0.0003 
7
2
 h
rs
 AB 
MTT 
0.0035±0.0002 
0.0031±0.0002 
0.0068±0.0013 
0.002±0.0001 
ACT affects mitochondrial transcription (Bayona-Bafaluy, Manfredi, and Moraes, 2003; 
Chrzanowska-Lightowlers, Preiss, and Lightowlers, 1994), inducing disruption of 
mitochondrial activity (Suen, Norris, and Youle, 2008) and, as the MTT assay is a 
reflection of mitochondrial activity within the cell, its earlier response and higher 
sensitivity compared to the AB assay, which measures the global cell metabolism, is 
understandable (Farhane, Bonnier, Casey, and Byrne, 2015). For reproducibility and 
comparatively purposes, the IC50 determined by MTT was used for the Raman analysis. 
8.3.2. Raman micro-spectroscopy: 
As seen in Figure 8.2, the ACT spectrum shows characteristic features at 465 and 1215 
cm-1, corresponding to C–O vibration and 1445 cm-1, related to skeletal vibration. 
However, for the case of A549 cells after exposure to the IC50 concentration for 48 hrs, 
no specific Raman features of the ACT spectrum are identifiable in the cellular spectra 
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and for this reason it is impossible to track ACT itself inside the cells. Nevertheless, the 
evolution of the spectroscopic signature of binding and subsequent cellular responses can 
be tracked.  
A.                                                                B. 
   
C.                                                                  D. 
 
Figure 8.2: A. Pre-processed Raman spectrum of ACT stock solution dissolved in sterile 
water and mean spectrum with standard deviation of B. Nucleolus, C. Nucleus and D. 
Cytoplasm of A549 cell lines control and after 48 hrs exposure to the corresponding IC50. 
Compared to the mean spectra of non exposed control cancer cells of each cell line, 
(specific discriminating features are highlighted in Figure 8.2), in the spectra of exposed 
cells, there is a decrease of the spectral features at 669 cm−1 (thymine and guanine), 785 
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cm−1 (cytosine and thymine, DNA backbone O–P–O Stretching), 1047 cm−1 (RNA P–O 
stretch, sugar phosphate –C–O–stretching), 1095 cm-1 (DNA PO2− symmetric 
stretching), 1300 cm-1 (RNA cytosine and adenine ring stretching) and 1340-1577 cm-1 
bands (adenine and guanine) for both nucleolar and nuclear spectra, due to ACT binding 
to nucleic acids, and a decrease in the features at 760 cm-1 (tryptophan ring breathing) 
and 1005 cm-1 (phenylalanine), corresponding to protein denaturation.  
The decrease in both bands at 785 and 813 cm−1, corresponding respectively to DNA 
backbone O–P–O and RNA O–P–O phosphodiester band stretching, is consistent with 
the main mechanism of action of ACT, by DNA intercalation, interfering with RNA 
polymerase, inducing DNA and RNA expression blockage. A similar decrease in those 
bands was found for Calu-1 cells (Figure S.8.1) and reported previously after DOX 
exposure and can therefore be considered a Raman signature of DNA intercalation 
(Farhane, Bonnier, and Byrne, 2017). 
In order to analyse in more details the changes in the spectral features after exposure to 
ACT, multivariate data analysis, consisting of PCA, was employed. As seen in Figure 
8.3, showing PCA of nucleolar, nuclear and cytoplasmic regions, for A549 control cells 
and after 48 hrs exposure to ACT, there is a differential distribution of the combined 
nuclear and the cytoplasmic areas, for both cell lines, predominatly according to positive 
and negative weightings of PC1. The corresponding loading of PC1, differentiating the 
combined nuclear and the cytoplasmic areas, is dominated on the positive side by features 
related to proteins, for example at 1005 cm-1, and lipids, for example at 1303 cm-1 (C-H 
vibration) and 1450 cm-1 (CH2 deformation) and on the negative side, corresponding to 
the combined nuclear region, by DNA and RNA features at 785 and 1577 cm-1. There is 
a slight separation between control and exposed cells according to PC2 and loading 2 is 
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dominated by negative features at 785, 1005, 1450 and 1660 cm-1, related respectively to 
nucleic acids, proteins and lipids corresponding to control cells which indicate a decrease 
in all cellular features as a consequence of  exposure to ACT. 
When a pairwise PCA of the three cellular regions was performed independently (Figure 
8.3 B), it is notable that a separation is apparent in the data of the nucleolar area, 
confirming again the important role of this sub-nuclear region and the interaction of ACT 
by inhibition of nucleoli transcription which is related to its extreme toxicity (Farhane, 
Bonnier, Casey, and Byrne, 2015; Farhane, Bonnier, Casey, Maguire, et al., 2015; Sobell, 
1985; Yung, Bor, and Chan, 1990). Only a slight separation is evident for the nuclear 
region, showing that ACT also effects the nucleus, although less so than the nucleolus. 
Notably, no separation of the cytoplasmic regions is observable. 
After 72 hrs exposure and according to PCA analysis (Figure 8.4 A), an obvious 
separation between the combined nuclear and cytoplasmic regions is observed, according 
to PC2. A slight separation between control and exposed cells according to PC1 is also 
evident, and the loading of PC1 is dominated by negative nucleic acid and protein 
features, highlighting once again the ACT mechanism of action by DNA intercalation 
inhibiting RNA polymerase and subsequent cellular responses including reduced RNA 
transcription and protein synthesis. 
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A. 
 
B. 
 
Figure 8.3: PCA of nucleolar, nuclear and cytoplasmic regions of A. A549 non exposed 
control and after 48 hrs exposure to ACT with corresponding loadings of PC1 and PC2 
B. PCA of each cell localisation for control and exposed and the corresponding loadings 
of PC1 and PC2. 
Cytoplasm    Nucleus     Nucleolus    A549 control 
Cytoplasm    Nucleus     Nucleolus    A549 48 hrs exposure to ACT 
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A pairwise PCA of each cellular compartment (Figure 8.4 B) reveals, as seen for pairwise 
PCA 48 hrs, a separation according to the nucleolar area with negative features at 669 
cm-1 (thymine and guanine), 728 cm-1 (adenine), 785 cm-1 (cytosine and thymine, DNA 
backbone O–P–O Stretching), 813 cm-1 (RNA O–P–O phosphodiester) and 1340, 1486, 
1577 cm-1 (adenine and guanine), related to the ACT mechanism of action by intercalation 
between guanine and cytosine. Negative features at 1005 cm-1 (phenylalanine) and 1670 
cm-1 (Amide I) related to protein are also observed, as well as 1320, 1450 cm-1 (CH2 
deformation) related to lipids, both due to the depletion of cellular components as a result 
of ACT exposure. However, a better separation of the spectra of the nuclear compartment 
than observed for 48 hrs is evident after 72 hrs exposure, explained by 82.5 % of variance 
of loading of PC1, which is dominated by DNA features at 728, 785, 1095 and 1577 cm-
1 and proteins and lipids one respectively at 625, 645, 1005 and 1450 cm-1. 
According to PCA of the data for 48 and 72 hrs exposure, it appears that ACT interacts 
first with the nucleolus and subsequently with the nucleus. Notably, the same 
observations were made previously for DOX uptake, suggesting that the anthracycline 
chemotherapeutic group may be targeting the nucleolus first and nucleus second 
(Farhane, Bonnier, and Byrne, 2017). 
For both 48 and 72 hrs exposure to ACT and for the two cell lines (Figure 8.3 and 8.4 for 
A549 and Figure S.8.2 and S.8.3 for Calu-1 cells) for the cytoplasmic region, there is no 
obvious separation between control and exposed cells and similar loadings are observed 
with negatives features related to control cells at 1450 and 1660 cm-1 indicating a partial 
or initial denaturation of cytoplasmic constituents as a consequence of the arrest of 
transcription due to ACT treatment. 
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In order to analyse in more detail the ACT mechanisms of action, ICA for A549 cell line 
was made for 24 hrs exposure to a high ACT dose (0.3 µM) (Choong et al., 2009; Kleeff 
et al., 2000), 48 hrs and 72 hrs and was compared to control cells. 
As seen in Figure 8.5, the ICs are similar for control and 24 hrs exposure, confirming the 
absence of any ACT effects at 24 hrs. Starting from 48 hrs, ICA identifies in the nucleolus 
a decrease in DNA features at 728 cm-1 (adenine), 752 cm-1 (DNA), 785 cm-1 (DNA 
backbone O–P–O), 1095 cm-1 (DNA PO2− symmetric stretching), 1376 cm-1 (thymine) 
and 1486, 1577 cm-1 (adenine, guanine), confirming the ACT mechanism of action by 
DNA intercalation with a decrease in RNA features at 1270 cm-1 (RNA uracil and 
cytosine ring stretching) and 1300 cm-1 (RNA cytosine and adenine ring stretching), 
consistent with inhibition of RNA transcription (Kleeff et al., 2000). 
Besides nucleic acids depletion, a notable increase in protein features at 625 cm-1 (C-C 
protein) and 645, 855 cm-1 (tyrosine) (Farhane, Bonnier, and Byrne, 2017; Movasaghi, 
Rehman, and Rehman, 2007) indicates a possible synthesis of anti-apoptotic proteins as 
a cellular reaction against ACT, while the decrease at 1660 cm-1 (Amide I) and the 
increase at 1280 cm-1 (Amide III) may be related to protein denaturation of the 
surrounding membrane. 
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A. 
 
B. 
 
Figure 8.4: PCA of nucleolar, nuclear and cytoplasmic regions of A. A549 non exposed 
control and after 72 hrs exposure to ACT with corresponding loadings of PC1 and PC2 
B. PCA of each cell localisation for control and exposed and the corresponding loadings 
of PC1 and PC2. 
Cytoplasm    Nucleus     Nucleolus     A549 control 
Cytoplasm    Nucleus     Nucleolus    A549 72 hrs exposure to ACT 
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In the nucleus, a decrease in DNA features at, for example, 785, 1095 and 1577 cm-1 is 
also observed. An increase in features at 700 cm-1 (C–C–N+ symmetric stretching in 
phosphatidylcholine), 715 cm-1 (choline), 877 cm-1 (tyrosine ring breathing) and 1450 cm-
1 (lipids CH2 deformation) is consistent with the synthesis of anti-apoptotic proteins and 
lipidic vesicules as a way to remove ACT to the extracellular environment. A more 
pronounced increase at 72 hrs in RNA features at 847 (ribose phosphate), 1270 and 1300 
cm-1 is consistent with nucleolar fragmentation and spread of  RNA characteristic of cells 
going under apoptosis (Boulon et al., 2010; Farhane, Bonnier, and Byrne, 2017; Kasim et 
al., 2013; Kleeff et al., 2000; Lu et al., 2015; Nazari et al., 2012). 
In the cytoplasm, similar ICs were found for control and exposed A549 cells to ACT, 
whereby at 72 hrs, a slight decrease at 700, 848 (tyrosine) and 873 cm-1 (tryptophan) and 
an increase at 1355, 1365 cm-1 (tryptophan) and 1440, 1460 cm-1 (CH2 deformation) are 
observed, indicating an onset of denaturation of lipids and proteins. 
According to PCA analysis, the two cell lines appear to react similarly to ACT exposure 
and in order to explore any differences in cellular response, ICA was employed. After 48 
hrs, IC components for the two cell lines are similar, confirming again that ACT affects 
both cells subtypes in similar ways (data not shown), resulting in decreases in features at, 
for example, 728, 785 and 1577 cm-1, as found in the PCA results. The IC exhibits also 
prominent peaks at 1430-1456 cm-1, related to guanine and cytosine, corresponding to a 
hyperchromic effect of ACT intercalation on the response of the bases (Farhane, Bonnier, 
and Byrne, 2017).  
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C. 
 
Figure 8.5: ICA components of control cells and after 24, 48 and 72 hrs exposure to ACT 
for A549 cell line of A. Nucleolus B. Nucleus C. Cytoplasm. 
Moreover, after 72 hrs exposure, in the ICs for both nucleolus and nucleus regions for 
both cell lines (Figure 8.6), there are negatives peaks corresponding to a decrease in 
nucleic acid features at 728, 785, 1095, 1376, 1486 and 1577 cm-1. Positive features are 
related to proteins,1005, 1030 cm-1 (phenylalanine), 1151 cm-1 (protein) and 1660 cm-1 
(Amide I) and to lipids at 700, 715, 1127 cm-1 (lipids), 1410, 1450 cm-1 (lipids CH2 
deformation), which may be associated with an efflux of anti-apoptotic protein and a 
synthesis of lipidic vesicules as cellular defence reactions to ACT exposure.   
However, in the IC of the nucleolus of A549 cells (Figure 8.6 A), there are also positive 
features showing a greater increase in proteins at 645, 855 cm-1 (tyrosine), 1207 cm-1 
(phenylalanine, tryptophan and tyrosine) and 1230 cm-1 (Amide III) than in Calu-1 cells, 
which may correspond to a more active synthesis of anti-apoptotic proteins in the former. 
300 
 
In the ICs identified in the nucleus (Figure 8.6 B), a notable increase in proteins for both 
cell lines is evident; positive features at 877 cm-1 (tyrosine), 1176 cm-1 (tyrosine and 
phenylalanine) for A549 and at 936, 951, 973 cm-1 (protein) for Calu-1, while A549 
exhibits signatures of apoptosis corresponding to strong positive peaks at 549 cm-1 
(cholesterol) due to alteration of the endoplasmic membrane, a marker of apoptosis, and 
at 847 cm-1 (ribose phosphate) which may be due to the spread of RNA into the nucleus 
as a result of nucleolar fragmentation. 
In the IC of cytoplasm for both cell lines there is a decrease at 785 cm-1 and an increase 
at 700-715, 1128 cm-1 (C–N stretch), 1268 (Amide II), 1303 and 1660 cm-1, indicating a 
decrease in cytoplasmic RNA related to the ACT mechanism of action which inhibits all 
RNA species, and synthesis of lipidic vesicles. 
A. 
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B. 
 
C. 
 
Figure 8.6: ICA components after 72 hrs exposure to ACT for A549 and Calu-1 cell lines 
of A. Nucleolus B. Nucleus C. Cytoplasm. 
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For Calu-1 cells, negative features related to proteins at 830 cm-1 (tyrosine), 873 cm-1 
(tryptophan), 940 cm-1 (C–C stretching of protein) and 1005 cm-1 (phenylalanine) 
corresponds to a decrease in protein contributions, indicating more advanced ACT effects 
in Calu-1 associated with their higher chemosensitivity compared to A549. 
8.4. Discussion:  
Raman micro spectroscopic results elucidate both the ACT mechanism of action at a 
subcellular level and different subsequent cellular reactions. In fact, the results identify a 
spectral signature of ACT interaction with nucleic acids in both the nucleolus and nucleus 
of the cell, consisting of a simultaneous decrease in the Raman features at 785 and 813 
cm−1. Notably, the same spectroscopic response was found in previous studies of the 
action of DOX in the same cell lines, and therefore the spectroscopic signature can be 
considered as a fingerprint of the mechanism of action by intercalation. ACT and DOX 
have similar chemical structures, in terms of the core anthracyclic rings, and the 
identification of such common spectroscopic signatures associated with a mode of action 
of these chemotherapeutic agents can potentially be exploited for preclinical screening of 
the mode of action of new candidate chemotherapeutic agents. 
Despite the fact that a similar spectral signature of chemical interaction was found 
compared to DOX for the two cell lines, the difference in cellular response times between 
the two anthracyclines is notable. Whereas DOX elicited marked responses in the 
spectroscopic signatures of the nucleoli of A549 and Calu-1cells within 6/12 hrs, 
respectively, the response to ACT exposure is considerably slower. This huge difference 
in the response time may be due to the different side chains which can affect the drug 
uptake and/or intracellular transport rates. Nevertheless, the IC50 is much lower for ACT, 
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in the range of nM as compared to M for DOX, as observed according to cytotoxicity 
assays, indicating that it has a higher efficacy once accumulated inside the cell. Although 
similar Raman activities of stock solutions of ACT and DOX are observed, as seen in 
Figure 8.7, the substantially lower IC50 dose of ACT employed (nM) compared to DOX 
(µM) means it is not visible inside the cell using Raman spectroscopy. However, the 
Raman results show that, even if DOX accumulates much faster than ACT in the 
combined nuclear area, the same uptake path is observed for both chemotherapeutic drugs 
with accumulation first in the nucleolus before the nucleus, and thus Raman can shed 
further light on understanding the mechanisms of action of known drugs. 
 
Figure 8.7: Pre-processed Raman mean spectra of stock solutions dissolved in sterile 
water of ACT (398 µM-green) and DOX (17.25 mM-blue).  
ACT affects the two cell lines in similar ways, as demonstrated by multivariate statistical 
analysis (PCA and ICA), with similar rates of uptake. However, the interaction of the 
drug in the nucleolus/nucleus elicits different cellular reactions in the two cell lines, Calu-
1 cells exhibiting higher sensitivity compared to A549. The difference in subsequent 
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cellular metabolic responses, as seen in the protein profile, with an increase in some 
protein features corresponding probably to a synthesis of anti-apoptotic proteins, is due 
to a differential drug retention rather than drug uptake, as the two cell lines have similar 
uptake rate, and those observations are consistent with previous findings showing that 
ACT retention is an important determining factor in cell sensitivity and is specific to the 
cells themselves (Roots and Smith, 1976; Schwartz, Sodergren, and Ambaye, 1968). 
Therefore, Raman micro-spectroscopy can be considered as a potential companion 
diagnostic tool providing information about drug mechanism of action, subcellular 
kinetics and differences in cellular reactions and resistance. 
8.5. Conclusion: 
Although not identifiable within the biochemical milieu of the cell, the effects of the 
subcellular uptake and interactions of the DNA targeting chemotherapeutic agent ACT 
can clearly be monitored using Raman micro-spectroscopy. As previously demonstrated 
for the similar anthracyline, DOX, the accumulation and biochemical interactions occur 
initially in the nucleolar, and then nuclear regions of the cell. The timescales of 
interactions are, however, substantially slower for ACT compared to DOX, perhaps due 
to the more complex nature of the polypeptide side chains. Nevertheless, the 
spectroscopic signature of the early stage interactions in the subcellular regions 
demonstrate a consistency for the two compounds, and can be considered as a 
spectroscopic signature of intercalation, This is may be the first step in the elaboration of 
a library of signatures of all chemotherapeutic groups, paving the way for Raman micro-
spectroscopy to be developed as an analytical tool for preclinical development in order to 
identify mechanism of action of new chemotherapeutic drugs. 
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According to cytotoxicity assays, the two cell lines exhibit different chemosensitivity to 
ACT as represented by the different IC50. The difference in chemosensitivity was 
confirmed by Raman investigations using multivariate data analysis which shows a higher 
increase in protein features in A549 cells and higher viability despite the fact that the two 
cell subtypes present similar ACT uptake rates. The difference in responses points 
towards the potential of Raman micro-spectroscopy to elucidate mechanisms of cellular 
resistance and ultimately to be used as a predictive tool for patient responses, or 
companion diagnostic. 
8.6. Acknowledgement: 
This work was supported by Science Foundation Ireland Principle Investigator Award 
11/PI/1108. 
 
 
 
 
 
 
 
 
 
306 
 
8.7. References: 
Bayona-Bafaluy, M P, Manfredi, G and Moraes, C T (2003) A Chemical Enucleation 
Method for the Transfer of Mitochondrial Dna to Ρ° Cells. Nucleic Acids Res., 
31(16), e98-e. 
Bensaude, O (2011) Inhibiting Eukaryotic Transcription: Which Compound to Choose? 
How to Evaluate Its Activity? Transcription, 2(3), 103-8. 
Bonnier, F and Byrne, H J (2012) Understanding the Molecular Information Contained 
in Principal Component Analysis of Vibrational Spectra of Biological Systems. 
Analyst, 137(2), 322-32. 
Boulon, S, Westman, B J, Hutten, S, Boisvert, F M and Lamond, A I (2010) The 
Nucleolus under Stress. Mol Cell., 40(2), 216-27. 
Brauchle, E and Schenke-Layland, K (2013) Raman Spectroscopy in Biomedicine Â€“ 
Non-Invasive in Vitro Analysis of Cells and Extracellular Matrix Components in 
Tissues. Biotechnol J., 8(3), 288-97. 
Byrne, H J. (2014). Biomedical Applications of Vibrational Spectroscopy Disease 
Diagnostics and Beyond, Biomed Opt. (pp. BS4B.1). Miami, Florida: Optical 
Society of America. 
Byrne, H J, Ostrowska, K M, Nawaz, H, Dorney, J, Meade, A D, Bonnier, F and Lyng, F 
M (2013). Vibrational Spectroscopy: Disease Diagnostics and Beyond In 
Baranska, M (Ed) Optical Spectroscopy and Computational Methods in Biology 
and Medicine, Springer Netherlands, Dordrecht. 
Cassé, C, Giannoni, F, Nguyen, V T, Dubois, M F and Bensaude, O (1999) The 
Transcriptional Inhibitors, Actinomycin D and Alpha-Amanitin, Activate the Hiv-
307 
 
1 Promoter and Favor Phosphorylation of the Rna Polymerase Ii C-Terminal 
Domain. J Biol Chem., 274(23), 16097-106. 
Chinsky, L and Turpin, P V (1978) Ultraviolet Resonance Raman Study of Dna and of 
Its Interaction with Actinomycin D. Nucleic Acids Res., 5(8), 2969-77. 
Choong, M L, Yang, H, Lee, M A and Lane, D P (2009) Specific Activation of the P53 
Pathway by Low Dose Actinomycin D: A New Route to P53 Based Cyclotherapy. 
Cell Cycle, 8(17), 2810-8. 
Chrzanowska-Lightowlers, Z M, Preiss, T and Lightowlers, R N (1994) Inhibition of 
Mitochondrial Protein Synthesis Promotes Increased Stability of Nuclear-
Encoded Respiratory Gene Transcripts. J Biol Chem., 269(44), 27322-8. 
Cibi, R and Jayakumaran Nair, A (2016) Evaluation of the Efficacy of the Compound 
Actinomycin D in Tumor Cell Lines. Int.J.Curr.Microbiol.App.Sci, 5(7), 405-11. 
El-Mashtoly, S F, Yosef, H K, Petersen, D, Mavarani, L, Maghnouj, A, Hahn, S, Kotting, 
G and Gerwert, K (2015) Label-Free Raman Spectroscopic Imaging Monitors the 
Integral Physiologically Relevant Drug Responses in Cancer Cells. Anal. Chem., 
87(14), 7297-304. 
Enache, M and Volanschi, E (2008) Fluorescence Study of the Interaction of Antitumor 
Drug Actinomycin D with Double Stranded Dna. Rev. Roumaine Chim, 9(53), 
841–6. 
Farhane, Z, Bonnier, F and Byrne, H J (2017) Monitoring Doxorubicin Cellular Uptake 
and Trafficking Using in Vitro Raman Microspectroscopy: Short and Long Time 
Exposure Effects on Lung Cancer Cell Lines. Anal Bioanal Chem, 409(5), 1333-
46. 
308 
 
Farhane, Z, Bonnier, F, Casey, A and Byrne, H J (2015) Raman Micro Spectroscopy for 
in Vitro Drug Screening: Subcellular Localisation and Interactions of 
Doxorubicin. Analyst, 140(12), 4212-23. 
Farhane, Z, Bonnier, F, Casey, A, Maguire, A, O'Neill, L and Byrne, H J (2015) Cellular 
Discrimination Using in Vitro Raman Micro Spectroscopy: The Role of the 
Nucleolus. Analyst, 140(17), 5908-19. 
Hasanzadeh, M and Shadjou, N (2016) Pharmacogenomic Study Using Bio- and 
Nanobioelectrochemistry: Drug-Dna Interaction. Mater Sci Eng C Mater Biol 
Appl., 61, 1002-17. 
Hyvärinen, A and Oja, E (2000) Independent Component Analysis: Algorithms and 
Applications. Neural Networks, 13, 411-30. 
Jamieson, L E and Byrne, H J (2016) Vibrational Spectroscopy as a Tool for Studying 
Drug-Cell Interaction: Could High Throughput Vibrational Spectroscopic 
Screening Improve Drug Development? Vib. Spectrosc., DOI: 
10.1016/j.vibspec.2016.09.003. 
Kasim, N R, Kuželová, K, Holoubek, A and Model, M A (2013) Live Fluorescence and 
Transmission-through-Dye Microscopic Study of Actinomycin D-Induced 
Apoptosis and Apoptotic Volume Decrease. Apoptosis, 18(4), 521-32. 
Kleeff, J, Kornmann, M, Sawhney, H and Korc, M (2000) Actinomycin D Induces 
Apoptosis and Inhibits Growth of Pancreatic Cancer Cells. Int J Cancer, 86, 399-
407. 
Lee, T W (1998). Independent Component Analysis In Independent Component Analysis: 
Theory and Applications, Springer US, Boston, MA. 
Liu, X F, Xiang, L, Zhou, Q, Carralot, J P, Prunotto, M, Niederfellner, G and Pastan, I 
(2016) Actinomycin D Enhances Killing of Cancer Cells by Immunotoxin 
309 
 
Rg7787 through Activation of the Extrinsic Pathway of Apoptosis. Proc. Natl. 
Acad. Sci, 113(38), 10666-71. 
Lohani, N, Singh, N H and Moganty, R R (2016) Structural Aspects of the Interaction of 
Anticancer Drug Actinomycin-D to the Gc Rich Region of Hmgb1 Gene. Int J 
Biol Macromol., 87, 433-42. 
Lu, D F, Wang, Y S, Li, C, Wei, G J, Chen, R, Dong, D M and Yao, M (2015) 
Actinomycin D Inhibits Cell Proliferations and Promotes Apoptosis in 
Osteosarcoma Cells. Int. J. Clin. Exp. Med. , 8(2), 1904-11. 
Movasaghi, Z, Rehman, S and Rehman, I U (2007) Raman Spectroscopy of Biological 
Tissues. Applied Spectroscopy Reviews, 42(5), 493-541. 
Nawaz, H, Bonnier, F, Meade, A D, Lyng, F M and Byrne, H J (2011) Comparison of 
Subcellular Responses for the Evaluation and Prediction of the Chemotherapeutic 
Response to Cisplatin in Lung Adenocarcinoma Using Raman Spectroscopy. 
Analyst, 136(12), 2450-63. 
Nawaz, H, Garcia, A, Meade, A D, Lyng, F M and Byrne, H J (2013) Raman Micro 
Spectroscopy Study of the Interaction of Vincristine with A549 Cells Supported 
by Expression Analysis of Bcl-2 Protein. Analyst, 138(20), 6177-84. 
Nazari, M, Emamzadeh, R, Hosseinkhani, S, Cevenini, L, Michelini, E and Roda, A 
(2012) Renilla Luciferase-Labeled Annexin V: A New Probe for Detection of 
Apoptotic Cells. Analyst, 137(21), 5062-70. 
Pavićević, A, Glumac, S, Sopta, J, Popović-Bijelić, A, Mojović, M and Bačić, G (2012) 
Raman Microspectroscopy as a Biomarking Tool for in Vitro Diagnosis of 
Cancer: A Feasibility Study. Croat Med J., 53(6), 551-. 
310 
 
Roots, R and Smith, K C (1976) Effects of Actinomycin D on Cell Cycle Kinetics and 
the Dna of Chinese Hamster and Mouse Mammary Tumor Cells Cultivated 
&Lt;Em&Gt;in Vitro&Lt;/Em&Gt. Cancer Res., 36(10), 3654. 
Schwartz, H S, JSodergren, J E, Garofalo, M and Sternberg, S S (1965) Actinomycin D 
Effects on Nucleic Acid and Protein Metabolism in Intact and Regenerating Liver 
of Rats. Cancer Res. , 25(3 Part 1), 307. 
Schwartz, H S, Sodergren, J E and Ambaye, R Y (1968) Actinomycin D: Drug 
Concentrations and Actions in Mouse Tissues and Tumors. Cancer Res., 28(2), 
192. 
Sha, F and Chen, F M (2000) Actinomycin D Binds Strongly to D(Cgacgacg) and 
D(Cgtcgtcg). Biophys J., 79(4), 2095-104. 
Sobell, H M (1985) Actinomycin and Dna Transcription. Proc Natl Acad Sci U S A., 
82(16), 5328-31. 
Suen, D F, Norris, K L and Youle, R J (2008) Mitochondrial Dynamics and Apoptosis. 
Genes Dev., 22(12), 1577-90. 
Takahashi, A and Ohnishi, T (2005) Does Gammah2ax Foci Formation Depend on the 
Presence of Dna Double Strand Breaks? Cancer Lett, 229(2), 171-9. 
Yosef, H K, Mavarani, L, Maghnouj, A, Hahn, S, El-Mashtoly, S F and Gerwert, K (2015) 
In Vitro Prediction of the Efficacy of Molecularly Targeted Cancer Therapy by 
Raman Spectral Imaging. Anal. Bioanal. Chem., 407(27), 8321-31. 
Yung, B Y M, Bor, A M S and Chan, P K (1990) Short Exposure to Actinomycin D 
Induces "Reversible" Translocation of Protein B23 as Well As "Reversible" 
Inhibition of Cell Growth and Rna Synthesis in Hela Cells. Cancer Res., 50(18), 
5987. 
311 
 
8.8. Supplementary Information: 
A.                                                               B. 
   
     C.                                                                    D. 
  
Figure S.8.1: A. Pre-processed Raman spectrum of ACT stock solution dissolved in 
sterile water and mean spectrum with standard deviation of B. Nucleolus, C. Nucleus and 
D. Cytoplasm of Calu-1 cell lines control and after 48hrs exposure to the corresponding 
IC50. 
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A. 
 
B. 
 
Figure S.8.2: PCA of nucleolar, nuclear and cytoplasmic regions of A. Calu-1 non 
exposed control and after 48hrs exposure to ACT with corresponding loadings of PC1 
and PC2 B. PCA of each cell localisation for control and exposed and the corresponding 
loadings of PC1 and PC2. 
Cytoplasm    Nucleus     Nucleolus     Calu-1 control 
Cytoplasm    Nucleus     Nucleolus     Calu-1 48hrs exposure to ACT 
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A. 
 
B. 
 
Figure S.8.3: PCA of nucleolar, nuclear and cytoplasmic regions of A. Calu-1 non 
exposed control and after 72hrs exposure to ACT with corresponding loadings of PC1 
and PC2 B. PCA of each cell localisation for control and exposed and the corresponding 
loadings of PC1 and PC2. 
Cytoplasm    Nucleus     Nucleolus     Calu-1 control 
Cytoplasm    Nucleus     Nucleolus     Calu-1 72hrs exposure to ACT 
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Chapter 9: In vitro label free screening of chemotherapeutic 
drugs using Raman micro-spectroscopy: towards a new 
paradigm of spectralomics 
 
The following chapter reproduces a review in Journal of Biophotonics (DOI: 
10.1002/jbio.201700258), Z. Farhane, H. Nawaz, F. Bonnier and H.J. Byrne, in which 
section and figure numbers have been adapted to the prescribed thesis format. 
It is a conclusion of the study which summarises the cellular uptake binding and cellular 
responses of the anthracyclic chemotherapeutic agents with Vincristine and Cisplatin in 
the lung cancer cell lines, and confirms the ability of Raman micro-spectroscopy for a 
potential clinical application as a companion diagnostic in personalised therapy by 
elucidating subcellular transport and accumulation pathways of chemotherapeutic agents 
with characterisation and fingerprinting of their mode of action and identification of 
potential cellular resistance. 
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Abstract: 
 
This overview groups some of the recent studies highlighting the potential application of 
Raman micro-spectroscopy as an analytical technique in preclinical development to 
predict drug mechanism of action and in clinical application as a companion diagnostic 
and in personalised therapy due to its capacity to predict cellular resistance and therefore 
to optimise chemotherapeutic treatment efficacy.  
Notably, the anthracyclines, Doxorubicin and Actinomycin D, elicit similar spectroscopic 
signatures of subcellular interaction characteristic of the mode of action of intercalation. 
Although Cisplatin and Vincristine show markedly different signatures, at low exposure 
doses, their signatures at higher doses show marked similarities to those elicited by the 
intercalating anthracyclines, confirming that anticancer agents can have different modes 
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of action with different spectroscopic signatures, depending on the dose. 
The study demonstrates that Raman micro-spectroscopy can elucidate subcellular 
transport and accumulation pathways of chemotherapeutic agents, characterise and 
fingerprint their mode of action, and potentially identify cell resistant strains. The 
consistency of the spectroscopic signatures for drugs of similar modes of action, in 
different cell lines, suggests that this fingerprint can be considered a “spectralome” of the 
drug-cell interaction suggesting a new paradigm of representing spectroscopic responses.  
 
Keywords: Raman micro-spectroscopy, cancer cells, chemotherapeutic drugs, 
mechanism of action, cellular resistance, spectralomics 
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9.1. Introduction: 
Vibrational spectroscopy can perform cellular imaging in a (benchtop) microscopic 
geometry, and can provide non invasive label free screening of, for example, nanoparticle 
or drug uptake, trafficking and interaction mechanisms, as well as cellular responses and 
toxicity (Byrne, 2014; Byrne et al., 2013; Efeoglu, Casey, and Byrne, 2016; El-Mashtoly 
et al., 2015; Farhane et al., 2015), eliminating the need for multiple assays in toxicological 
screening and drug discovery and preclinical screening stages, by elaborate robotic High 
Content Analysis systems. Vibrational spectroscopy has also been demonstrated for 
diagnostics applications, in vivo and ex vivo, in tissue (Bonnier et al., 2012; F Bonnier et 
al., 2010), cells (Farhane et al., 2015; Huser and Chan, 2015) and body fluids (Bonnier et 
al., 2014; Bunaciu et al., 2017). A further potential application which is currently 
attracting increasing attention is in understanding and screening cellular resistance to 
therapeutic treatments to guide strategies for personalised therapies (Cho, Jeon, and Kim, 
2012; Overby and Tarczy-Hornoch, 2013). Both Infrared absorption (IR) and Raman 
spectroscopy can be performed on live cells (F  Bonnier et al., 2010; Whelan et al., 2013), 
although the significantly lower contribution of water in the latter favour it for live cell 
analysis (Bonnier et al., 2014). Raman micro-spectroscopy also provides superior spatial 
resolution to IR spectroscopy, being an optically based microscopy technique, commonly 
employed in a confocal mode, enabling subcellular analysis of biological processes at an 
organelle level (F  Bonnier et al., 2010). Raman spectral maps of whole live cells can be 
performed over minutes to hours, but in cases where spectral quality is favoured over 
speed, for detailed analysis, measurement protocols often entail fixing the cells at fixed 
time points after exposure to exogenous agents, for example radiation or toxicants, having 
optimised protocols for cell fixation (Meade et al., 2010). Both IR and Raman 
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spectroscopy have been used to assess the effects of drugs on cells, demonstrating their 
potential to measure changes in a high throughput manner and therefore can be used in 
drug screening (Derenne, Gasper, and Goormaghtigh, 2011; Hughes, Clemens, and 
Baker, 2015; Nawaz et al., 2010). Many studies have reported the use of vibrational 
spectroscopy to monitor the effects of anticancer agents, including polyphenols (Derenne 
et al., 2013) cardiotonic steroids (Gasper et al., 2010), and platinum compounds (Nie et 
al., 2010), on cancer cells, and Hughes et al. (Hughes, Clemens, and Baker, 2015), 
Mignolet et al. (Mignolet et al., 2016) and Jamieson and Byrne (Jamieson and Byrne, 
2016) have recently reviewed the potential for vibrational micro-spectroscopy as a label 
free in vitro platform for screening the mechanisms of action and efficacies of candidate 
drugs at the discovery and pre-clinical screening stages. The development of such in vitro 
screening techniques is particularly pertinent at present, given the increasing legislative 
pressure to develop in vitro alternatives to animal models for scientific research and 
product development as prioritised by the EU Directive-2010/63/EU on the replacement, 
reduction and refinement of animal experimentation. 
Using Fourier Transform IR (FTIR) microscopy, Derenne et al. demonstrated that drugs 
of similar mode of action have similar spectroscopic signatures (Derenne, Gasper, and 
Goormaghtigh, 2011), indicating potential applications in pre-clinical screening of the 
mode of action of new candidate drugs. Analysis of spectral variations in prostate cell 
lines, induced by drug exposure, clustered drugs classified as anti-microtubules 
(Methotrexate, Mercaptopurine), anti-topoisomerases (Vincristine, Vinblastine, 
Paclitaxel) and anti-metabolites (Doxorubicin, Daunorubicin) separately. Derenne et al. 
further demonstrated that the spectral changes were not cell line specific, but were 
consistent over seven different cell lines (Derenne, Verdonck, and Goormaghtigh, 2012). 
Mignolet et al. (Mignolet et al., 2016) reviewed the body of work exploring IR signatures 
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of anti-cancer drugs inside cancer cells and changes induced after drug exposure, 
including the effects of cell cycle and cell culture model, arguing that FTIR can be 
employed for screening of new drug candidate molecules for known or unknown modes 
of action.  
Using Raman spectroscopy, subcellular resolution can be achieved due to the high spatial 
resolution achievable with optical microscopy, allowing intracellular organelles to be 
resolved. Raman spectra are also typically recorded at higher spectral resolution than IR 
spectra, and therefore more detailed biochemical information can be gained (Ali et al., 
2013), with more potential for elucidating ‘modes of action’ by analysis of the detailed 
spectral changes. El-Mashtoly et al. (El-Mashtoly et al., 2014) demonstrated the 
capability of Raman spectroscopy for monitoring the distribution of the distinct structure 
of erlotinib, containing a carbon-carbon triple bond, and its metabolic products in 
colorectal adenocarcinoma SW480 cells. Le Roux et al. (Le Roux, Prinsloo, and Meyer, 
2014) explored cell death routes after exposure to gold based metallodrugs. Salehi et al. 
(Salehi, Derely, et al., 2013; Salehi, Middendorp, et al., 2013) and Feofanov et al. 
(Feofanov et al., 2000) probed the resonance Raman response to detect and study cellular 
responses after exposure to paclitaxel, and the nonfluorescent transition-metal complex, 
Theraphtal, respectivelly. Draux et al. (Draux et al., 2011) investigated the effect of 
Gemcitabine on cell biomolecules in the lung cancer cell line Calu-1, after 48 hrs 
exposure. Moritz et al. (Moritz et al., 2010) used laser tweezers Raman spectroscopy to 
study the effects of Doxorubicin on leukaemia cells and demonstrated that drug exposed 
cells exhibited an increase in DNA features after prolonged exposure time. Schie et al. 
(Schie et al., 2014) also investigated the effect of Doxorubicin on malignant lymphocytes 
at late stages, from 24 to 96 hrs, while Guo et al. (Guo et al., 2009) explored the effects 
of Doxorubicin on malignant hepatocytes after 12 hrs exposure, showing a decrease in 
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DNA features and an increase in proteins and lipids features. Hartmann et al. (Hartmann 
et al., 2012) studied the effect of Docetaxel on human breast adenocarcinoma cell line, 
MCF-7, comparing the treated cells with the untreated ones and investigating the cellular 
morphological changes induced by the chemotherapeutic drug. Lin et al. (Lin et al., 2011) 
used Raman spectroscopy to assess the cytotoxicity of Paclitaxel in CA46, human 
Burkitt’s lymphoma cells. Zoladek et al. (Zoladek et al., 2011) showed the potential of 
Raman micro-spectroscopy for label free time course imaging (at 2 hrs intervals over 6 
hrs) of live human breast cancer cell (MDA-MB-231) undergoing apoptosis after 
exposure to Etoposide. 
In monitoring the response to exogenous agents in vitro, it has also been demonstrated 
that both FTIR and Raman spectroscopy can potentially be employed to understand 
cellular resistance pathways in different cell lines. Cellular resistance pathways were 
specifically targeted by Yosef et al. (Yosef et al., 2015) who used Raman spectral imaging 
to investigate the oncogenic mutation resistance to epidermal growth factor receptor 
targeting therapy and colon cancer cells with and without oncogenic mutations such as 
KRAS and BRAF mutations were treated with erlotinib, an inhibitor of epidermal growth 
factor receptor, in order to detect the impact of these mutations on Raman spectra of the 
cells as markers of cell resistance. Rutter et al. (Rutter et al., 2014) utilised a cell cloning 
technique to specifically isolate sensitive and resistant cells from a mixed cell population, 
and investigated the difference in response of gemcitabine-sensitive and gemcitabine-
resistant Calu-1 epidermoid lung cancer cells to the commercial drug, using IR 
spectroscopy. Furthermore, Siddique et al. (Siddique et al., 2017) showed that it was also 
possible to identify differences of nilotinib-sensitive and nilotinib-resistant K562 (a 
chronic myelogenous leukaemia cell line) cloned cells, using both FTIR and Raman 
micro-spectroscopies. The ability of vibrational spectroscopy to characterise and 
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differentiate responses of resistant and sensitive cell types to drugs opens up potential 
clinical applications as a Companion Diagnostics (CD) tool, and ultimately personalised 
medicine approaches (Agarwal, Ressler, and Snyder, 2015; Naylor and Cole, 2010). 
Although the potential of in vitro spectroscopic screening of cellular processes has been 
well demonstrated, research has been somewhat fragmented, lacking in coherence and 
standardisation of measurement protocols. Critically, the analysis and interpretation of 
the spectral responses remains a challenge, even in the hands of “specialists”. At the 
recent Faraday Discussions (Baker et al., 2016), the question as to what extent individual 
spectral features can be assigned to specific molecular responses, given the complex 
nature of the samples under investigation, featured highly. By their very nature, label free 
techniques register all species within the sampling area, and identification of specific 
responses requires more sophisticated techniques to data-mine the differential responses 
due to cell injury or change. Regression and correlation approaches can be employed to 
extract the specific spectroscopic signatures of cellular changes which are correlated with 
external stimuli, and, for example independently elucidate the spectroscopic signatures 
of the direct chemical effects of the stimulus from the subsequent cellular metabolic 
responses. In the case of chemotherapeutic agents, the uptake, distribution and 
accumulation, chemical interactions and subsequent cellular metabolic responses can be 
monitored (Hughes, Clemens, and Baker, 2015; Nawaz et al., 2010). Nevertheless, these 
differential spectral responses remain multivariate in nature, and contain contributions of 
the multitude of biochemical constituents involved. The conditioned thinking, based on a 
labelled approach, is to search for specific “Biomarkers”. However, it is becoming 
increasingly apparent that the spectral response can have (additive) contributions of 
increased or decreased concentrations of constituent biomolecules, but also more 
complex contributions due to conformational, environmental (pH etc.) changes, and that 
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identification of the (differential) spectroscopic signature, rather than specific bands 
associated with specific biomolecules, may be more appropriate. For realistic applications 
potential, however, it is important that these combinatorial signatures are characteristic 
of the cellular interaction and/or response pathway, and are translatable across cell lines 
and ultimately patient samples. Although Derenne et al. demonstrated that drugs of 
similar mode of action have similar spectroscopic signatures using FTIR microscopy 
(Derenne, Gasper, and Goormaghtigh, 2011), there have been few other studies which 
have attempted to demonstrate consistency between spectroscopic signatures of drug 
interactions and cellular responses (El-Mashtoly et al., 2015; Jamieson and Byrne, 2016). 
The identification of specific spectral signatures which are common for drug mechanisms 
of action and cellular responses opens the perspective to a new “spectralomics” paradigm, 
in label-free fingerprinting and monitoring of biological processes in cells in vitro using 
Raman spectroscopy, with potential applications in fundamental cytological research, 
pre-clinical pharmacological development, and ultimately improved individualised 
clinical therapeutics. 
Herein, the results of a number of independent studies of the action of chemotherapeutic 
agents in vitro are gathered and reviewed, with a view towards assessment of the 
consistencies of spectroscopic signatures of the subcellular interactions of the drugs, and 
the subsequent cellular responses. Specifically, Raman micro-spectroscopic studies of the 
subcellular interactions of Doxorubicin (DOX), Actinomycin D (ACT), Cisplatin (Cisp) 
and Vincristine (Vinc) in human lung cancer cell lines, and their subsequent responses, 
are considered. The dose response profiles are examined in the context of classical 
cytotoxicological screening assays. 
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9.2. Cytotoxicity assays and their limits:  
A range of cytotoxicological assays are commonly employed to measure the in vitro 
responses of cell populations, including cell proliferation, viability and toxicity, after 
exposure to external agents such drugs, nanoparticles or radiation. Amongst these are the 
tetrazolium bromide (MTT), Alamar Blue (AB) and Neutral Red (NR) assays, each of 
which targets different aspects of the response pathway.  
NR is a fluorometric dye, which measures the lysosomal activity using 3-Trimethyl-2,8-
phenazinediamine, monohydrochloride, which binds to the lysosomes of viable cells after 
penetration by passive diffusion due to its cationic charge. This uptake depends on the 
ability of the cell to maintain a pH gradient by production of ATP. Therefore, the dye 
cannot penetrate inside dead cells and the amount of retained dye is proportional to the 
number of viable cells (Maher et al., 2014; Repetto, del Peso, and Zurita, 2008). The MTT 
test is a colorimetric assay that measures the reduction of yellow 3-(4, 5-dimethythiazol-
2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) by mitochondrial succinate 
dehydrogenase into purple formazan crystals, insoluble in aqueous solution (Al-Nasiry et 
al., 2007; Hamid et al., 2004). Succinate dehydrogenase or succinate-coenzyme Q 
reductase (SQR) or respiratory Complex II is an enzyme complex, bound to the inner 
mitochondrial membrane of mammalian mitochondria and many bacterial cells. It is the 
only enzyme that participates in both the citric acid cycle and the electron transport chain, 
so the MTT assay is the reflection of mitochondrial activity.  
Alamar blue (AB), on the other hand, is a water-soluble dye and one of the most highly 
used cytotoxicity assays for in vitro quantification of the cell viability(Fields and 
Lancaster, 1993). When added to cell cultures, the active dye, resazurin or 7-hydroxy-10-
oxidophenoxazin-10-ium-3-one, diffuses into the cytosol and acts as an intermediate 
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electron acceptor allowing the oxidised blue non-fluorescent form to be reduced by both 
mitochondrial and cytosolic enzyme activity to the fluorescent pink form which is easily 
measured by its absorption or fluorescence (Al-Nasiry et al., 2007; Fields and Lancaster, 
1993; Hamid et al., 2004). 
Both AB and NR are considered an expression of general cellular metabolism and, while 
reduced conversion compared to controls is used as a measure of reduced cellular viability 
for both AB and MTT assays, the MTT response is more specifically sensitive to 
mitochondrial enzymes while AB is related to both mitochondrial and cytosolic activities. 
Quantitatively, the cytotoxic response is commonly quoted in terms of the effective 
concentration with elicits 50% of the maximum response of the cell population to the 
exogenous agent (IC50), determined through dose-response curves. However, toxicity 
studies are commonly conducted at different time points, using different cell lines, leading 
to a lack of consistency in toxicological data for chemotherapeutic agents. Figure 9.1 
shows, for example the accumulated cytotoxicity data as measured using the MTT assay, 
for Cisp (Nawaz et al., 2010) and Vinc (Nawaz et al., 2013) in A549, human lung 
adenocarcinoma cells, and DOX (Farhane, Bonnier, Howe, et al., 2017) and ACT 
(Farhane, Bonnier, and Byrne, 2017a) in both A549 and Calu 1, a human lung epidermoid 
carcinoma cell line, at differing time points. The inverse IC50, as a comparative measure 
of the toxicity (Ragnvaldsson et al., 2007), is plotted against the exposure time. For the 
case of DOX, the toxicity increases monotonically as a function of exposure time. The 
two cell lines show comparable results, although that of A549 seems to saturate at 
prolonged exposures. In the case of ACT, although negligible response was observed at 
24 hrs (IC50>50 M), the toxicity at 48 hrs and 72 hrs far exceeds that of DOX, in both 
cell lines (Farhane, Bonnier, and Byrne, 2017a). Cisp also requires a more prolonged 
exposure time to elicit appreciable responses in A549 (Nawaz et al., 2013), while, for the 
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same exposure time, Vinc requires substantially lower concentration to elicit the same 
toxic response (Nawaz et al., 2013). 
 
Figure 9.1: Plot of the inverse IC50 against exposure time for DOX and ACT exposure to 
A549 and Calu-1 cell lines and Vinc and Cisp to the A549 cell line. 
Maher et al. (Maher et al., 2014) developed a numerical model to simulate nanoparticle 
uptake, cytotoxicity and subsequent cellular response and highlighted the fact that 
differences in the quantitative responses of cytotoxicity assays can arise due to the fact 
that each assay measures different underlying cellular responses which can occur at 
different rates. An assessment of the action and efficacy of, for example a 
chemotherapeutic agent, according to a single endpoint is therefore extremely limited. 
Computational Modelling approaches to predictive toxicity, such as that of Adverse 
Outcome Pathways (Wittwehr et al., 2017), have sought to deconvolute the action of 
exogenous agents, in terms of the molecular initiating event (MIE) and the subsequent 
cascade of key events (KE) that reflect the causal progression from the initial perturbation 
of the system towards the adverse outcome. In the context of the action of 
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chemotherapeutic drugs in vitro, the MIE can be considered the chemical interaction of 
the drug, for example in the cell nucleus, while the subsequent cascade of events can 
determine the efficacy of a drug action. Understanding of the chemistry of the MIE can 
be key to establishing quantitative structure activity relationships to guide synthetic 
strategies, while understanding the subsequent pathways may be key to understanding 
mechanisms of drug resistance and sensitivity in different cell lines and ultimately 
patients. 
Therefore, to have a global idea of the effects of external agents such as drugs or 
nanoparticles on cells and identify any subsequent cellular responses, there is a need for 
a more developed label free method which gives a holistic picture of the cascade of events 
which occurs after cell exposure. 
9.3. Data processing: pre and post processing: 
To consider vibrational spectroscopy and specifically Raman micro-spectroscopy as an 
analytical tool for clinical applications, it should be able to address the many challenges 
related to the complexity of biological samples and their chemical and physical 
heterogeneity. In this context, data pre and post processing play an important role in 
dealing with variations in instrumental responses, between different biological samples 
and improving spectral quality. 
Byrne et al. (Byrne et al., 2016) summarised the pre-processing steps routinely used to 
improve recorded spectra quality, and the commonly used post-processing techniques for 
the classification, discrimination and analysis of data set from biological samples. In fact, 
many factors, including background coming from sample scattering and/or fluorescence, 
substrate contributions, specifically when analysing thin samples, and instrumental 
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enhanced scattering contributions, can influence spectra quality and therefore need to be 
subtracted. In some cases, those factors can be minimised experimentally, for example 
analysing samples in immersion to reduce laser scattering (F Bonnier et al., 2010) or use 
of substrates with negligible Raman scattering (Kerr, Byrne, and Hennelly, 2015). In 
others cases, there is a need for pre-processing algorithms for background subtraction 
prior to analysis, using for example a NCLS (non-negatively constrained least squares) 
(Ibrahim et al., 2017) or EMSC (extended multiplicative signal correction) algorithm 
(Kerr and Hennelly, 2016). Spectra are also commonly smoothed to reduce noise using 
the Savitsky-Golay algorithm or singular value decomposition (SVD) (Schie and Chan, 
2016), baseline corrected (fifth order polynomial) and vector or area normalised. 
After pre-processing, data post-processing or data mining is necessary to detect and 
analyse changes in spectral profiles associated, for example, with biological process, 
drug, nanoparticle, radiation exposure etc., mostly in a large and complex data set. The 
most common method in terms of multivariate spectral data analysis is Principal 
Components Analysis (PCA), a powerful unsupervised approach for the analysis of large 
multidimensional data sets, which allows the reduction of the number of variables, 
although retaining most of the variation within the dataset. It represents the spectra in data 
groupings of similar variability, allowing the identification and differentiation of different 
spectral subgroups. The loadings of the PCs represent the variance for each variable 
(wavenumber) for a given PC, the order of the PCs denoting their importance to the 
dataset. PC1 describes the highest amount of variation, and analysis of the loadings can 
give information about the source of the variability inside a dataset, derived from 
variations in the molecular components contributing to the spectra.  
It has been demonstrated that the PC loadings can be most simply understood when 
analysis of data subgroups is undertaken in a pairwise fashion (Bonnier and Byrne, 2012; 
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Farhane, Bonnier, Maher, et al., 2017), whereby the loading of the PC can be interpreted 
as differences of the biochemical content of the two differentiated datasets (Bonnier and 
Byrne, 2012), highlighting its ability to provide molecular information and biochemical 
differences of analysed samples. Notably, PCA does not cluster the data, per se, in the 
same manner as for example Hierarchical or K-Means Cluster Analysis, whereby 
differential distribution of the data according to negative or positive loadings associates 
specific spectral features with that dataset. 
As an extension to PCA, independent components analysis (ICA) can also be employed 
as an unsupervised statistical technique to identify latent variables, called independent 
components, in each data set separately. In the case of Raman micro-spectroscopy, ICA 
can be used to identify spectral contributions such as those from substrate, which can then 
be removed or plotted and studied in their own (Farhane, Bonnier, Maher, et al., 2017; 
Lee, 1998).  
More sophisticated spectral analysis is required to extract specific information related to 
an external variable such as exogenous exposure dose or time, requiring supervised 
methods such Partial Least Squared Regression (PLSR). PLSR is a statistical regression 
technique which reduces the dimensionality of the data and correlates information, here 
represented by the spectra data set, to, for example, time evolution or drug concentrations 
or to a gold standard assay, to track the dependent evolution of the spectral signatures in, 
for example, subcellular regions. The regression coefficients obtained by PLSR can be 
analysed and provide information about the contribution of spectral variations. As a 
function of frequency, the co-efficients illustrate the spectral features which are 
influenced by the external factor selected (Farhane, Bonnier, and Byrne, 2017b).  
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9.4. Raman micro-spectroscopy for chemotherapeutic pre-clinical 
screening: 
Raman spectroscopic analysis of drug-cell interactions has focused both on changes in 
the cellular Raman spectra upon drug application, and also during intracellular tracking 
of the drug and its metabolites (Dana et al., 2015; El-Mashtoly et al., 2014; Farhane, 
Bonnier, and Byrne, 2017a; Farhane et al., 2015; Farhane, Bonnier, Howe, et al., 2017). 
Farhane et al. (Farhane, Bonnier, and Byrne, 2017b; Farhane et al., 2015; Farhane, 
Bonnier, Howe, et al., 2017; Farhane, Bonnier, Maher, et al., 2017) used Raman 
spectroscopy to determine not only the subcellular location of the drug DOX in A549 and 
Calu- 1 human lung adenocarcinoma cells, but also the differing pharmacodynamics of 
the drug uptake and subcellular localization, as well as the subsequent cellular responses, 
over a period 0-72 hrs. In fact, using Raman micro-spectroscopy, DOX could be clearly 
detected in both the nucleolus and surrounding nucleus, while Confocal Laser Scanning 
Microscopy (CLSM) images show that only the nucleus appears red (compared to the 
corresponding controls, in which no fluorescence is detected), due to the characteristic 
DOX fluorescence (Figure 9.2), the clearly visible dark spots of the nucleoli suggesting 
that DOX does not accumulate in the nucleoli.  
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A. 
1.     2.       3.        4.         5.          6. 
 
B. 
1.     2.       3.        4.         5.          6. 
 
Figure 9.2: Confocal Laser Scanning Fluorescence images of A. A549 cells and B. Calu-
1 cells after DOX exposure and corresponding controls: 1. 2 hrs DOX exposure, 2. 6 hrs 
DOX exposure, 3. 12 hrs DOX exposure, 4. 24 hrs DOX exposure, 5. 48 hrs DOX 
exposure and 6. 72 hrs DOX exposure (Farhane, Bonnier, and Byrne, 2017b). 
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However, Raman micro-spectroscopy clearly demonstrates that DOX does accumulate in 
the nucleoli, indicating that the dark spots are a result of fluorescence quenching in the 
environment. The study also indicated that DOX selectively targets the RNA in the 
nucleolus, before the nuclear and cytoplasmic regions.  
Using multivariate data analysis, consisting of PCA, ICA and PLSR, Raman micro-
spectroscopy was shown to be capable of tracking the kinetics of the uptake and 
accumulation of DOX at a subcellular level in vitro (Farhane, Bonnier, and Byrne, 2017b; 
Farhane, Bonnier, Howe, et al., 2017). Results show that the chemotherapeutic drug 
accumulates first in, and saturates, the nucleolus, then the nucleus and is only detectable 
in the cytoplasm at later stages, after nuclear disruption (Figure 9.3 A). Raman micro-
spectroscopy can differentiate the biochemical responses associated with the subcellular 
regions of nucleolus, nucleus and cytoplasm, both in terms of the mechanisms of action 
(DNA intercalation in nuclear area and ROS production in cytoplasmic region), and the 
subsequent cellular metabolic responses for the same cell lines and between different cell 
lines (Figure 9.3 B), the faster uptake in Calu-1 cells (Figure 9.3 A) highlighting different 
cellular kinetics, effects and resistance related to expression of anti-apoptotic proteins and 
tolerance to DNA damage and implication of DNA repair mechanisms manifest as an 
increase in DNA signatures at late stages (Figure 9.3 B). 
A similar response profile was observed for Actinomycin D (ACT) in the same cell lines, 
both in terms of time evolution and spectroscopic signatures (Farhane, Bonnier, and 
Byrne, 2017a). In fact, a similar chemical binding signature, related to RNA/DNA 
interaction, resulting in a decrease of both bands at 785 cm−1 (DNA backbone O–P–O) and 
813 cm−1 (RNA O–P–O phosphodiester band stretching) was observed after DOX and ACT 
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exposure (Figure 9.4). The substantially slower uptake rate for ACT (48-72 hrs) compared 
to DOX (6-12 hrs) may be due to different side chain composition. 
A. 
 
B. 
 
Figure 9.3: A. Evolution of DOX, represented by the Raman band at 465 cm-1, as a 
function of time for the A549 and Calu-1 cell line for each cellular compartment, 
nucleolus, nucleus and cytoplasm. B. Evolution of selected DNA and RNA features as 
function of time.  
Intensities are expressed as percentage according to the maximum value over the three 
cellular compartments for each cell line and standard deviation corresponds to the spectral 
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variations of the Raman band over the 30 measurements per location (Farhane, Bonnier, 
and Byrne, 2017b; Farhane, Bonnier, Howe, et al., 2017). 
Nevertheless, both exploit similar cellular pathways, accumulating first in the nucleolus 
and then the nucleus, which suggests that the anthracycline chemotherapeutic group 
targets the nucleolus first, binding with RNA, and nucleus second, binding with DNA, 
before accumulating in the cytoplasm. This is not the accepted view of the mode of action 
of anthracycline drugs, which considers only the interaction with nuclear DNA and 
parallel interactions in the cytoplasm (Minotti et al., 2004; Rabbani, Finn, and Ausió, 
2005; Yaqub, 2013), and so, in both cases, Raman micro-spectroscopy has shed further 
light on the current understanding of the mode of action of the clinically prescribed 
chemotherapeutic agents. 
Nawaz et al. (Nawaz et al., 2010; Nawaz et al., 2011) explored the effects of Cisplatin 
(Cisp), which primarily interacts with DNA via inter-strand and intra-strand cross-links 
with purine bases, mostly by forming a 1,2-intrastrand cross-link between the N7 atoms 
of two adjacent guanine bases, on the Raman spectra of the nuclear region of A549 human 
lung adenocarcinoma cells after 96 hours exposure. The difference spectrum of cells 
exposed to the Cisp IC50 concentration and unexposed control cells reveals specific bands 
at, for example, 669 (thymine and guanine), 833 (DNA B form) and 1095 cm-1 (DNA 
PO2− symmetric stretching), associated with intra-strand cross linkages between 
guanine/guanine and guanine/thymine, inducing conformational changes, consistent with 
the accepted mode of action of Cisp, as also demonstrated by Huang et al. (Huang et al., 
2013), who monitored cellular apoptosis of nasopharyngeal carcinoma cells C666 after 
Cisp treatment.  
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A. 
 
B. 
 
Figure 9.4: Loading 1 of PC1 of control versus exposed cells of Nucleolus A. A549 
control versus 6 hrs DOX exposure compared to that of control versus 48 hrs exposure 
ACT B. Calu-1 control versus 2 hrs DOX exposure compared to that of control versus 48 
hrs exposure ACT. 
Using the drug dose and MTT cytotoxicity assay as independent regression targets in 
PLSR, Nawaz et al. (Nawaz et al., 2010; Nawaz et al., 2011) showed that it was possible 
335 
 
to distinguish cellular responses in the Raman spectrum as a result of Cisp interactions 
within the cell nucleus by chemical binding, and the subsequent cellular physiological 
response of the cell. Keating et al. (Keating et al., 2015) confirmed these results with 
simulated data, further emphasising the power of this technique, with application to High 
content analysis  for in vitro drug testing.  
It should be noted that, PLSR over the high concentration range, up to 50 M, (Figure 
9.5 A) results in a spectral profile which is similar to those of DOX and ACT (Figure 9.4) 
exhibiting strong features at 785 cm−1 (DNA backbone O–P–O) and 813 cm−1 (RNA O–
P–O phosphodiester band stretching), while regression over the lower concentration up 
to the IC50 of 1.2 ± 0.2 M showed a decrease in features at 728, 830 and 1425 cm−1, 
related to DNA B form and an increase in features at 668 and 675 cm−1, related to DNA 
A form, indicative of conformational changes due to partial transition of the DNA B-form 
to DNA A-form due to Cisp binding (Ghosh, Dey, and Saha, 2014; Nawaz et al., 2010; 
Vaverkova et al., 2014). 
In acellular circular dichroism studies of drug DNA interactions, the spectral changes 
observed for the ACT-DNA complexes due to a B to A-type DNA transition upon 
interaction, are distinct from those of Cisp-DNA complexes, which reflect distortions in 
DNA of a nondenaturational nature (Chang, Chen, and Hou, 2012). Therefore, it is not 
expected that Cisp will induce similar conformational changes to DOX or ACT.  
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A. 
 
B. 
 
Figure 9.5: Regression coefficients obtained by PLSR analysis for A549 cell line as a 
function of drug dose at low and high doses for chemotherapeutic drugs A. Cisp and B. 
Vinc. 
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In a similar, more recent, study of the effects of Vinc, Raman spectroscopy demonstrated 
that, as well as the accepted mechanism of action of microtubule binding, intercalation 
with nuclear DNA occurs at high doses (Nawaz et al., 2013). Using Flow Cytometry to 
measure the anti-apoptotic bcl-2 protein expression reveals that it depends on the Vinc 
concentration; at low concentration, the bcl-2 protein expression increases, inhibiting cell 
death by apoptosis and drops at higher concentrations due to higher levels of DNA 
damage. 
This is confirmed by a PLSR regression of the spectral responses of the nucleus versus 
Vinc dose at low and high doses, as shown in Figure 9.5 B. At low doses (<IC50), a single 
negative feature is observed at 795 cm-1, whereas regression over the doses above the IC50 
results in the double feature at 785 cm-1 and 810 cm-1, characteristic of DNA intercalation 
and resultant conformational changes.  
The studies of Cisp and Vinc demonstrate that a drug can have different modes of action, 
dependent on dose (Mohammadgholi, Rabbani-Chadegani, and Fallah, 2012; Nawaz et 
al., 2010; Nawaz et al., 2013; Tyagi et al., 2010), and, indeed this is also demonstrated by 
the time evolution of the cellular DOX accumulation. Therefore, the characteristic 
spectroscopic signatures will vary as a function of dose, and exposure time, as also 
demonstrated by Moritz et al. (Moritz et al., 2010), Schie et al. (Schie et al., 2014) and 
Guo et al. (Guo et al., 2009), for DOX exposure, albeit with different cell lines, doses and 
exposure times. Employing a clinically relevant exposure dose, and monitoring the 
evolution of the response, however, perhaps yields the best quality information, in terms 
of independently monitoring the drug accumulation, chemical binding and cellular 
responses. 
338 
 
Using Raman micro-spectroscopy and multivariate data analysis, in a similar fashion as 
Derenne et al., drugs from the same chemotherapeutic group can be seen to exhibit similar 
chemical binding signatures which can be considered as a fingerprint of their mechanism 
of action, as shown by Farhane et al. (Farhane, Bonnier, and Byrne, 2017a) for the two 
anthracyclines DOX and ACT. Similar spectral signatures of the interaction with nucleic 
acids are observed in both the nucleolus and nucleus (Figure 9.4), consisting of a 
simultaneous decrease in the Raman features at 785 and 813 cm−1, corresponding 
respectively to DNA backbone O–P–O and RNA O–P–O phosphodiester band stretching, 
despite the fact that they reveal different pharmacokinetics and different cellular 
resistance for different cell lines. 
 
Figure 9.6: Regression coefficients obtained by PLSR analysis for A549 cell line as a 
function of drug dose for chemotherapeutic drugs DOX, Cisp and Vinc with common 
features highlighted on red.  
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Similar decreases in both the Raman bands at 785 and 813 cm−1 were also observed for 
drugs from different chemotherapeutic groups (Figure 9.6): DOX, an anthracycline with 
high affinity for DNA, Cisp an alkylating agent which binds with DNA forming inter and 
intra strand crosslinks and Vinc, an alkaloid which bind to microtubules. 
Despite the fact that those three chemotherapeutic drugs belong to different classes, they 
present a common mechanism of action by interaction with nucleic acids manifest in 
Raman analysis by the simultaneous decrease of features at 785 and 813 cm−1. This can 
therefore be considered as a marker and a fingerprint of DNA intercalation and can be 
explored for new chemotherapeutic candidates. A similar decrease in features at 728 
(adenine), 1095 (DNA PO2− symmetric stretching), 1376 (thymine), 1486 and 1577 cm−1 
(adenine and guanine) is also observed for the three drugs, indicating that they can interact 
with the four nucleic bases and bind externally with DNA.  
The identification of such common spectroscopic signatures associated with a mode of 
action of these chemotherapeutic agents or cellular reactions can potentially be exploited 
for pre-clinical screening of the mode of action and potential resistance of new candidate 
chemotherapeutic agents. 
Besides similar nucleic acids features, notable increases in protein features at 645 and 877 
cm−1, related to tyrosine, and 115-1130 cm−1, related to C-N protein stretching, and lipids 
at 700 cm−1, are also observed for the three drugs, which may be indicative of changes in 
protein structure and cellular resistance by synthesis of anti-apoptotic proteins and lipidic 
vesicules, as a way to remove DOX to the extracellular environment and thus could be 
considered as a marker of possible chemotherapeutic failure. 
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9.5. Raman micro-spectroscopy to distinguish cellular resistance: 
Farhane et al. (Farhane, Bonnier, Howe, et al., 2017), in a comparative study between the 
two lung cancer cell lines A549 and Calu-1 exposed to DOX at the dose corresponding 
to the IC50 of each, demonstrated that, despite the fact that there is a much faster uptake 
of DOX and cellular saturation in Calu-1 cells (Figure 9.3 A and Figure 9.7 B), they are 
more resistant than A549 cells and exhibit earlier evidence of a secondary mechanism of 
action of DOX, by ROS production (Farhane, Bonnier, Maher, et al., 2017). In fact, 
Raman investigations show that the accumulation of DOX in the cytoplasmic area 
happens due to nuclear disruption, and as a consequence, the ROS production starts only 
after nuclear saturation, and that the two mechanisms of action, nucleic acid intercalation 
and ROS production, do not happen simultaneously. Further investigations demonstrate 
that, for both cell lines, there is a decrease in cellular features concomitant with DOX 
saturation, Calu-1 cells exhibiting higher DNA damage. However, at later stages (Figure 
9.3 B and Figure 9.7 B) in Calu-1 cells, there is a recovery of DNA and protein features, 
which suggests the intervention of DNA repair mechanisms and synthesis of anti-
apoptotic proteins (confirmed by measurement of bcl-2, an anti-apoptotic protein and 
γH2AX, a marker of DNA damage and repair), both considered as mechanisms of cellular 
resistance. In fact, as seen in Figure 9.7 for A549 cells, there is an increase in γH2AX up 
to 24 hrs corresponding to an increase in DNA damage and the increase in Bcl-2 protein 
is only up to 12 hrs, with a continuous decrease in DNA, suggesting failure in anti-
apoptosis and DNA recovery mechanisms. However, in Calu-1 cells, the bcl-2 expression 
continues to increase until the later stage of 48 hrs, a decrease in γH2AX starting at 12 
hrs and a DNA recovery at late stages, consistent with a higher resistance than A549 cells 
(Figure 9.7).  
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The cellular DNA repair capacity influences the efficacy of anticancer treatment and can 
be used as a biomarker of chemotherapeutic resistance. Moreover, resistance to apoptosis, 
programmed cell death, by either increase of anti-apoptotic protein, mainly bcl-2 proteins, 
or higher tolerance to DNA damage or DNA repair, as seen in Calu-1 cells, is associated 
with chemoresistance and as a consequence a poor clinical prognosis in cancer therapy 
and therefore can be used as a marker for individualised treatment. 
A.              B. 
 
Figure 9.7: Evolution of DOX, represented by the Raman band at 465 cm-1, DNA, 
represented by the Raman band at 785 cm-1, Bcl-2 protein and γH2AX expression, as 
measured by Flow Cytometry, as a function of time for the A. A549 and B. Calu-1 cell 
line. Intensities are expressed as percentage according to the maximum value for each 
parameter and for each cell line.  
A similar study by Farhane et al. (Farhane, Bonnier, and Byrne, 2017a), using ACT, also 
demonstrates the difference in chemosensitivity between A549 and Calu-1 cells. A higher 
viability and larger increase in protein features was observed in A549 cells, despite the 
fact that the two cell subtypes present similar ACT uptake rates.  
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The cell/drugs interaction induces different cellular reactions in the two cell lines, Calu-
1 showing higher resistance for DOX and higher sensitivity for ACT. This difference in 
cellular reactions between cell lines and between the anthracyclines, as observed in 
protein features corresponding to synthesis of anti-apoptotic proteins and mobilisation of 
DNA repair proteins, may be due to differential drug retention rather than drug uptake, 
as ACT uptake is similar for the two cell lines and DOX uptake is faster in Calu-1 than 
A549 (which suggest higher sensitivity of Calu-1 to DOX than A549 and not the 
opposite).  
The ability of Raman micro-spectroscopy to characterise and differentiate responses of 
resistant and sensitive cell types to drugs opens up potential clinical applications as a 
Companion Diagnostics tool, and ultimately personalised medicine approaches as a 
predictive tool for patient responses in individualised treatment. 
9.6. Discussion: 
Cytotoxicity assays are routinely employed to monitor the cellular viability and toxicity 
to external treatment individually or in a high content format. However, they give a 
limited insight into the mode of action and efficacy of drugs. In this context, Raman 
micro-spectroscopy can provide a label free alternative to high content analysis, 
potentially in real-time analysis with subcellular resolution and more profound 
understanding of mechanism of action of drugs and the subsequent cellular response 
pathways. 
In the case of DOX, the IC50 concentration is high enough that it makes it possible to 
detect it inside cells and to monitor its uptake and accumulation at a subcellular level 
using Raman micro-spectroscopy. Investigations demonstrate that DOX accumulates and 
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intercalates first in the nucleolus then in the nucleus, highlighting the important role of 
the nucleolus and the interaction with RNA in its mode of action, to our knowledge not 
previously demonstrated. It also shows that the secondary mechanisms of metabolisation 
in the cytoplasm causing oxidative stress only occurs at later stages, after nuclear 
disruption, once the nuclear accumulation has saturated. Therefore, Raman micro-
spectroscopy sheds light on the cellular interactions and medicinal chemistry, in situ, 
which were not previously known. Moreover, using multivariate data analysis, Raman 
spectroscopy is able to distinguish the signature of the binding interactions with the 
biochemical of the subcellular region from that of the subsequent cellular responses. 
Notably, different cell lines, exposed to the same chemotherapeutic drug DOX, show the 
same binding signatures, despite the fact that they exhibit different accumulation rates 
with different cellular resistances observed corresponding to synthesis of anti-apoptotic 
proteins, higher tolerance to DNA damage and implication of DNA repair mechanisms. 
In contrast, although structurally similar, ACT cannot be detected inside cell due to its 
low IC50, of the order of nM compared to µM for DOX, which is indicative of its higher 
toxicity and efficacy. Nevertheless, it can be seen that ACT similarly interacts first in the 
nucleolus and then in the surrounding nucleus, albeit at a considerably slower rate, which 
is potentially due to the more bulky side chains of ACT slowing down its cellular transport 
and accumulation. Furthermore, similar Raman markers of cellular interactions are 
observed for both anthracyclines, which indicates that Raman can potentially be used for 
the screening of the mode of action of drugs, to guide drug discovery and development 
research and in a pre-clinical screening context. 
Moreover, Raman investigations demonstrate that different drugs can have different 
mechanisms of action, depending on applied dose, as observed for Cisp and Vinc, which 
at high doses are seen to intercalate with DNA, or as a function of time, as for example 
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for DOX which induce different cellular responses (decrease and increase of cellular 
features specifically DNA, proteins and lipids) as a function of time, dose and cell lines 
(Farhane et al., 2015; Farhane, Bonnier, Howe, et al., 2017; Guo et al., 2009; Moritz et 
al., 2010; Schie et al., 2014). Thus Raman can shed further light on understanding the 
mechanisms of action of known drugs with potential application in companion diagnostic. 
The consistency of the spectroscopic signatures for drugs of similar modes of action, in 
different cell lines, suggests that this fingerprint can be considered a “spectralome” of the 
drug-cell interaction suggesting a new paradigm of representing spectroscopic responses. 
Notably, although the signature can contain features which can be associated with specific 
biomolecules, such as RNA, the full spectrum of that biomolecule is not manifest in the 
“spectralome”, indicating that the spectral contributions can arise from conformational or 
other changes associated with the local environment of the biomolecule, and the 
“spectralome” also contains contributions of other molecules within that environment. In 
the absence of a labelling strategy, what you see is what you get, but the “spectralome”, 
is a more holistic view of the biochemical changes associated with the drug-cell 
intereaction.  
The ability of Raman micro-spectroscopy to characterise and differentiate responses of 
resistant and sensitive cell types to drugs opens up potential clinical applications as a 
Companion Diagnostics (CD) tool, and ultimately personalised medicine approaches 
(Agarwal, Ressler, and Snyder, 2015; Naylor and Cole, 2010; Overby and Tarczy-
Hornoch, 2013). The US Food and Drug Administration (FDA) defines CD as “a medical 
device, often an in vitro device (IVD), which provides information that is essential for the 
safe and effective use of a corresponding drug or biological product”. Ultimately, the IVD 
should screen for patient specific suitability of therapeutic treatments, and both the FDA 
and the European Medicines Agency (EMA) now actively encourage the use of CD in the 
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development and use of prescription drugs and even require CD marker testing prior to 
the prescription of certain drugs. Although more complex genomics based tests are 
emerging, most currently employed CD techniques are based on individual biomarkers in 
tissue or serum and, as is the case for fluorescent labels in microscopy, provide an 
extremely limited picture of the action of the drug and the cellular response. Emerging, 
more rapid spectroscopic screening technologies will afford more continuous and even 
real-time monitoring of such intracellular processes and response pathways, which 
ultimately may be analysed using more sophisticated data mining techniques such as 
Multivariate Curve Resolution Alternating Least Squares. It can be projected, therefore, 
that Raman micro-spectroscopy can potentially contribute significantly to this field, by 
screening responses to identified therapeutics in patient derived cells, label-free, 
identifying signatures of cell resistance/sensitivity. 
9.7. Conclusion: 
The potential of Raman micro-spectroscopy not only to track in vitro the kinetics and 
accumulation of chemotherapeutic drugs at a subcellular level but also to identify their 
different mechanisms of action, for example via DNA intercalation and ROS production, 
according to different time points and doses and to identify factors contributing to 
chemotherapeutic resistance has been demonstrated. 
In fact, Raman investigations show that drugs with similar mechanism of action, for 
example DNA intercalation, exhibit the same spectral signatures, which can be 
considered as a molecular fingerprint of their cellular interaction, opening the way to a 
new paradigm of in vitro analysis and characterisation, spectralomics. There is a dearth 
of techniques to visualise the action of drugs in situ in cells, and thus, Raman micro-
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spectroscopy can be used as an in vitro guide to medicinal chemistry strategies and a pre-
clinical screening technique for drug mechanism of action and efficacy in order to aid 
preclinical drug development. Furthermore, the ability of Raman micro-spectroscopy to 
monitor subcellular processes associated with drug resistances suggests its potential as an 
in vitro companion diagnostics technique to screen for personalised therapies. 
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